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STELLINGEN 
Met het oog op de biobeschikbaarheid van fenolen is het mogelijk dat 
modificatie van de vorm waarin fenolen in voeding voorkomen meer 
oplevert dan het verhogen van de hoeveelheid in voeding (n.a.v. dit 
proefschrift). 
Indien een hoog homocystemegehalte een risico blijkt te zijn voor de 
gezondheid, dan is de consumptie van fenolen en van voedingsmiddelen 
die rijk zijn aan fenolen een potentieel risico voor de gezondheid (n.a.v. dit 
proefschrift). 
3. Het is niet ondenkbaar dat in de toekomst op een pak koffie komt te 
staan: 'geniet, maar drink met mate'. 
4. De grote variatie tussen personen in de gevoeligheid voor gewichts-
toename bij een overmaat aan energie-inname kan mogelijk deels 
worden verklaard door verschillen in 'onbewust energieverbruik', zoals 
spieractiviteit om het lichaam in balans te houden, spontane 
spiercontracties en zenuwtrekjes (Levine et al., Science 1999;283:212-214). 
5. Matig alcoholgebruik beschermt vermoedelijk tegen hart- en vaatziekten. 
Mensen met hart- en vaatproblemen zouden de waarschuwing 'geniet, 
maar drink met mate' daarom ook kunnen zien als een voedingsadvies. 
6. Voorkomen van ziekte is veelal moeilijker dan genezen. 
7. Dat vrijwilligerswerk vrijwel onmisbaar is in de huidige welvarende 
maatschappij is een vorm van armoede. 
8. Reizen door Nederland met de auto of de trein is een goede oefening in 
'onthaasting'. 
Stellingen behorend bij het proefschrift 'Bioavailability of flavonoids and cinnamic acids and 
their effect on plasma homocysteine in humans' 
Margreet Olthof, Wageningen, 13 juni 2001 
Aan mijn ouders 
ABSTRACT 
Bioavailability of flavonoids and cinnamic acids and their effect on plasma 
homocysteine in humans. 
PhD thesis by Margreet R. Olthof, Division of Human Nutrition and Epidemiology, 
Wageningen University, the Netherlands. June 13, 2001 
Dietary antioxidants might prevent oxidative damage to tissues and therefore protect 
against cardiovascular disease and cancer. Dietary phenols are strong antioxidants in 
vitro but their role in vivo is uncertain. Furthermore, there are only limited data on their 
bioavailability in humans. The aim of this thesis was to investigate whether 
bioavailability data on flavonoids and cinnamic acids support the hypothesis that they 
can affect health in humans. Because the group of phenols in foods is huge, we 
focussed our research on major phenols in foods; the flavonol quercetin, black tea 
phenols and chlorogenic acid (5-caffeoylquinic acid). We studied their bioavailability 
and effect on plasma homocysteine in humans, a potential risk factor for 
cardiovascular disease. 
The bioavailability of quercetin and chlorogenic acid depends upon their conjugated 
moieties. Hollman et al. found that the bioavailability of quercetin-3-rutinoside, a major 
flavonol in tea, was only 20% of that of quercetin-4'-glucoside. We found that 
transformation of quercetin-3-rutinoside into quercetin-3-glucoside will improve its 
bioavailability because the 3-glucoside had the same high bioavailability as the 4'-
glucoside. Caffeic acid is a major phenol in coffee, but it is present as a conjugate with 
quinic acid, called chlorogenic acid. We found that the conjugation of caffeic acid with 
quinic acid hinders absorption in humans: absorption of chlorogenic acid was only 
30% of that of its caffeic acid moiety. 
Furthermore, we found that chlorogenic acid, black tea solids and quercetin-3-
rutinoside are extensively metabolized in the human body, mainly before they reach 
the circulation. Their metabolites have no, or less, antioxidant activity in vitro than their 
parent phenols. Therefore the role of dietary phenols as antioxidants in vivo might be 
less important than suggested by their in vitro antioxidant activity. 
Coffee consumption increases plasma homocysteine, a potential risk factor for 
cardiovascular disease. Chlorogenic acid from coffee is partly responsible for the 
homocysteine-raising effect of coffee, because we found that it increased plasma 
homocysteine. Black tea solids also raised plasma homocysteine, whereas quercetin-
3-rutinoside did not. Furthermore, we found that glycination of metabolites of phenols 
in the body is not involved in the homocysteine-raising effect of phenols. 
In conclusion, chlorogenic acid, tea phenols and quercetin are available in the human 
body, but their effects on health are uncertain. Further research on bioavailability and 
health effects of dietary phenols is needed. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Epidemiological studies suggest that consumption of a diet rich in fruits and 
vegetables reduces the risk of chronic diseases such as cardiovascular disease and 
cancer (Ness & Powles 1997, World Cancer research Fund/American Institute for 
Cancer Research 1997), although the epidemiological evidence is not conclusive 
(Nessetal. 1999). 
Dietary antioxidants present in fruits and vegetables might play a role in the prevention 
of disease because they can prevent oxidative damage to tissues. Oxidative damage 
is believed to be involved in several diseases (Halliwell 1994, Stohs 1995, Thomas 
1995). For example, oxidation of Low Density Lipoprotein (LDL) cholesterol plays a 
role in the pathogenesis of atherosclerosis (Chisolm & Steinberg 2000). Oxidative 
damage of tissues and/or DNA might be involved in the cancer process (Halliwell 
1994). 
Major antioxidants in the diet are antioxidant (pro)vitamins, such as beta-carotene, 
vitamin C and vitamin E, but their role in disease prevention is still not clear (Buring & 
Hennekens 1997, Marchioli 1999, Jha et al. 1995). Besides antioxidant vitamins, the 
interest in the potential role in human health of non-vitamin antioxidants, such as 
phenols, is increasing. Many phenols have higher antioxidant activities than 
antioxidant vitamins. For example, the antioxidant activity of the flavonoid quercetin is 
4 times higher than that of vitamin E (Rice-Evans et al. 1996). 
The term 'phenols' is used for compounds characterized by an aromatic ring structure 
with one or more hydroxyl groups (Figure 1.1). However a distinction can be made 
between 'simple phenols' and 'polyphenols'. Simple phenols are compounds 
containing a single aromatic ring and bearing one or more aromatic hydroxyl groups. 
Polyphenols are compounds containing at least two aromatic rings each bearing at 
least one aromatic hydroxyl group (Clifford 1999b). The number and position of 
hydroxyl groups is related to the antioxidant activity of phenols (Rice-Evans et al. 
1996). 
< 0 ~ O H OH 
OH O 
(A) (B) 
Figure 1.1 Basic chemical structure of 'simple phenols' (A) and an example of 'polyphenols' (B) 
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In order to study the health effects of phenols, research into the bioavailability of 
phenols, as well as research into the actual health effects of phenols, is necessary. 
The studies in this thesis describe the bioavailability, absorption and metabolism of 
major dietary phenols: the flavonol quercetin, tea phenols, and cinnamic acids. We 
also studied the effect of these phenols on plasma homocysteine. This introduction 
provides information on the occurrence of phenols in foods, on the current knowledge 
with regard to bioavailability of phenols and potential biological effects of phenols. At 
the end of the introduction the rationale and outline of this thesis are described. 
PHENOLS IN PLANTS 
Phenols are essential compounds in plants for growth and reproduction, and they 
protect the plant against UV radiation, pathogens and herbivorous predators (Parr & 
Bolwell 2000). Plant phenols are synthesized in the plant via the shikimic acid pathway 
in which the amino acid phenylalanine plays a central role (Figure 1.2) (van Genderen 
et al. 1996, Parr & Bolwell 2000). The phenylpropanoid unit C6-C3:<Q-<=-<=-<=is the basic 
structure from which a variety of phenols is synthesized. Phenols can be divided in 
subgroups based on their backbone carbon structure (Figure 1.2). Within these 
subgroups various compounds exist, for example more than 4,000 flavonoids have 
been identified. 
Tannins 
(C6-C3-C6)n 
Shikimic acid 
HO 
HO—( />— COOH 
HO 
Phenylalanine 
C/6-C3 
U rt— C-C-COOH 
\ 
Flavonoids 
C6-C3-C6 
/ 
Cinnamic acids 
rz=\ C6-C3 
^ - C = C - C < 
Phenolic acids 
C s - c , ^ - ' 
C6-C20-c-c 
c6-c3<Q-c -c-c-c 
\ 
Coumarins 
C6-C3 
Stilbenes 
.Ce-C2-C6 
Figure 1.2 Synthesis of plant phenols via the shikimic acid pathway 
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PHENOLS IN FOODS AND INTAKE IN HUMANS 
Phenols are ubiquitous in plants and therefore they are a basic part of the human diet. 
Furthermore, they are used in the food industry as additives such as colorants, flavors 
and preservatives. Phenols in foods are generally conjugated with sugars, but links 
with other compounds such as carboxylic and organic acids, amines, lipids and other 
phenols also occur (Figure 1.3) (Bravo 1998). Major phenols in the diet are flavonoids 
and cinnamic acids (Figure 1.2 and Table 1.1). Plant foods are the only dietary 
sources of flavonoids. Phenolic acids are also derived from plant foods, but they can 
also be formed in humans out of other phenols. 
?H 
JO—glucose 
B 
•C—O—quinic acid 
Figure 1.3 Examples of chemical structures of (A) the flavonol quercetin conjugated with glucose 
called quercetin-4'-glucoside, and of (B) the cinnamic acid caffeic acid conjugated with quinic acid, 
called chlorogenic acid. 
The daily intake of flavonoids and cinnamic acids is difficult to estimate because food 
composition tables are not available. Kuhnau (Kuhnau 1976) roughly estimated that 
the daily intake of flavonoids would be approximately 1 g, but later this turned out to 
be too high (Table 1.1). Flavonoids can be divided into 6 subgroups: flavonols, 
flavones, catechins, flavanones, isoflavones and anthocyanidins. More than half of the 
intake of the flavonols and flavones consists of the flavonol quercetin (Hertog et al. 
1993a). The estimate of the daily intake of 50 mg of catechins represents the intake of 
catechins present in foods as single catechin molecules (monomeric catechins) (Table 
1.1). However, black tea is a major source of catechins, and during processing of 
black tea, tea catechins form complex condensation products such as theaflavins and 
thearubigins, which are difficult to measure (Balentine et al. 1997). Therefore, the 
actual intake of catechins is probably higher. 
Caffeic acid and ferulic acid are major cinnamic acids in foods (Table 1.1). Caffeic acid 
occurs in food mostly as a conjugate with quinic acid, called chlorogenic acid (Figure 
1.3). In coffee drinkers, coffee provides about 90% of the caffeic acid intake (Clifford 
1999a, Radtke et al. 1998). Ferulic acid is associated with dietary fiber. The colonic 
microflora releases ferulic acid from fiber (Kroon et al. 1997). Other sources of 
14 
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cinnamic acids are fruits such as apples, pears, berries, prunes and peaches, and 
vegetables such as eggplants and artichokes (Clifford 1999a). 
Table 1.1 Chemical structure, major dietary sources, and estimated daily intake of fiavonoids and 
cinnamic acids. 
Phenol Chemical 
structure 
Major sources Estimates of daily intake 
OH 
Fiavonoids 
Flavonols 
and flavones 
Catechins 
Flavanones 
Isoflavones 
Anthocyanidins HO^ ^ ^ o^*„ 
OH 
Tea, onions, 
apples 
Cinnamic acids 
Caffeic acid 
Ferulic acid 
HO 
H 0 _ O~ c = ' 
HjCO 
H
°-0-C=' 
Tea, chocolate 
Citrus fruits 
Legumes 
(soybeans) 
Fruits such as 
berries and 
cherries, and wine 
Coffee 
3-5 mg 
(Finland and Spain) 
10-30 mg 
(The Netherlands, UK and USA) 
40-70 mg 
(Japan and Hawai) 
Monomeric catechin: 50 mg 
(The Netherlands) 
No estimate available 
25-50 mg (Japan) 
0-10 mg (western world) 
180-215 mg 
d) 
(2) 
(3) 
(4) 
(5) 
(6) 
(5) 
Cereal bran, 
;c
-
C0OH
 coffee 
Coffee drinkers; ~500 mg (7) 
Non-coffee drinkers: <25 mg 
~100mg (8) 
(1) = (Garcia-Closas et al. 1998, Garcia-Closas et al. 1999, Knekt et al. 2000, Knekt et al. 1997) 
(2) = (Hertog et al. 1993a, Rimm et al. 1996, Yochum et al. 1999, Hertog et al. 1997a) 
(3) = (Le Marchand et al. 2000, Hertog et al. 1995) 
(4) = (Arts et al. 2001, Arts et al. 1999) 
(5) = (Pedersen & Dwyer 1998, Kuhnau 1976, Clifford 2000b) 
(6) = (Kirk et al. 1999, Nagata et al. 1998, Somekawa et al. 2001) 
(7) = (Clifford 1999a, Radtke et al. 1998) 
(8) = (Kroon et al. 1997, Clifford 1999a) 
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Especially beverages such as tea and coffee, seem to be important quantitative 
sources of flavonoids and cinnamic acids (Table 1.1). However, the estimates of 
intake of total flavonoids and cinnamic acids are based on the intake of just a few 
individual flavonoids and cinnamic acids. Thus, in order to determine the total intake of 
flavonoids and cinnamic acids, and of other subgroups of phenols, more information is 
needed. 
Based on the available estimates, the intake of antioxidants via dietary phenols is 
comparable with, or even more than that via (pro)vitamins, such as vitamin C, E and 
carotenoids. Therefore dietary phenols are important as antioxidants in the prevention 
of diseases. 
BIOAVAILABILITY OF PHENOLS 
Bioavailability can be defined as 'the fraction of the ingested nutrient that is utilized for 
physiological functions and storage' (Jackson 1997). 
Knowledge about the bioavailability of dietary phenols is very limited. The 
bioavailability of a compound is mainly determined by its chemical structure. In 
addition to variations in their basic phenolic structure, plant phenols might differ in 
degree of glycosylation, conjugation with other phenols, molecular size, degree of 
polymerization, and solubility. Furthermore, in foods, mixtures of phenols occur. Until 
now mainly the bioavailability of individual phenols has been studied (Bravo 1998, 
Hollman 1997a). 
Bioavailability of a dietary component is determined by 4 processes (Figure 1.4): A) 
absorption from the small intestine or colon determines whether or not a phenol will 
become available in the blood circulation and in specific target tissues. In theory it is 
possible that despite the presence of large amounts of phenols in foods, none of them 
actually reach the target tissues; B) metabolism in the body; C) distribution in the 
body, and D) excretion from the body. 
Small intestine 
' > 
colon 
A
 k liver 
1 
' 
kidneys 
other body tissues 
A= absorption 
B= metabolism 
C= distribution 
D= excretion 
feces urine 
Figure 1.4 Schematic overview of the main bioavailability processes 
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Absorption of flavonoids and cinnamic acids 
For a long time flavonoids from foods were considered to be non-absorbable because 
they are bound to sugars, the so-called glycosides. These glycosides were supposed 
not to be liberated into the free flavonoid (aglycone) due to the absence of beta-
glucosidase enzymes in the small intestine of mammals (Griffiths & Smith 1972). 
Therefore oral intake of flavonoids was thought to be of no use (Gugler et al. 1975, 
Clark & Mackay 1950). However, in contrast to this belief, Hollman et al. showed that 
flavonoid glycosides could be absorbed from the small intestine. Indeed, the sugar 
moiety proved to be a very important determinant of absorption of flavonoid 
glycosides: the flavonol quercetin-4'-glucoside is better absorbed than quercetin-3-
rutinoside (Hollman et al. 1995, 1997b and 1999, Felgines et al. 2000). The catechins 
occur as aglycones in foods. Monomeric catechins are absorbed in humans (Hollman 
& Arts 2000). The absorption of the complex condensation products of catechins, 
present in black tea, is uncertain, but they seem to be at least partly absorbable 
(Hollman et al. 1997c). 
Cinnamic acids in foods occur mostly as esters with, among others, quinic acid 
(Clifford 2000a). The free cinnamic acids are well absorbed in animals and humans 
(Ader et al. 1996, Jacobson et al. 1983, Camarasa et al. 1988, Fahelbum & James 
1977). However, it is unknown whether the esterification of cinnamic acids with other 
compounds influences their absorption. There are indications that these esters must 
be hydrolyzed before the cinnamic acids can be absorbed in humans (Booth et al. 
1957, Czok et al. 1974, Plumb et al. 1999, Clifford 2000a). 
Metabolism, distribution and excretion of phenols 
Metabolism, distribution and excretion processes determine the type of circulating 
metabolites, the sites that these metabolites can reach and the period of time that they 
are available to target tissues. Metabolism mainly takes place by the colonic microflora 
and in the liver. However, other organs such as the gut wall and the kidney also play 
an important role in the metabolism. 
Flavonoids are extensively metabolized in the human body as indicated by the low 
excretion of the original flavonoid structure in urine after ingestion. Only 1-3% of the 
original quercetin (Hollman et al. 1995) or catechins (Hackett et al. 1983 and 1985) 
was excreted in urine after volunteers had ingested large amounts. Cinnamic acids 
are also extensively metabolized because the recoveries in urine were low after 
ingestion. Of the caffeic acid ester chlorogenic acid none was recovered in urine after 
ingestion (Booth et al. 1957, Choudhury et al. 1999). Of free caffeic acid and ferulic 
acid, about 10% was recovered in urine (Camarasa et al. 1988, Choudhury et al. 
1999). 
Due to extensive metabolism of phenols in humans, it is possible that the metabolites 
of phenols are the actual compounds that reach the circulation and target tissues. 
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Therefore, the metabolites of phenols might be more important for potential health 
effects than the original phenols. Thus, information on the amount and the types of 
metabolites of dietary phenols, and on their elimination kinetics in humans, is 
essential. 
BIOLOGICAL EFFECTS OF PHENOLS 
Beneficial effects of dietary phenols 
In the 1930s, flavonoids were thought to have vitamin properties because they 
seemed to decrease the permeability and fragility of capillary blood vessels. 
Consequently, they were called 'vitamin P" (derived from permeability) (Bentsath et al. 
1936 and 1937). In later years, the interest in vitamin 'P' weakened due to the belief 
that flavonoids were not bioavailable (Clark & Mackay 1950). Recently, flavonoids and 
other phenols have gained interest mainly because of their antioxidant activity and 
because they were proven to be bioavailable (Hollman 1997a, Rice-Evans et al. 
1996). 
Oxidation is an essential energy producing process in the body, which generates 
oxygen free radicals. However, an excess of free radicals might be involved in the 
pathogenesis of several diseases including cardiovascular disease, cancer and 
inflammatory diseases (Stohs 1995, Thomas 1995). 
Antioxidants can protect against an excess of free radicals by reacting with free 
radicals, scavenging free radicals, inhibit their formation, or assist with other 
antioxidant defences (Shahidi & Wanasundara 1992, Pietta 2000, van Acker et al. 
2000, Zhu et al. 1999). For example, antioxidant phenols protect against oxidized Low 
Density Lipoprotein (LDL) cholesterol in vitro (de Whalley et al. 1990, Castelluccio et 
al. 1995). Oxidized LDL seems to be involved in the development of cardiovascular 
disease (Chisolm & Steinberg 2000, Steinberg 1997). Phenols might protect against 
cancer by inhibiting the formation of free radicals and in that way prevent damage of 
tissues and of DNA (Kasai et al. 2000, Noroozi et al. 1998). 
However, the role of antioxidants in humans is still not clear. Epidemiological studies 
do not show a clear protective effect of the flavonoid subgroups flavonols and flavones 
on cardiovascular disease and cancer (Table 1.2). However, these flavonols and 
flavones might not represent the total group of phenols. In addition, inconclusive 
results from large intervention trials with antioxidant vitamins such as beta-carotene, 
vitamin C and E also raise doubts about the effects of antioxidants on cardiovascular 
disease and cancer (Buring & Hennekens 1997, Marchioli 1999, Jha et al. 1995). 
Moreover, it remains difficult to study the effects of antioxidants in humans, because 
there are no adequate biomarkers available for measurement of effects of antioxidants 
in vivo (Witztum 1998). 
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Adverse effects of dietary phenols 
Although phenols are mainly thought to be beneficial to human health, they might also 
have adverse effects (Skibola & Smith 2000). It is well known that antioxidants can 
also be pro-oxidants, depending on the circumstances and the dose (Skibola & Smith 
2000, Stich 1991, Shahidi & Wanasundara 1992). Therefore, an excess of 
antioxidants might be harmful. 
Traditionally, phenols have been considered to be anti-nutrients. This is due to the fact 
that they can decrease the digestibility of food as they bind and precipitate 
macromolecules such as protein, carbohydrates and digestive enzymes (Jung & 
Fahey 1983, Bravo 1998). Further, phenols form complexes with metals and therefore 
inhibit the bioavailability of nutrients such as zinc and iron (Brune et al. 1989, Coudray 
et al. 1998, Layrisse et al. 2000). 
A new potential role of phenols in human health is that phenols might raise the plasma 
concentration of homocysteine in humans. Homocysteine is a sulfur-containing amino 
acid that is present in human blood. It is produced from methionine through 
demethylation of S-Adenosylmethionine (SAM) (Figure 1.5) (Finkelstein 1990). A high 
concentration of homocysteine in blood is a potential risk factor for cardiovascular 
disease (Nygard et al. 1995, Refsum et al. 1998). However, it is still unsure whether a 
high plasma homocysteine concentration is a causal risk factor for disease, or whether 
it merely is a consequence of disease (Brattstrom & Wilcken 2000, Ueland et al. 
2000). 
^tetrahydroiolate'**s<CH3 
^ * Methyl- y / 
tetrahydrofolate 
• methionine 
\ 
S-Adenosylmethionine 
\ * C H 3 
S-Adenosylhomocysteine 
homocysteine 
\ 
degradation via 
transsulfuration pathway 
Figure 1.5 Schematic overview of homocysteine metabolism 
Nygard et al. (Nygard et al. 1997) found that high coffee consumption is associated 
with a higher homocysteine concentration in blood. Other epidemiological studies and 
intervention studies confirmed this (Oshaug et al. 1998, Stolzenberg-Solomon et al. 
1999, Grubben et al. 2000, Urgert et al. 2000). The responsible compounds in coffee 
are unknown. The lipid soluble compounds kahweol and cafestol, that are present in 
unfiltered coffee and known to raise cholesterol, are not responsible because 
unfiltered coffee as well as filtered coffee raises plasma homocysteine (Grubben et al. 
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2000, Urgert et al. 2000). Two other obvious candidates for the homocysteine-raising 
effects of coffee are caffeine and chlorogenic acid. Caffeine is currently under 
investigation (personal communication with Dr. P. Verhoef, Wageningen Centre for 
Food Sciences, Wageningen, The Netherlands). We investigated in chapter 5 whether 
the phenol chlorogenic acid might be responsible because it occurs in large amounts 
in coffee, but in only small amounts in other foods (Clifford 1999a). 
Table 1.2 Overview of epidemiological studies of the effect of flavonols and flavones on cardiovascular 
disease and cancer. 
Cardiovascular disease 
• (Hertog et al. 1993b, Hertog et al. 1997b) 
• (Hertog etal. 1995) 
• (Knekt etal. 1996) 
• (Keli etal. 1996) 
• (Rimm etal. 1996) 
• (Hertog etal. 1997a) 
• (Yochumetal. 1999) 
• (Knekt et al. 2000) 
• (Hirvonen etal. 2001) 
• (Hirvonen et al. 2000) 
Cancer 
• (Hertog etal. 1994) 
• (Hertog etal. 1995) 
• (Goldbohm etal. 1995) 
• (Knekt etal. 1997) 
• (Le Marchand et al. 2000) 
• (Hertog etal. 1997a) 
• (Garcia-Closas et al. 1998, Garcia-Closas 
etal. 1999, Garcia etal. 1999) 
Outcome 
CHD* mortality 
Fatal and non-fatal Ml* 
CHD* mortality 
Coronary mortality 
Stroke 
Non-fatal Ml* 
Total CHD* 
CHD* mortality 
Ischemic heart disease mortality 
Risk of ischemic heart disease 
CHD* mortality 
Stroke mortality 
CVA* 
Coronary death 
Nonfatal Ml 
Stroke 
Risk of cancer and cancer mortality 
Cancer mortality 
Risk of cancer 
Risk of cancer 
Risk of cancer 
Cancer mortality 
Risk of cancer 
Effect* 
+ 
0/+ 
+ 
0/+ 
+ 
0 
0 
0 
0/-
0 
+ 
0 
0 
0/+ 
+ 
0 
0 
0 
0 
0/+ 
0/+ 
0/-
0/+ 
0 = no effect; 
+ = protective; 
- = increased risk; 
0/+ = protective, but not statistically significant; 
0/- = increased risk, but not statistically significant. 
"abbreviations: CHD 
disease 
coronary heart disease; Ml = myocardial infarction; CVA = cerebrovascular 
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RATIONALE AND OUTLINE OF THIS THESIS 
The objective of this thesis was to investigate whether bioavailability data on 
flavonoids and cinnamic acids support the hypothesis that they can affect health in 
humans. Information on the bioavailability processes of dietary phenols will provide 
valuable insight into the plausibility that they might affect health. Because the group of 
phenols represents a huge variety of compounds, we focussed our studies on major 
flavonoids and cinnamic acid in foods: quercetin, black tea phenols, and chlorogenic 
acid (5-caffeoylquinic acid). 
1) Impact of conjugated moieties of quercetin and chlorogenic acid on their 
bioavailability 
Flavonols are important dietary phenols and quercetin is their major representative. In 
foods quercetin occurs as quercetin glycosides and Hollman et al (Hollman et al. 
1995, 1997b and 1999) showed that the sugar moiety determines the bioavailability: 
the bioavailability of quercetin-3-rutinoside (quercetin attached to a glucose with 
rhamnose) was only 20% of that of quercetin-4'-glucoside (quercetin attached to a 
glucose). Quercetin-3-rutinoside is the major quercetin form in tea, and tea is the 
major source of quercetin. Therefore it would be interesting to see whether the 
bioavailability of quercetin-3-rutinoside from tea could be improved if quercetin-3-
rutinoside is transformed into quercetin-3-glucoside, which in theory is possible 
(Bokkenheuser et al. 1987, Gunata et al. 1988, Kurosawa et al. 1973). However, it is 
not known whether the bioavailability of quercetin-3-glucoside is similar to that of the 
well-bioavailable quercetin-4'-glucoside, i.e. whether the position of glucose plays a 
role in the bioavailability of quercetin. In chapter 2 vie investigated whether quercetin-
3-glucoside had the same high bioavailability as quercetin-4'-glucoside. 
Another important group of phenols in foods are the cinnamic acids, of which 
chlorogenic acid is the major representative (Clifford 1999a). Very little is known about 
the bioavailability of chlorogenic acid. Therefore we studied the absorption of 
chlorogenic acid and of its caffeic acid moiety in volunteers without a colon (ileostomy 
volunteers) in chapter 3. 
2) Metabolism of phenols in humans 
Phenols are extensively metabolized in the human body. Therefore it is important to 
identify the metabolites of phenols that are actually circulating in the body and may 
have biological effects. Information on the metabolites of phenols and on the site of 
metabolism of phenols in humans is essential but scarce. We measured 59 phenolic 
acids as potential metabolites in the urine of 20 healthy volunteers with a colon after 
they had ingested chlorogenic acid, phenols from black tea and quercetin-3-rutinoside. 
Furthermore, to investigate the role of the colonic microflora in the metabolism of 
phenols we measured potential metabolites of chlorogenic acid, caffeic acid, and 
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quercetin-3-rutinoside in volunteers without a colon (ileostomy volunteers) in chapter 
4). 
3) Effect of phenols on plasma homocysteine 
Coffee increases plasma homocysteine concentrations, a potential risk factor for 
cardiovascular disease (Nygard et al. 1997, Oshaug et al. 1998, Stolzenberg-Solomon 
et al. 1999, Grubben et al. 2000, Urgert et al. 2000). Because chlorogenic acid occurs 
in large amounts in coffee, it might be the responsible compound for the 
homocysteine-raising effect of coffee. Therefore we investigated whether chlorogenic 
acid raised plasma homocysteine concentrations. Because metabolism of chlorogenic 
acid and other phenols is likely to occur via the same pathways, we also determined 
the effect of black tea solids and quercetin-3-rutinoside on plasma homocysteine 
(chapter 5). We found that chlorogenic acid and black tea solids raised plasma 
homocysteine, therefore we looked into the mechanism underlying the potential 
homocysteine-raising effects of phenols in chapter 6. 
Chapter 7 discusses the implications our findings. 
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Bioavailabilities of quercetin-3-glucoside and quercetin-4'-
glucoside do not differ in humans 
Margreet R. Olthof, Peter C.H. Hollnian, Tom B. Vree and Martijn B. Katan 
The flavonoid quercetin is an antioxidant which occurs in foods mainly as glycosides. The sugar moiety 
in quercetin glycosides affects their bioavailability in humans. Quercetin-3-rutinoside is an important 
form of quercetin in foods, but its bioavailability in humans is only 20% of that of quercetin-4'-glucoside. 
Quercetin-3-rutinoside can be transformed into quercetin-3-glucoside by splitting off a rhamnose 
molecule. We studied whether this 3-glucoside has the same high bioavailability as the quercetin-4'-
glucoside. To that end we fed five healthy men and four healthy women (19-57 y) a single dose of 325 
nmol of pure quercetin-3-glucoside and a single dose of 331 nmol of pure quercetin-4'-glucoside and 
followed the plasma quercetin concentrations. The bioavailability was the same for both quercetin 
glucosides. The mean peak plasma concentration of quercetin was 5.0 ± 1.0 ^ o l / L (±SE) after 
subjects had ingested quercetin-3-glucoside and 4.5 ± 0.7 nmol/L after quercetin-4'-glucoside 
consumption. Peak concentration was reached 37 ± 12 min after ingestion of quercetin-3-glucoside and 
27 ± 5 min after quercetin-4'-glucoside. Half-life of elimination of quercetin from blood was 18.5 ± 0.8 h 
after ingestion of quercetin-3-glucoside and 17.7 ± 0.9 h after quercetin-4'-glucoside. We conclude that 
quercetin glucosides are rapidly absorbed in humans, irrespective of the position of the glucose moiety. 
Conversion of quercetin glycosides into glucosides is a promising strategy to enhance bioavailability of 
quercetin from foods. 
Journal of Nutrition; 130; 1200-1203,2000 
CHAPTER 2 
INTRODUCTION 
Flavonoids are polyphenols compounds that occur in foods of plant origin. The 
average daily intake of the flavonoid subclasses of flavonols and flavones in The 
Netherlands is 23 mg (expressed as aglycones) of which quercetin supplies 16 mg 
(Hertog et al. 1993b). Quercetin is an antioxidant in vitro because it can scavenge 
radicals, inhibit lipid peroxidation and chelate metals (Rice-Evans et al. 1996). 
Quercetin was able to inhibit oxidation of LDL in vitro at a concentration as low as 
0.25 u.mol/L, which is in the physiological range (Manach et al. 1998, de Whalley et al. 
1990). Therefore quercetin might contribute to the prevention of cardiovascular 
disease (Hertog et al. 1993a). However, to induce these health effects in humans, 
quercetin must enter the systemic circulation. Quercetin in foods is bound to sugars, 
mainly as p-glycosides, and the bioavailability of these various quercetin glycosides is 
affected by their sugar moiety (Hollman et al. 1995, 1996a and 1999). Quercetin-3-
rutinoside and quercetin-4'-glucoside are important forms of quercetin in foods (Figure 
2.1). 
OH OH 
»d OH o i ^ r bH 
Quercetin-3-rutinoside Quercetin-4'-glucoside 
H 
.OH 
*'\ 
HO / W T O H OH OH 
Quercetin-3-glucoside 
Figure 2.1 Structure of quercetin glycosides 
Quercetin-3-rutinoside accounts for ~40% of quercetin in black tea (Engelhardt et al. 
1992), and consumption of black tea contributes about 48% to the total flavonol and 
flavone intake in The Netherlands (Hertog et al. 1993b). Quercetin-4'-glucoside 
accounts for ~45% of quercetin in onions (Kiviranta et al. 1988), and consumption of 
onions contributes another 29% to the total flavonol and flavone intake (Hertog et al. 
1993b). Although the intake of quercetin-3-rutinoside is twice that of quercetin-4'-
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glucoside, the absorption of quercetin-3-rutinoside is only 17% of ingested dose, 
whereas the absorption of quercetin-4'-glucoside is 52% of ingested dose (Hollman et 
al. 1995). Furthermore, the bioavailability of quercetin-3-rutinoside is only 20% of that 
of quercetin-4'-glucoside (Hollman et al. 1999). Therefore it would be interesting to 
attempt to increase the bioavailability of quercetin-3-rutinoside. Rutinose is a dimer of 
glucose and rhamnose; therefore quercetin-3-rutinoside can be transformed into 
quercetin-3-glucoside by splitting of the rhamnose molecule with the enzyme alpha-L-
rhamnosidase (Bokkenheuser et al. 1987, Gunata et al. 1988, Kurosawa et al. 1973). 
The resulting quercetin-3-glucoside differs only from the highly bioavailable quercetin-
4'-glucoside in the position of the glucose moiety on the quercetin aglycone. However 
the bioavailability of quercetin-3-glucoside is unknown. Therefore we tested whether 
the position of the glucose moiety affected the bioavailability of quercetin glucosides 
in humans. 
MATERIALS AND METHODS 
Subjects 
The protocol was approved by the Ethical Committee of Nijmegen University Hospital. 
All subjects were fully informed about the study and signed an informed consent form. 
Five women and five men started with the study, but one woman was excluded 
because of problems with blood sampling. Mean age of the remaining nine subjects 
was 25 y (range 19 - 57 y) and mean body mass index was 21.3 kg/m2 (range 19.8 -
24.8 kg/m2). All subjects were healthy based on a medical questionnaire, the absence 
of protein and glucose in urine and normal values for blood hematocrit, hemoglobin 
concentration and leukocyte and platelet counts. Subjects were not allowed to use 
any medicine during the study, except for acetaminophen (paracetamol) and oral 
contraceptives. 
Study design and supplements 
The subjects ingested quercetin-3-glucoside or quercetin-4'-glucoside (Figure 2.1) on 
two different days in random order, and subsequently we measured quercetin in blood 
over 72 h and in urine over 24 h. Subjects followed a quercetin-low diet from d 3 to 
16. To ensure a quercetin-low diet, subjects were given a list of fruits and vegetables 
which contained more than 15 mg quercetin/kg and of beverages with more than 4 mg 
quercetin/L (Hertog et al. 1992 and 1993c) and they were instructed not to consume 
any of them. During the mornings of d 7 and of d 13 the subjects came to the 
University Hospital Nijmegen after they had fasted overnight. Five of the subjects 
ingested 325 nmol (151 mg) quercetin-3-glucoside (#011095, Extrasynthese, Genay, 
France) on d 7 and 331 nmol (154 mg) quercetin-4'-glucoside (#4564, Carl Roth, 
Amsterdam, The Netherlands) on d 13. The other four subjects received the same 
supplements in reverse order. Each supplement was dissolved in 10 mL ethanol plus 
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200 mL of hot water (5% v/v alcohol content). Subjects ingested 2 g of sodium 
chloride dissolved in 10 mL of water just before they ingested the supplement 
because the sodium glucose cotransporter might play a role in the absorption of 
quercetin glucosides and sodium is necessary for the active transport of glucose. 
During the first 3 h after ingestion of the supplements subjects were allowed to 
consume water only. We checked compliance with the dietary guidelines with a 24-h 
recall for d 6 and 12. We calculated intakes with the Dutch food composition table. 
Average energy intake was 13.4 ± 0.9 (SE) MJ, of which protein provided 14.8 ± 0.5 
%, fat 34.7 ± 2.8 %, and carbohydrates 49.8 ± 3.2 %. The mean daily quercetin intake 
from regular foods during the study was not different between supplement periods 
and was 7.6 ± 2.3 (xmol. Because this was about 2% of the dose of the supplements 
we conclude that intake of quercetin from regular foods did not affect our results. 
Collection off blood and urine samples 
We took venous blood samples (10 mL blood per blood sample) into vacuum tubes 
containing EDTA once before subjects ingested the supplement, and at 15 min, 30 
min, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 60 and 72 h after ingestion. Platelet-poor plasma 
was prepared by centrifuging the blood for 10 minutes at 2500 x g at 4°C. The plasma 
was stored at -80°C until analysis. On d 7 and 13, subjects collected urine during 24 h 
in plastic bottles, one for each voiding, with thymol (# 8167; Merck, Amsterdam, the 
Netherlands) dissolved in isopropanol as preservative. They stored each bottle in dry 
ice immediately after voiding. At the laboratory we thawed the urine bottles in a water 
bath of ~40°C, pooled and mixed urine per subject and per supplement day, froze 
aliquots of urine in liquid nitrogen and stored the urine samples at -80°C until analysis. 
Subjects took 300 (j.mol lithium chloride dissolved in 10 mL of water every morning 
from d 1 until d 14. Urinary recovery of lithium was 94.4 + 17.2% (mean + SD), which 
indicates that collection of urine was complete (Sanchez-Castillo et al. 1987a and 
1987b). 
Analytical methods 
Quercetin, isorhamnetin (3'-methoxyquercetin) and their conjugates with glycosides, 
glucuronic acid or sulfates in plasma or urine were simultaneously extracted and 
hydrolyzed to their aglycones with 2 mol/L HCL in aqueous methanol (Hollman et al. 
1997). We measured the aglycones by HPLC with fluorescence detection (Hollman et 
al. 1996b). The limit of detection, i.e. the concentration producing a peak height three 
times the standard deviation of the baseline noise was 0.007 nmol/L (2 ng/mL) for 
quercetin in plasma and 0.01 nmol/L (3 ng/mL) for quercetin in urine (Hollman et al. 
1997). The limits of detection for isorhamnetin were one-third of those for quercetin 
(Hollman et al. 1996b). Lithium was measured in undiluted, acidified urine by atomic 
absorption spectrophotometry (Anonymous 1976). 
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Data analysis 
We used a two-compartment model to describe the pharmacokinetics of quercetin 
and isorhamnetin. We calculated peak plasma concentration, time to reach peak 
plasma concentration, elimination half-life and area under the plasma concentration -
time curve (AUC0 ^ 72 h) with the MW/Pharm computer package (Proost & Meijer 
1992). We calculated the AUCo ^
 72 h with the linear trapezoidal rule. Differences 
between results after ingestion of quercetin-3-glucoside and after quercetin-4'-
glucoside were tested for significance by paired t-test with a significance level of 
P<0.05 (SAS Institute Inc., Cary, NC, USA). 
RESULTS 
The time course of the quercetin (measured as the quercetin aglycone) concentration 
in blood after ingestion of quercetin-3-glucoside was not different from that after 
ingestion of quercetin-4'-glucoside (Figure 2.2). The plasma kinetic variables of the 
two glucosides also did not differ, as did the bioavailability, as indicated by the similar 
AUCo ^ 72 h (Table 2.1). 
The concentration of quercetin in plasma rose rapidly after ingestion of quercetin-3-
glucoside as well as after ingestion of quercetin-4'-glucoside. The mean peak plasma 
concentration of quercetin, the time to reach peak concentration, and the elimination 
half-life of quercetin in plasma did not differ when subjects consumed quercetin-3-
glucoside or quercetin-4'-glucoside (Table 2.1). 
Table 2.1 Kinetic variables of quercetin absorption and elimination in plasma of nine subjects after one-
time ingestion of quercetin-3-glucoside or quercetin-4'-glucoside1 
Variable 
Plasma total quercetin 
Peak concentration 
Time to reach peak concentration 
Elimination half-life 
Area under the plasma concentration-
time curve (AUCo _»72 h) 
nmol/L 
(ng/mL) 
(min) 
(h) 
(h x umol/L) 
(h x ng/mL) 
Supplement* 
Quercetin-3-
glucoside 
5.0 ±1.0 
1526 ±315 
37 ±12 
18.5 ±0.8 
19.1 ±2.9 
5775 ± 876 
Quercetin-4'-
glucoside 
4.5 ± 0.7 
1345 ±212 
27 ± 5 
17.7 ±0.9 
17.5 ±2.4 
5276 ± 730 
2
 Subjects ingested 325 nmol (151 mg) of quercetin-3-glucoside or 331 nmol (154 mg) of quercetin-4'-
glucoside. Each subject received each supplement in random order at a 6-d interval. 
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Figure 2.2 Total quercetin concentration in plasma of nine human subjects after ingestion of 325 
nmol (151 mg) quercetin-3-glucoside (mean + SE) or 331 nmol (154 mg) quercetin-4'-glucoside 
(mean - SE). Each subject received each supplement in random order at a 6-d interval. 
The amount of quercetin excreted in 24h urine after intake of the 3-glucoside was not 
different from that after intake of the 4'-glucoside (Table 2.2). Only about 3% of the 
ingested quercetin was excreted in urine as quercetin aglycone or its conjugates, 
which indicates that quercetin is extensively metabolized in the human liver and other 
organs and by the colonic microflora. One of the metabolites of quercetin is 
isorhamnetin (3'-methoxyquercetin) (Manach et al. 1998, Morand et al. 1998). We 
indeed found isorhamnetin in plasma and urine after ingestion of both quercetin 
supplements. Peak concentration of isorhamnetin did not differ between the 
glucosides and was reached in 51 ±19 min after the quercetin-3-glucoside and in 32 ± 
5 min after the quercetin-4'-glucoside. Other kinetic variables of isorhamnetin did not 
differ between the quercetin glucosides (data not shown). In urine, ~0.6% of the 
ingested quercetin glucosides was recovered as isorhamnetin (Table 2.2). 
Table 2.2 Excretion of quercetin and isorhamnetin in urine of subjects during the first 24 h after one-
time ingestion of quercetin-3-glucoside or quercetin-4'-glucoside1 
Supplement2 Intake 
Excretion in urine 
Quercetin Isorhamnetin 
Quercetin-3-glucoside 
Quercetin-4'-glucoside 
nmol 
325 
331 
% quercetin glucoside intake 
3.0 ±0.3 
2.6 ±0.4 
0.61 ± 0.08 
0.53 ± 0.07 
1
 Values are mean ± SE, n=9. None of the variables differed significantly between supplements 
2
 Subjects ingested 325 nmol (151 mg) of quercetin-3-glucoside or 331 nmol (154 mg) of quercetin-4'-
glucoside. Each subject received each supplement in random order at a 6-d interval 
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DISCUSSION 
The bioavailability of quercetin-3-glucoside is similar to that of quercetin-4'-glucoside. 
We found that the time to reach peak concentrations was ~30 minutes for both 
quercetin glucosides and the peak concentration was ~5 nmol/L This corresponds 
well with the peak concentration of 3.5 nmol/L for quercetin-4'-glucoside, reported by 
Hollman et al. (1999), who also found that the bioavailability of quercetin-3-rutinoside 
was 20% of that of quercetin-4'-glucoside. Therefore our results suggest that 
enzymatic conversion of quercetin-3-rutinoside into quercetin-3-glucoside will increase 
bioavailability. Quercetin-3-glucoside itself also occurs commonly in foods such as 
tea, tomatoes and apples (Engelhardt et al. 1992, Herrmann 1976 and 1988). We 
may now conclude that this naturally occurring 3-glucoside has the same high 
bioavailability as the 4'-glucoside. 
Quercetin glucosides are absorbed more rapidly than other quercetin glycosides 
(Hollman et al. 1997 and 1999). The mechanism for quercetin absorption is not 
known. Hollman et al. (1995 and 1999) speculated that the intestinal sodium-glucose 
cotransporter is able to transport glucose attached to quercetin through the intestinal 
cell wall. This idea was supported by the results of Aziz et al. (1998), who found the 
quercetin-4'-glucoside in human plasma after volunteers had consumed onions. If the 
sodium-glucose cotransporter plays a role in the absorption of quercetin glucosides, 
our results would suggest that the absorption of glucose is not affected by its position 
on the attached quercetin. However, transport of quercetin glucosides by the glucose 
cotransporter has not been proven yet in vivo. For the interpretation of the bioactivity 
of quercetin from foods in humans, it is important to know in what form quercetin 
actually circulates in blood. From the results in this study it is unclear in what form 
quercetin circulates in blood because we measured the concentration of quercetin 
after hydrolysis to the quercetin aglycone. With regard to bioactivity of various forms 
of quercetin, quercetin conjugated with glycosides, glucuronic acid, or sulfates also 
has antioxidant activity in vitro, although the antioxidant activity is lower than that of 
the quercetin aglycone (Manach et al. 1998, Williamson et al. 1996). 
In addition to bioavailability data, our study also provided information on the 
metabolism of quercetin into isorhamnetin (3'-methoxyquercetin). Of the ingested 
quercetin glucosides ~50% is absorbed in the small intestine and subsequently 
metabolized, for example into isorhamnetin, in the liver and in other organs. The 50% 
of ingested quercetin which is not absorbed in the small intestine is metabolized by 
the colonic microflora into quercetin aglycone and phenolic acids which might be 
absorbed from the colon (Hollman & Katan 1998, Hollman et al. 1995, Manach et al. 
1998). Only 3% of the ingested quercetin is recovered in urine as aglycone or its 
conjugates. The quercetin in urine might originate from quercetin absorbed in the 
small intestine and from quercetin absorbed in the colon. Metabolites of quercetin 
may also be biologically important, because they have antioxidant activity in vitro 
33 
CHAPTER 2 
(Manach et al. 1998, Rice-Evans et al. 1996) and might exert antioxidant effects in 
humans. In this study we measured isorhamnetin as a metabolite of quercetin. 
Isorhamnetin concentration in plasma peaked shortly after the quercetin concentration 
peak. This suggests that both quercetin glucosides are methylated into isorhamnetin 
immediately after absorption. Methylation of the catechol group of quercetin produces 
isorhamnetin and it is catalyzed by the enzyme catechol-O-methyltransferase in the 
liver (Zhu et al. 1994). In quercetin-4'-glucoside the 4' position is occupied by a 
glucose and thus there is no catechol group available for methylation. Deglucosylation 
of the 4'-glucoside is needed to release the catechol group. Because the time to reach 
peak concentrations of isorhamnetin after intake of the 3-glucoside was the same as 
after intake of the 4'-glucoside this could imply that deglucosylation of the 4'-glucoside 
is not rate limiting for isorhamnetin formation. Furthermore, isorhamnetin is not an 
important final metabolite of quercetin because only 0.6% of the ingested quercetin 
glucosides was excreted in urine as isorhamnetin. 
This study shows that it might be possible to increase or decrease bioavailability of 
quercetin, and maybe of other components in foods and of drugs, by attaching or 
detaching a glucose molecule. Specifically, treatment of the poorly absorbed 
quercetin-3-rutinoside from tea with rhamnosidase would transform it into the highly 
bioavailable quercetin-3-glucoside. Recent research has reinforced the evidence for 
an inverse association between the intake of flavonoids and death from coronary 
heart disease (Yochum et al. 1999). If intake of quercetin and related flavonols can 
indeed be proven to reduce coronary heart disease risk, then production of foods with 
a more highly bioavailable form of quercetin might become a realistic proposition. 
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Chlorogenic acid and caffeic acid are absorbed in humans 
Margreet R. OKhof, Peter C.H. Hollman, Martijn B. Katan 
Chlorogenic acid, an ester of caffeic acid and quinic acid, is a major phenolic compound in coffee; daily 
intake in coffee drinkers is 0.5-1 g. Chlorogenic acid and caffeic acid are antioxidants in vitro and might 
therefore contribute to the prevention of cardiovascular disease. However, data on the absorption of 
chlorogenic acid and caffeic acid in humans are lacking. We determined the absorption of chlorogenic 
acid and caffeic acid in a cross-over study with 4 female and 3 male healthy ileostomy subjects. In such 
subjects, degradation by the colonic microflora is minimal and absorption can be calculated as the 
amount ingested minus the amount excreted in ileostomy effluent. The ileostomy subjects ingested 2.8 
mmol chlorogenic acid and 2.8 mmol caffeic acid on separate days in random order and subsequently 
collected ileostomy fluid and urine for 24 h. Absorption of chlorogenic acid was 33 ± 17% (mean ± SD) 
and of caffeic acid 95 ± 4%. Traces of the ingested chlorogenic acid and 11 % of the ingested caffeic 
acid were excreted in urine. Thus, one-third of chlorogenic acid and almost all of the caffeic acid were 
absorbed in the small intestine of humans. This implies that part of chlorogenic acid from foods will 
enter into the blood circulation, but most will reach the colon. 
Journal of Nutrition; 131; 66-71,2001 
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INTRODUCTION 
Phenolic compounds form a substantial part of plant foods. Most of these phenolic 
compounds are antioxidants in vitro (Rice-Evans et al. 1996) and antioxidants might 
protect against cardiovascular disease. 
A major class of phenolic compounds are hydroxycinnamic acids, which are found in 
almost every plant (Herrmann 1976, Kuhnau 1976). The major representative of 
hydroxycinnamic acids is caffeic acid, which occurs in foods mainly as an ester with 
quinic acid called chlorogenic acid (5-caffeoylquinic acid) (Figure 3.1). Coffee is a 
major source of chlorogenic acid in the human diet; daily intake in coffee drinkers is 
0.5-1 g, coffee abstainers will usually ingest <100 mg/d. Other dietary sources of 
chlorogenic acid include apples, pears, berries, artichoke, eggplant (Clifford 1999). 
Knowledge concerning the absorption of chlorogenic acid in humans is essential to 
evaluate possible health effects in vivo because the absorbed fraction of chlorogenic 
acid will enter into the blood circulation and thus can induce biological effects in the 
blood circulation. Furthermore, the fraction that is not absorbed will enter into the 
colon where it might have biological effects. Chlorogenic acid and caffeic acid are 
antioxidants in vitro (Castelluccio et al. 1995, Rice-Evans et al. 1996), and they might 
inhibit the formation of mutagenic and carcinogenic N-nitroso compounds because 
they are inhibitors of the N-nitrosation reaction in vitro (Kono et al. 1995). Further, 
chlorogenic acid can inhibit DNA damage in vitro (Kasai et al. 2000, Shibata et al. 
1999). Therefore, the inverse association between coffee intake and colon cancer in 
some epidemiological studies (Giovannucci 1998, Baron et al. 1994, Favero et al. 
1998, La Vecchia et al. 1989, Tavani et al. 1997) might be explained in part by the 
chlorogenic acid present in coffee. However, there are no data on absorption of 
chlorogenic acid or caffeic acid in humans. The major problem in measuring the 
absorption of chlorogenic acid and caffeic acid in humans is their bacterial 
degradation in the colon (Scheline 1968). Thus, measurement of fecal excretion of 
chlorogenic acid and caffeic acid would lead to an overestimation of the amount 
absorbed. Therefore, we determined the absorption of chlorogenic acid and caffeic 
acid in healthy ileostomy subjects, who lack a colon. Ileostomy subjects were 
successfully employed previously to determine the absorption of flavonoids (Hollman 
et al. 1995), coffee diterpenes (De Roos et al. 1998), and dietary polysaccharides 
(Englyst & Cummings 1985). 
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Figure 3.1 Structure of caffeic acid (A) and chlorogenic acid (B) 
MATERIALS AND METHODS 
Subjects 
The study was approved by the Ethical committee of the Division of Human Nutrition 
and Epidemiology. We recruited subjects by approaching volunteers who participated 
in previous studies at our division (Hollman et al. 1995, De Roos et al. 1998). 
Exclusion criteria were as follows: signs of diseases related to the gastrointestinal 
tract; resection of >50 cm of the terminal ileum; an ileostomy that did not function 
properly; use of drugs which influenced gastrointestinal transit; present illness; 
pregnancy or lactation. Four women and three men, with a mean age of 63 y (range: 
46-74 y), and a mean body mass index of 27.1 kg/m2 (range 23.3 - 34.9 kg/m2) were 
admitted to participate and signed an informed consent form. All subject had had a 
total colectomy between 7 and 27 y ago for ulcerative colitis or polyposis coli. The 
subjects were healthy, based on a medical questionnaire, normal blood values for 
hemoglobin, hematocrit and white blood cell counts, and absence of glucose and 
protein in urine. 
Study design and supplements 
Subjects followed a diet that was low in chlorogenic acid and quercetin from d 1 to 14. 
The diet was low in quercetin because one of the supplements we tested was 
quercetin-3-rutinoside. To ensure adherence to the dietary guidelines, we gave the 
subjects a list of forbidden foods and beverages. Foods were prohibited if they 
contained >15 mg/kg of quercetin or chlorogenic acid. Beverages were prohibited if 
they contained >4 mg/L of quercetin or chlorogenic acid (Clifford 1999, Hertog et al. 
1992 and 1993). Because subjects were not allowed to drink coffee and tea during the 
study, we supplied coffee and tea substitutes. The coffee substitute was an extract 
made of chicory, rye and barley ('Swiss coffee-like', Tayala AG, Birsfelden, 
Switzerland) and the tea substitute was an extract of a mixture of herbs ('droommix', 
Piramide, Veenendaal, the Netherlands). We analyzed the coffee substitute and tea 
substitute for quercetin and chlorogenic acid and the amounts were within the range 
of the dietary guidelines (results not shown). Compliance with the dietary guidelines 
was good. None of the subjects reported consumption of any foods or beverages that 
were on the list of forbidden foods and beverages during the study. Furthermore, the 
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low chlorogenic acid and caffeic acid excretion in presupplement ileostomy effluent 
confirmed that subjects adhered to the dietary guidelines (Table 3.1). 
On d 5, all subjects consumed a placebo supplement, which was 200 mL of water. On 
d 6, 10 and 14 all subjects consumed one of the following supplements in random 
order: 1000 mg (2.8 mmol) chlorogenic acid (Fluka Chemie, Buchs, Switzerland) or 
500 mg (2.8 mmol) caffeic acid (Fluka Chemie) or 220 mg (0.3 mmol) quercetine-3-
rutinoside (Rutosidum DAB; BUFA B.V., Uitgeest, The Netherlands). The placebo and 
the quercetin-3-rutinoside supplements were part of another study; these results will 
be reported elsewhere. Subjects received the supplements as a powder and were 
instructed to add 200 mL hot water and to consume the beverage within 5 minutes 
after preparation. Subjects ingested the supplements between 0700 and 0900 h at 
home, together with a light breakfast that we provided. The breakfast consisted of 
wheat bread, cheese, strawberry jam, milk and the coffee and tea substitutes: 
subjects had a free choice. After this breakfast with supplements, subjects were only 
allowed to drink water for 3 hours. 
Collection of ileostomy effluent and urine 
On d 5, 6, 10 and 14 subjects collected one sample of ileostomy effluent and urine 
just before ingestion of the supplements. After ingestion of the supplements, they 
collected ileostomy effluent and urine during 24 h. During the daytime, they changed 
the ileostomy bags every 2 h and immediately stored the bags on dry ice to minimize 
degradation of the contents by residual bacterial flora. At night, subjects had to 
change the bags as often as possible. 
Subjects collected urine in 0.5 L plastic bottles, with 0.13 g thymol (# 8167; Merck, 
Amsterdam, The Netherlands) as a preservative and stored the bottles with urine on 
dry ice immediately after voiding. We checked the completeness of urine collection by 
assessment of recovery of 270 nmol lithium in urine. It was ingested daily by the 
subjects as lithium chloride dissolved in 10 mL of tap water from 7 d before the first 
urine collection. Lithium chloride is completely absorbed and 95% is excreted in urine 
(Sanchez-Castillo et al. 1987a and 1987b). Urinary recovery of lithium was 94 ± 12% 
(mean ± SD), indicating good compliance in collecting urine. 
Sample preparation 
The ileostomy bags were kept frozen with liquid nitrogen during separation of the 
plastic bags from the contents. The frozen contents were freeze-dried, ground to pass 
through an 0.5-mm sieve and stored at -20°C until analysis. We thawed the urine 
bottles in a water bath of ~40°C, pooled and mixed urine per subject and per 
supplement day, froze aliquots of urine in liquid nitrogen and stored the urine samples 
at -80°C until analysis. We prepared the samples collected before breakfast 
(presupplement sample) and the final collection at the end of the 24-h collection 
period (final sample) separately. 
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Incubation of chlorogenic acid and caffeic acid with gastrointestinal fluids 
To check for degradation of chlorogenic acid and caffeic acid in gastrointestinal fluids, 
we incubated them in vitro in gastric juice and duodenal fluid, and ex vivo in ileostomy 
fluid. We incubated 30 mg of chlorogenic acid and 15 mg of caffeic acid with 3 mL 
human gastric juice and 9 mL of water at 37°C for 0.5 and 2 h (Roxburgh et al. 1992, 
Jebbink et al. 1992). Similar amounts were incubated with 3 mL human duodenal fluid 
and 9 mL water at 37°C for 1 and 4 h, corresponding to the average and maximal 
transit time in the small intestine (Layer et al. 1990, Malagelada et al. 1984). Gastric 
juice and duodenal fluid were obtained from two fasted healthy volunteers with a 
colon and stored at -20°C. 
We also studied the stability of chlorogenic acid and caffeic acid ex vivo during 
collection of ileostomy fluid and during sample preparation in the laboratory. For this 
purpose, two ileostomy subjects, who also participated in this study, followed a diet 
low in chlorogenic acid and quercetin for 4 d. On d 4, they applied three ileostomy 
bags in total, one bag with 300 mg chlorogenic acid mixed with ~5 g of strawberry jam 
and one with 150 mg caffeic acid mixed with 5 g of strawberry jam and one bag with 5 
g of strawberry jam only. Strawberry jam was used as a vehicle for chlorogenic acid 
and caffeic acid powder. Strawberry jam itself does not contain chlorogenic acid or 
caffeic acid. The subjects allowed ileostomy fluid to drain into the bag for ~2 h and 
kneaded the contents regularly. The ileostomy fluids were stored and analyzed as 
described. 
Analysis of chlorogenic acid and caffeic acid in ileostomy effluent and urine 
Chlorogenic acid and caffeic acid in ileostomy effluent were extracted simultaneously 
by mixing 0.500 g freeze-dried effluent with 25 mL 40% (v/v) aqueous methanol 
containing 2 g terf-butylhydroxyquinone/L. The effluent extract was refluxed at 90 °C 
for 1 h with regular swirling, allowed to cool down and subsequently brought to 50 mL 
with methanol. The effluent extract was then sonicated for 5 min and filtered through a 
0.45 urn filter for organic solvents (Acrodisc CR PTFE; German Sciences, Ann Arbor, 
Ml) before HPLC injection. For HPLC analysis, we injected 20 nL of the effluent 
extract onto an Inertsil ODS-2 (GL Siences, Tokyo, Japan) column (4.6 x 150 mm, 5 
urn particle size) protected by an MPLC Newguard RP-18 (Brownlee; Applied 
Biosystems Inc, San Jose, CA) column (3.2 x 15 mm, 7 urn particle size) using 
acetonitrile /0.025 mol/L phosphate buffer, pH 2.4 (8:92) as the mobile phase, at a 
flow rate of 1 mL/min. The columns were placed in a column oven set at 40°C. 
Ultraviolet absorption was measured at 325 nm. Excretion of chlorogenic acid was 
calculated as the sum of the excretion of 3-caffeoylquinic acid, 4-caffeoylquinic acid 
and 5-caffeoylquinic acid in ileostomy effluent (Figure 3.2). Isomers of chlorogenic 
acid were produced by incubation of a solution of 5-caffeoylquinic acid (pH 8) at 
100°C for 30 min (Trugo & Macrae 1984). 
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The limit of detection, i.e. the concentration producing a peak height three times the 
standard deviation of the baseline noise, was 3 ng/g freeze-dried ileostomy effluent. 
For'analysis of caffeic acid in urine, urine was treated with p-glucuronidase/sulfatase 
before analysis. For analysis of chlorogenic acid in urine, urine was not treated with (3-
glucuronidase/sulfatase. Urine for measurement of chlorogenic acid and caffeic acid 
was acidified and brought onto an SPE extraction column. The column was eluted 
with ethyl acetate. Ethyl acetate was evaporated and acids were derivatized with 
bis(trimethylsilyl)trifluoroacetamide (BSTFA). Derivates were injected onto a capillary 
column CP-Sil-5 (Chrompack, Middelburg, The Netherlands) and separated using a 
temperature gradient. On-line mass spectrometry was used to quantify and identify 
the acids (Hollman, unpublished results). The detection limit in urine was 0.8 mg/L 
urine for chlorogenic acid and 0.4 mg/L for caffeic acid. 
Lithium was measured in undiluted, acidified urine by atomic absorption 
spectrophotometry (Anonymous 1976). 
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Figure 3.2 Chromatograms of chlorogenic acid isomers and of caffeic acid in standard mixture (A) 
and ileostomy effluent (B). Peak 1: 3-caffeoylquinic acid or 4-caffeoylquinic acid; Peak 2: 5-
caffeoylquinic acid; Peak 3 : 3-caffeoylquinic acid or 4-caffeoylquinic acid; Peak 4: caffeic acid 
RESULTS 
The HPLC method used for the determination of chlorogenic acid and caffeic acid in 
ileostomy fluid showed well-resolved isomer peaks. Quantification was not hampered 
by potential interferences from the sample matrix (Figure 3.2). 
Of the ingested chlorogenic acid, 67% was excreted in ileostomy fluid, whereas only 
5% of the caffeic acid was excreted (Table 3.1). Traces of the ingested chlorogenic 
acid and 11% of the ingested caffeic acid were excreted in urine (Table 3.2). 
Chlorogenic acid and caffeic acid were recovered almost completely after in vitro 
incubation in gastric juice and duodenal fluid and after ex vivo incubation in ileostomy 
fluid (Table 3.3). Thus, the amounts not excreted in ileostomy effluent were likely 
absorbed rather than degraded in the gut or in the ileostomy bag. The absorption of 
chlorogenic acid therefore equaled 100% - 67% = 33% and that of caffeic acid 95%. 
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Table 3.1 Intake of chlorogenic acid and caffeic acid and subsequent excretion in ileostomy effluent 
over 24 h in 7 subjects1 
Supplement 
Chlorogenic acid5 
Caffeic acid 
Intake 
1000 
500 
Presupplement 
sample2 
2.3 ±2.5 
0.3 ±0.6 
Excretion 
24-h 
excretion3 
667 ±165 
27 ±18 
Final 
sample4 
2.6 ± 3.8 
0.1 ±0.1 
Absorption 
% of intake 
33 ±17 
95 ± 4 
Values are mean ± SD. 
2
 Ileostomy effluent sample collected before ingestion of the supplements; amounts represent the mean 
of 6 subjects because 1 subject did not collect the presupplement ileostomy effluent. 
3
 Includes the final but not the presupplement sample. 
4
 Ileostomy effluent sample collected at the end of the 24-h collection period. 
5
 Excretion of chlorogenic acid was calculated as the sum of the excretion of 3-caffeoylquinic acid, 4-
caffeoylquinic acid and 5-caffeoylquinic acid in ileostomy effluent. 
Table 3.2 Intake of chlorogenic acid and caffeic acid and subsequent mean excretion of chlorogenic 
acid and caffeic acid in urine over 24 h in 7 subjects1 
24-hour excretion 
Supplement intake Caffeic acid Chlorogenic acid 
mg 
Chlorogenic acid 1000 1.7 ±0.8 2.9 ±1.5 
Caffeic acid 500 53.4 ±14.1 ND 
Values are mean ± SD; ND, not detected. 
2
 Excretion of chlorogenic acid was calculated as the excretion of 5-caffeoylquinic acid. 3-caffeoylquinic 
acid and 4-caffeoylquinic acid were not present in large amounts in urine. 
Table 3.3 Stability of chlorogenic acid and caffeic acid expressed as the percentage recovered after 
incubation with human gastric juice or duodenal fluid in vitro, or with ileostomy effluent ex vivo. 
Gastric juice' Duodenal fluid1 
Supplement 0.5 h 2h 
Incubation period 
1 h 4h 
Ileostomy effluent* 
2h 
Chlorogenic acid 101 99 
% 
95 99 98 (97-98) 
Caffeic acid 98 101 97 93 97 (96-98) 
mean of duplicate analyses 
2
 mean (range) of recoveries in ileostomy bags on the bodies of 2 subjects. 
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DISCUSSION 
A maximum of 33% of the ingested chlorogenic acid and 95% of the ingested caffeic 
acid was absorbed from the small intestine in humans. Traces of chlorogenic acid in 
urine were recovered after ingestion of chlorogenic acid, whereas 11% of caffeic acid 
in urine was recovered after ingestion of caffeic acid. This indicates that at least some 
of the chlorogenic acid was absorbed intact. Indications that caffeic acid and 
chlorogenic acid are absorbed in the small intestine were also found in a rat intestine 
perfusion model (Spencer et al. 1999). However, because the recovery in urine was 
not nearly complete, chlorogenic acid and caffeic acid are probably metabolized 
extensively into other compounds after absorption. Unfortunately, data on metabolism 
of chlorogenic acid and caffeic acid in the human body are scarce. 
Validity of ileostomy model 
We measured absorption as the difference between the amount of supplement 
ingested and the amount excreted in ileostomy fluid in subjects without a colon. 
Absorption of nutrients in the small intestine of ileostomy subjects is probably not 
affected by the lack of the colon (Christl & Scheppach 1997), as indicated by their 
normal serum cholesterol concentrations (Ellegard & Bosaeus 1991), normal 
absorption of para-aminobenzoic acid (Hollman et al. 1995), and of lithium in this 
study (Sanchez-Castillo et al. 1987a and 1987b). 
It is unlikely that appreciable amounts of chlorogenic acid or caffeic acid disappeared 
through degradation in the gastric juice, duodenal fluid, in the ileostomy bag or during 
analysis on the laboratory because chlorogenic acid and caffeic acid were recovered 
completely after in vitro and ex vivo incubations in gastrointestinal fluids (Table 3.3). 
However, we cannot exclude that part of the supplements were lost somewhere in the 
gastrointestinal tract; therefore, the absorption values we found in this study should be 
regarded as maximum absorption values rather than as fixed absorption values. In 
subjects with a colon absorption of dietary phenolic compounds and their metabolites 
in the colon is possible. Therefore, in subjects with a colon caffeic acid in urine might 
originate from dietary chlorogenic acid. 
Collection of ileostomy effluent 
The amounts of caffeic acid and chlorogenic acid that were not recovered in ileostomy 
effluent cannot be explained by loss of ileostomy effluent. None of the subjects 
reported loss of ileostomy effluent during the 24-h collection periods, and the 9-11 
ileostomy bags that subjects collected during 24 h also indicated that they had 
collected all ileostomy effluent. Therefore we conclude that collection of ileostomy 
effluent was complete. 
The subjects in this study collected ileostomy effluent for 24 h, which should be long 
enough to detect all nonabsorbed supplement in ileostomy effluent because the mean 
44 
ABSORPTION OF CHLOROGENIC ACID AND CAFFEIC ACID 
transit time through the stomach and small intestine is ~8-11h (Fallingborg et al. 1989 
and 1990). This was also supported by the fact that the amount of chlorogenic acid 
and caffeic acid excreted in the final collection of ileostomy effluent at the end of the 
24-h period was similar to that in the presupplement collection (Table 3.1). 
Furthermore, the recovery of 84 ± 19 % (mean ± SD) of quercetin in ileostomy effluent 
during 24 hours after ingestion of quercetin-3-rutinoside in this study was similar to the 
recovery during the first 13 h in a previous study (Hollman et al. 1995). 
Comparison with previous studies 
We found that the absorption of caffeic acid esterified with quinic acid (chlorogenic 
acid) is three times lower than that of caffeic acid itself. To our knowledge, there are 
no previous quantitative data on absorption of chlorogenic acid and caffeic acid in 
humans. The studies that were done on absorption of chlorogenic acid and caffeic 
acid measured the recoveries of these compounds and their metabolites in urine of 
rats (Booth et al. 1957, Camarasa et al. 1988). 
We recovered 0.3% of chlorogenic acid in urine after ingestion. After ingestion of 
chlorogenic acid by rats, no chlorogenic acid was found in urine (Choudhury et al. 
1999). We recovered 11% of caffeic acid in urine after ingestion, which was 
comparable to the recovery of 13% found by Camarasa (1988) after ingestion of 
caffeic acid in rats. After intravenous injection of chlorogenic acid and caffeic acid in 
rats, only 9% of chlorogenic acid and 26% of caffeic acid were recovered in urine 
(Choudhury et al. 1999). This indicates that the fraction of chlorogenic acid and of 
caffeic acid that is absorbed is metabolized extensively in the body and therefore only 
small amounts are recovered in urine. 
Mechanisms of absorption 
The absorption of caffeic acid esterified with quinic acid (chlorogenic acid) was less 
than that of caffeic acid itself. It is possible that chlorogenic acid and caffeic acid are 
absorbed through different absorption mechanisms. We can envisage two 
mechanisms for the absorption of chlorogenic acid in humans. The first mechanism 
might involve absorption of chlorogenic acid as an intact molecule as indicated by the 
presence of traces of chlorogenic acid in urine after ingestion of chlorogenic acid in 
our study. We probably only found traces of the absorbed chlorogenic acid in urine 
because chlorogenic acid is metabolized intensively after absorption (Choudhury et al. 
1999). The second mechanism might involve hydrolysis of chlorogenic acid in the 
stomach and/or small intestine into caffeic acid and quinic acid before absorption. The 
caffeic acid moiety and the quinic acid moiety are subsequently absorbed (Czok et al. 
1974, Westendorf & Czok 1978). If this mechanism plays a role in the absorption of 
chlorogenic acid, we would expect to find caffeic acid in urine as we found after intake 
of the caffeic acid supplement. If we assume that the absorption of chlorogenic acid is 
33% and the amount of caffeic acid in urine after ingestion of caffeic acid is 11% then 
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we would expect to recover ~4% of chlorogenic acid in urine as caffeic acid. However, 
we found only 0.3% of chlorogenic acid as caffeic acid in urine after ingestion of 
chlorogenic acid, which is ~10 times lower than we expected. This indicates that 
hydrolysis of chlorogenic acid in the stomach or small intestine is not very important. 
This is also supported by the fact that we found a large amount of the ingested 
chlorogenic acid unchanged in ileostomy effluent. Thus, this second mechanism likely 
does not play an important role in the absorption of chlorogenic acid. Therefore, we 
propose that in ileostomy subjects most of the absorbed chlorogenic acid is absorbed 
intact and is metabolized extensively in the liver. 
Caffeic acid is probably absorbed through different absorption mechanisms than 
chlorogenic acid. We can envisage two mechanisms for the absorption of caffeic acid 
in humans. The first mechanism for absorption of caffeic acid might involve passive 
absorption of caffeic acid in the stomach. This is supported by the fact that caffeic 
acid and the structurally related compound cinnamic acid were rapidly absorbed in 
rats (Fahelbum & James 1977). Further, in the acid environment of the stomach, 
caffeic acid will be primarily in the nonionic form, which can be absorbed by passive 
nonionic diffusion. Passive absorption in the small intestine is not very likely because 
at a pH of -7 in the small intestine, caffeic acid will be mainly in the ionic form, which 
is difficult to absorb by passive diffusion (Wolffram et al. 1995). The second 
mechanism for absorption of caffeic acid might involve absorption by an active 
transport mechanism in the small intestine. Results from in vitro studies indicate that 
in the small intestine, an active Na+-dependent transport mechanism might be 
involved in the absorption of cinnamic acids such as caffeic acid (Ader et al. 1996, 
Wolffram et al. 1995). Both mechanisms, passive absorption in the stomach and 
active absorption in the small intestine, might play a role in the absorption of caffeic 
acid in humans. 
Chlorogenic acid, caffeic acid and health 
The absorbed fraction of chlorogenic acid and caffeic acid and its metabolites might 
induce biological effects in the blood circulation. Chlorogenic acid and caffeic acid 
inhibit oxidation of Low Density Lipoproteins in vitro (Laranjinha et al. 1994, Nardini et 
al. 1995) and might therefore protect against cardiovascular disease. There are no in 
vivo data available that show that chlorogenic acid is present in the blood circulation 
after ingestion, but caffeic acid is present in blood after ingestion by rats (Camarasa et 
al. 1988). In our human study we did find chlorogenic acid and caffeic acid in urine, 
which also suggests that a small part will be present as such in blood. We did not 
measure chlorogenic acid and caffeic acid in blood because we did not have an 
available method of analysis. 
The fraction of chlorogenic acid that escapes absorption is present throughout the 
whole gastrointestinal tract, where it might induce biological effects. Chlorogenic acid 
and caffeic acid are antioxidants in vitro (Castelluccio et al. 1995, Rice-Evans et al. 
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1996), and they might inhibit the formation of mutagenic and carcinogenic N-nitroso 
compounds (Kono et al. 1995). Further, chlorogenic acid can inhibit DNA damage in 
vitro (Kasai et al. 2000, Shibata et al. 1999). Therefore, chlorogenic acid, the major 
phenolic compound in coffee, might be involved in the inverse association between 
coffee consumption and colon cancer that was found by some epidemiological studies 
(Baron et al. 1994, Favero et al. 1998, Giovannucci 1998, La Vecchia et al. 1989, 
Tavani et al. 1997), but not all (Baron et al. 1997). Thus the one-third of ingested 
chlorogenic acid that is absorbed could have biological effects in the blood circulation, 
and the fraction of chlorogenic acid that is not absorbed could have biological effects 
in the colon in humans. 
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50 
Metabolism of chlorogenic acid, quercetin-3-rutinoside and 
black tea phenols in humans 
Margreet R. OKhof, Peter C. Hollman, Johan M.M. van Amelsvoort, Martijn B. Katan 
Dietary phenols are antioxidants and their consumption might contribute to the prevention of 
cardiovascular disease. Coffee and tea are major dietary sources of phenols. Dietary phenols are 
extensively metabolized in the body. Lack of quantitative data on their metabolites hinders a proper 
evaluation of the potential biological effects of dietary phenols in vivo. We identified and quantified 
phenolic acid metabolites in urine of twenty healthy humans with an intact colon after they had ingested 
chlorogenic acid (major phenol in coffee), quercetin-3-rutinoside (major flavonol in tea) and black tea 
phenols. Half of the ingested chlorogenic acid and 43% of the tea phenols were metabolized into 
hippuric acid, but quercetin-3-rutinoside was mainly metabolized into phenylacetic acids: 3-
hydroxyphenylacetic acid (40%), 3-methoxy-4-hydroxyphenylacetic acid (9%) and 3,4-
dihydroxyphenylacetic acid (6%). In contrast, in seven humans without a colon we found only traces of 
phenolic acid metabolites after they had ingested chlorogenic acid and quercetin-3-rutinoside. This 
implies that the colonic microflora converts most of these dietary phenols into metabolites which then 
reach the circulation. Metabolites of phenols have lower antioxidant activity than their parent 
compounds, therefore the contribution of dietary phenols to the antioxidant activity in vivo is probably 
lower than expected from in vitro tests. 
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CHAPTER 4 
INTRODUCTION 
Dietary phenols are antioxidants in vitro, and might therefore contribute to the 
prevention of cardiovascular disease (Hollman et al. 1999a, Halliwell 1994). Two 
important groups of phenols in foods are flavonoids and cinnamic acids. Major 
flavonoids in foods are flavonols, flavones and catechins. The intake of flavonols and 
flavones from foods in The Netherlands is about 23 mg/day, of which 16 mg/day is 
quercetin (Hertog et al. 1993a) and the intake of monomeric catechins is 50 mg/day 
(Figure 4.1) (Arts et al. 2001). Tea is an important dietary source of flavonoids: 1 L of 
strong tea can provide about 0.5 g of phenols, of which a large part consists of 
polymerized flavonoids (mainly catechins) such as theaflavins and thearubigins 
(Figure 4.1) (Balentine et al. 1997). In The Netherlands, tea provides almost 50% of 
the daily intake of flavonols and flavones (Hertog et al. 1993a) and 55% of the daily 
intake of monomeric catechins (Arts et al. 1999). 
The major representative of dietary cinnamic acids is caffeic acid. In foods caffeic acid 
is mainly conjugated with quinic acid, which yields chlorogenic acid (5-caffeoylquinic 
acid) (Figure 4.1). Coffee is the major source of dietary chlorogenic acid: 1 L of coffee 
provides 500-800 mg of chlorogenic acid, which corresponds with about 250-400 mg 
of caffeic acid (Clifford 1999). Coffee consumption provides up to 90% of the daily 
intake of cinnamic acids, mainly caffeic acid: coffee drinkers ingest about 0.5 - 1 g 
cinnamic acids/day, whereas coffee abstainers ingest not more than 100 mg/day 
(Radtke et al. 1998, Clifford 1999). 
HO 
quinic acid 
/ \ \ 
-OH 
| 0 H 
OH caffeic acid OH 
B 
HO. 
Figure 4.1 Chemical structures of chlorogenic acid (A), monomeric catechin (B), quercetin-3-
rutinoside (C), theaflavin (D) 
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Dietary phenols are antioxidants and they can protect Low Density Lipoprotein (LDL) 
cholesterol from oxidation in vitro (de Whalley et al. 1990, Meyer et al. 1998, Nardini et 
al. 1995, Natella et al. 1999). Oxidized LDL might play a role in the pathogenesis of 
atherosclerosis and it might therefore be associated with an increased risk for 
cardiovascular disease (Heinecke 1998, Witztum 1998, Steinberg 1997). However, the 
relationship between intake of flavonoids and cardiovascular disease in 
epidemiological studies is inconclusive (Geleijnse et al. 1999, Hertog et al. 1993b, 
1995 and 1997, Yochum et al. 1999, Keli et al. 1996, Knekt et al. 1996 and 2000, 
Rimmetal. 1996). 
Thus, dietary phenols are strong antioxidants in vitro (Rice-Evans et al. 1996), but 
their contribution to the antioxidant defense in vivo is uncertain. One reason for this 
uncertainty is that dietary phenols are extensively metabolized in the body into 
unknown compounds. As an example, only 1-2% of ingested phenols is excreted 
intact in urine (Hollman & Katan 1998). If metabolism of phenols occurs before they 
can reach the circulation and act as antioxidants, then in vitro tests of antioxidant 
activity might be less relevant to the in vivo situation. Therefore it is important to 
identify the circulating metabolites of phenols and the site where they are produced. 
These metabolites might actually have antioxidant activity in vivo, although most of the 
metabolic reactions reduce the antioxidant activity of the parent phenol (Pietta et al. 
2000, Rice-Evans et al. 1996, Manach et al. 1998, Morand et al. 1998). In the liver and 
kidney the hydroxyl groups of phenols are conjugated with glucuronic acid or sulfate, 
or a carboxyl group is esterified with glycine to increase water solubility. In addition, 
hydroxyl groups of phenols can be O-methylated, and oxidation of the side chain may 
occur. The colon bacteria can deconjugate phenols, cleave the rings, and remove 
hydroxyl and methyl groups (Scheline 1978b). Knowledge about the metabolites of 
dietary phenols is thus crucial, because the in vivo biological activity of the circulating 
metabolites of dietary phenols might be different from that of the dietary phenols 
themselves. 
There are only few data on the metabolism of dietary phenols in humans. Together 
with data from animal and in vitro studies all these studies indicate that dietary 
phenols are metabolized mainly into phenolic acids, or into even smaller compounds 
(Hollman & Katan 1998). However, no controlled dietary trial in humans has been 
done to identify and quantify the profile of phenolic acid metabolites after ingestion of 
important dietary phenols. Furthermore, data on the site of metabolism in humans are 
also scarce. 
Therefore, we studied in humans the potential phenolic acid metabolites of 3 major 
dietary phenols: chlorogenic acid, quercetin-3-rutinoside, and black tea phenols which 
consist of mainly catechins (Figure 4.1). These phenols are important dietary phenols 
and are stronger antioxidants in vitro than antioxidant vitamins (Rice-Evans et al. 
1996, Williamson et al. 1999). For this purpose Hollman et al. (P.C.H. Hollman et al, 
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manuscript in preparation) developed a method to measure 59 phenolic acids in urine. 
Furthermore we investigated the site of metabolism of dietary phenols by comparing 
the metabolites formed in volunteers with an intact colon with those formed in 
volunteers who lack a colon (ileostomy subjects). 
SUBJECTS AND METHODS 
Subjects 
Subjects with a colon 
Ten women and ten men with a mean (±SD) age of 24 ± 8 y and a mean body mass 
index of 22.2 ± 2.5 kg/m2 participated. They were healthy as judged by a medical 
questionnaire; normal blood values for hemoglobin, hematocrit and white blood cell 
counts; and absence of glucose and protein in urine. They were not allowed to take 
any drugs or other supplements during the study, except for acetaminophen 
(paracetamol) and oral contraceptives. The study was fully explained to the subjects 
and they gave their written informed consent. 
Subjects without a colon (ileostomy subjects) 
Four women and three men, with a mean (± SD) age of 63 ± 10 y, and a mean body 
mass index of 27.1 ± 3.8 kg/m2 were admitted to participate (Olthof et al. 2001a). All 
subject had had a total colectomy between 7 and 27 years ago for ulcerative colitis or 
polyposis coli. Exclusion criteria were as follows: signs of diseases related to the 
gastrointestinal tract; resection of more than 50 cm of the terminal ileum; an ileostomy 
that did not function properly; use of drugs which influenced gastrointestinal transit; 
present illness; pregnancy or lactation. They were healthy as judged by a medical 
questionnaire; normal blood values for hemoglobin, hematocrit and white blood cell 
counts; and absence of glucose and protein in urine. The study was fully explained to 
the subjects and they gave their written informed consent. 
Methods 
Subjects with a colon 
The study in subjects with a colon was approved by the Medical Ethical Committee 
(Wageningen University). Throughout the 4-weeks cross-over study subjects 
consumed a controlled diet low in phenols which was largely provided by us. In 
addition to the diet subjects ingested 4 supplements, each for 1 week in random order. 
We had a menu cycle of 7 days, so that the menu on the day that blood and urine 
were collected in each supplement week (i.e. day 7) was always the same, as were 
the other days (i.e. days 1-6) in each of the four supplement weeks. To achieve the 
diet low in phenols, we supplied the subjects daily with foods low in phenols, which 
provided 90% of the energy required to maintain body weight. The remaining 10% of 
energy was chosen by the subjects from a list of food items low in phenols. Foods 
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were considered low in phenols if they contained <15 mg quercetin or chlorogenic 
acid/kg, and beverages if they contained <4 mg quercetin or chlorogenic acid/L 
(Clifford 1999, Hertog et al. 1992 and 1993c). Because coffee and tea consumption 
were not allowed we provided the volunteers with the following substitutes: for coffee, 
an extract made of chicory, rye and barley (Swiss coffee-like; Tayala AG, Birsfelden, 
Switzerland) and for tea, tea bags containing a mix of herbs (droommix; Piramide, 
Veenendaal, The Netherlands) or tea bags containing stinging nettle (Jacob Hooy, 
Limmen, The Netherlands). Chemical analyses of these coffee and tea substitutes 
showed that the amounts of chlorogenic acid and flavonols such as quercetin were 
within the allowed ranges, as described before. 
In addition to the diet subjects ingested each day one of the following supplements 
(Figure 4.1): 2 g (5.5 mmol) of chlorogenic acid (Fluka Chemie AG, Buchs, 
Switzerland), or 4 g of black tea solids (LN-0173-02, kindly provided by Unilever 
Research Vlaardingen, The Netherlands), or 440 mg (0.7 mmol) of quercetin-3-
rutinoside (Rutosidum DAB, BUFA B.V., Uitgeest, The Netherlands), or 0.5 g of citric 
acid as placebo (AC Citricum; Fagron, Nieuwerkerk a/d Ussel, The Netherlands). The 
2 g of chlorogenic acid corresponds with the amount of chlorogenic acid present in 
~1.5 L of strong coffee. The 4 g of black tea solids corresponds with ~2 L of strong 
black tea. Black tea solids contain 30-40 g of polyphenols per 100 g, thus 4 g of black 
tea solids provided ~4.3 mmol polyphenols, mainly catechins (Balentine et al. 1997). 
The amount of quercetin in 440 mg quercetin-3-rutinoside corresponds with the 
amount in -13 L of black tea (Hertog et al. 1993c) and is 13 times higher than the 
daily intake of quercetin (Hertog et al. 1993a). The chlorogenic acid, quercetin-3-
rutinoside and citric acid, and half of the black tea extract (2g) were dissolved in hot 
water before ingestion. Subjects took the supplements under our supervision, just 
before the hot meal at noon. The other one-half of the black tea solids was used for 
tea preparation and consumption at home: 1 g between 0800 and 1000 (on Saturdays 
and Sundays: between 0800 and 1100), and 1 g between 1800 and 2000. The 
volunteers were urged to maintain their usual pattern of physical activity during the 
study. 
Subjects without a colon (ileostomy subjects) 
The study in volunteers without a colon was approved by the Medical Ethical 
committee (Wageningen University). The design is described in detail in Olthof et al. 
(2001a). In summary, in this 2-weeks cross-over study subjects followed a diet which 
was low in chlorogenic acid and quercetin from day 1 to day 14. To achieve this, 
subjects had to follow dietary guidelines. To ensure adherence to the dietary 
guidelines we gave the subjects a list of prohibited foods and beverages, which were 
high in phenols. Foods were considered high in phenols if they contained >15 mg 
quercetin or chlorogenic acid/kg, and beverages if they contained >4 mg quercetin or 
chlorogenic acid/L (Clifford 1999, Hertog et al. 1992 and 1993c). Because subjects 
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were not allowed to drink coffee and tea during the study we supplied the coffee and 
tea substitutes. Compliance with the dietary guidelines was good. None of the 
subjects reported that he or she consumed any foods or beverages that were on the 
list of prohibited foods and beverages during the study. 
On day 5 all subjects consumed a placebo supplement, which was 200 mL of water. 
On day 6, 10 and 14 all subjects consumed one each of the following supplements in 
random order: 1000 mg (2.8 mmol) of chlorogenic acid (Fluka Chemie AG, Buchs, 
Switzerland) or 500 mg (2.8 mmol) of caffeic acid (Fluka Chemie AG, Buchs, 
Switzerland) or 220 mg (0.3 mmol) of quercetine-3-rutinoside (Rutosidum DAB; BUFA 
B.V., Uitgeest, The Netherlands). Subjects received the supplements as a powder and 
were instructed to add 200 mL hot water and to consume the beverage within 5 
minutes after preparation. Subjects ingested the supplements between 0700 and 0900 
at home, together with a light breakfast that we provided. 
Collection of urine and blood 
Subjects with a colon 
On day 7 of each of the four supplement weeks subjects collected urine during 24 
hours. Thus each subject collected urine 4 times. Subjects collected urine in 0.5 L 
plastic bottles with 0.13 g thymol (# 8167; Merck, Amsterdam, The Netherlands) as a 
preservative and stored the bottles with urine on dry ice immediately after voiding. We 
measured the recovery of 277 nmol lithium in the 24 h urine of day 7 to check the 
completeness of urine collection. Lithium was ingested daily during the study by the 
subjects as lithium chloride dissolved in 10 mL of tap water. Lithium chloride is 
completely absorbed and 95% is excreted in urine (Sanchez-Castillo et al. 1987a, and 
1987b). Lithium was measured in undiluted, acidified urine by atomic absorption 
spectrophotometry (Anonymous 1976). Urinary recovery of lithium was 105.0 ± 9.0% 
(mean ± SD), which indicates good compliance in collecting urine. 
On day 7 of each supplement period we collected two blood samples for 
measurement of plasma homocysteine. These results are published elsewhere (Olthof 
etal. 2001b). 
Subjects without a colon 
On days 5, 6,10 and 14 subjects collected 24 h urine as described above. We took no 
blood from these subjects. 
Analyses of phenolic acids in urine 
Subjects with a colon 
We analyzed the urine samples twice: 1) without deconjugation of the phenolic acid 
metabolites and 2) after deconjugation with p-glucuronidase/arylsulfatase. Chlorogenic 
acid was measured without prior deconjugation, and it was not measured after 
deconjugation. After that, urine was acidified and brought onto a Solid Phase 
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Extraction (SPE) column. The column was eluted with ethyl acetate. Ethyl acetate was 
evaporated and acids were derivatized with bis(trimethylsilyl)trifluoroacetamide 
(BSTFA). Derivates were injected onto a capillary gas chromatography column and 
separated using a temperature gradient. On-line Mass Spectrometry was used to 
quantify and identify phenolic acids (Table 4.1). The method will be described in full 
elsewhere (P.C.H. Hollman et al, manuscript in preparation). This method for phenolic 
acid metabolites in urine was optimized to measure the following classes of 
metabolites: phenylpropionic and cinnamic acids (phenyl^: a benzene ring with a 
side chain of 3 C-atoms), phenylacetic acids (phenyl^ ) and benzoic acids (phenyl-
Ci). We could purchase standards of 59 different phenolic acids and we detected 27 
of them in the urine samples of our volunteers. Two phenolic acids were excluded 
because more than half of the samples had concentrations of these acids that were 
below the detection limit in all supplement periods, thus 25 phenolic acids were 
regarded as potential metabolites of the supplements (Table 4.1). The detection limit 
in urine was 4 mg/L urine for chlorogenic acid, 5 mg/L for hippuric acid and 0.4 mg/L 
for other phenolic acids. 
Subjects without a colon 
We analyzed the urine samples of subjects without a colon only after deconjugation 
with p-glucuronidase/arylsulfatase as described above (Table 4.2), except for 
chlorogenic acid which was measured without prior deconjugation. Of the 27 phenolic 
acids that were detected in urine of subjects without a colon 10 phenolic acids were 
excluded because more than half of the samples had concentrations of these acids 
that were below the detection limit in all supplement periods. Thus 17 phenolic acids 
were regarded as potential metabolites of the supplements. 
Statistical analyses 
For each subject, we calculated the excretion of each of the phenolic acids after each 
of the three treatments minus its excretion after the placebo. Statistical significance 
and 95% confidence intervals of the mean differences were calculated using Student's 
f test. We chose to use a one-sided significance level because we reasoned that rises 
in the excretion of phenolic acids on placebo relative to the phenol supplements must 
be spurious. Further, because we tested several phenolic acids as potential 
metabolites (multiple testing) we decided to use an alpha of 0.001 for statistical testing 
in order to distinguish genuine metabolites of dietary phenols from compounds that 
were present by accident. To indicate possible other (quantitatively less important) 
metabolites we reported p-values between 0.01 and 0.001 separately (one-sided) 
(Tables 4.1 and 4.2). Statistical analyses were done with SAS (SAS Institute Inc, Cary, 
USA). 
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RESULTS 
Volunteers with a colon 
Hippuric acid (N-benzoylglycine) was the major metabolite of chlorogenic acid and of 
phenols from tea (Table 4.1 and 4.3). Additional phenyl-Ci and phenyl-C3 metabolites 
were formed after chlorogenic acid and after black tea supplementation, but their 
amounts were small. No hippuric acid or other phenolic acids of the phenyl-Ci group 
and the pheny l ^ group were formed after quercetin-3-rutinoside. Phenylacetic acids 
(phenyl-C2 metabolites) were the major metabolites of quercetin-3-rutinoside (Tables 
4.1 and 4.3). 
Almost all of the chlorogenic acid ingested was recovered in urine as hippuric acid if 
we assume that only the caffeic acid moiety of chlorogenic acid yields hippuric acid. 
However, the quinic acid moiety of chlorogenic acid might also be metabolized into 
hippuric acid in humans (Quick 1931, Adamson et al. 1970, Scheline 1978a). If we 
assume that each molecule of chlorogenic acid yields 2 molecules of hippuric acid, 
then 49.5 mol% of the ingested chlorogenic acid was recovered in urine as hippuric 
acid (Table 4.3). Of the ingested chlorogenic acid 1.7% was recovered unchanged in 
urine. We did not assess quercetin-3-rutinoside or tea phenols in urine. However, in 
other human studies less than 0.5% of ingested quercetin-3-rutinoside was recovered 
in urine in the form of as quercetin or its conjugates (Hollman et al. 1995 and 1997a), 
and about 1-6% of monomeric catechins were recovered in urine of humans after 
ingestion of green tea (Yang et al. 1998, Li et al. 2000). 
The absolute excretion of 4-hydroxyphenylacetic acid in urine was in general higher 
than that of other phenolic acids after all treatments including placebo, but excretion 
was not influenced by the supplements ingested (Table 4.1). 4-hydroxyphenylacetic 
acid is probably a metabolite of dietary phenylalanine and tyrosine (Teuchy & Van 
Sumere 1971, Booth et al. 1960). These amino acids were present to an equal extent 
in the background diet of all supplement periods. 
Treatment of the urine with p-glucuronidase and arylsulfatase enzymes before GC-MS 
analysis markedly increased the number and amounts of phenolic acids detected in 
urine (Table 4.4). This indicates that most phenolic acids were conjugated with 
glucuronic acid or sulfates. 
Volunteers without a colon 
We did not recover hippuric acid as a metabolite of chlorogenic acid in volunteers 
without a colon and we found only trace amounts of caffeic acid (3,4-
dihydroxycinnamic acid) and ferulic acid (3-methoxy-4-hydroxycinnamic acid) as 
metabolites of chlorogenic acid (Tables 4.2 and 4.3). This contrasts with the results in 
volunteers with a colon. After volunteers without a colon had ingested caffeic acid we 
recovered caffeic acid and ferulic acid as main metabolites in urine plus small 
amounts of phenyl-Ci and phenyl-C3 metabolites (Tables 4.2 and 4.3). After subjects 
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had ingested quercetin-3-rutinoside we did not find any metabolites in urine (Tables 
4.2 and 4.3). 
Table 4.1 Amount (nmol/24h; mean ± SE) of phenolic acids excreted in urine of subjects with a colon. 
Twenty subject ingested placebo, 2 g (5.5 mmol) chlorogenic acid, 440 mg (0.7 mmol) quercetin-3-
rutinoside and 4 g black tea solids (-4.3 mmol phenols) each for 7 days each. Supplements were 
ingested in random order. 
Phenolic acids in urine 
Placebo 
Supplements 
Chlorogenic acid Quercetin-3-
rutinoside 
Black tea solids 
Total phenolic acids 3300 ± 200 9300 ± 800 3800 ± 200 5300 ± 400 
Phenyl-C, metabolites 
Benzoic acid 
3-OH-benzoic acid 
4-OH-benzoic acid 
2,4-diOH-benzoic acid 
3,4-diOH-benzoic acid 
(protocatechuic acid) 
3,5-diOH-benzoic acid 
3,4,5-triOH-benzoic acid 
(gallic acid) 
3-OCH3-4-OH-benzoic 
acid (vanillic acid) 
3,5-diOCH3-4-OH-
benzoic acid (syringic 
acid) 
N-benzoylglycine 
(hippuric acid) 
N(2-OH-benzoyl)glycine 
(salicyluric acid) 
Phenyl-Cz metabolites 
Phenylacetic acid 
2-OH-phenylacetic acid 
3-OH-phenylacetic acid 
4-OH-phenylacetic acid 
3,4-diOH-phenylacetic 
acid 
3-OCH3-4-OH-
phenylacetic acid 
(homovanillic acid) 
26 ± 2 
ND 
51 
15 
25 
45 
± 4 * 
± 3 
± 2 
± 5 
ND 
96 
6.7 
2500 
5.5 
125 
8.4 
21 
180 
19 
59 
± 16 
± 0.6 
±200 
±0.6 * 
± 7 
± 0.5 * 
± 3 
+ 20 * 
± 1 
± 3 
33 
6.3 
54 
13 
44 
42 
+ 
+ 
± 
+ 
+ 
± 
ND 
114 
13.6 
8100 
9.2 
143 
8.0 
18 
180 
24 
49 
± 
± 
± 
± 
± 
+ 
+ 
+ 
+ 
+ 
3 
0.8 
4 
2 
5 
4 
16 
2.2 
800 
1.5 
10 
0.6 
2 
20 
2 
3 
r* 
± 
*** 
* 
±* 
f 
t 
r 
27 ± 
ND 
51 ± 
16 ± 
27 ± 
47 ± 
ND 
91 ± 
8.3 ± 
2700 ± 
6.2 ± 
131 ± 
8.2 ± 
259 ± 
170 ± 
52 ± 
110 ± 
2 
4 
2 
2 
4 
11 
1.9 
200 
1.2 * 
7 
0.6 
51 " 
20 * 
6 ** 
15 ** 
32 
6.6 
56 
15 
31 
48 
15 
83 
6.2 
4400 
9.7 
162 
6.5 
68 
190 
26 
63 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
t 
± 
4 
1.3 
6 
3 
3 
5 
1 
7 
0.7 
400 
1.4 
17 
0.6 
6 
20 
2 
5 
#* 
t 
V 
t 
V 
# 
Phenylhydroxyacetic acid 
(mandelic acid) 
37 ± 2 41 ± 3 38 ± 2 48 ± 6 
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Table 4.1 continued 
Supplements 
Placebo Chlorogenic acid Quercetin-3- Black tea solids 
rutinoside 
Phenolic acids in urine 
Phenyl-C3 metabolites 
3-OH-cinnamic acid 
4-OH-cinnamic acid 
3,4-diOH-cinnamic acid 
(caffeic acid) 
3-OCH3-4-OH-cinnamic 
acid (ferulic acid) 
3,5-diOCH3-4-OH-
cinnamic acid (sinapinic 
acid) 
3-(3,4-diOH-
phenyl)propionic acid 
5-caffeoylquinic acid 
(chlorogenic acid) 
ND 
3.5 ± 0.3 * 
ND 
30 ± 3 
2.8 ± 0.5 * 
ND 
ND 
20 ± 
4.2 ± 
56 ± 
75 ± 
ND 
97 ± 
100 ± 
3 
0.5 
8 
6 
16 
20 
f 
# 
*** 
*** 
ND 
ND 
ND 
30 ± 3 
2.6 ± 0.5 * 
ND 
ND 
ND 
ND 
ND 
38 ± 4 
ND 
5 ± 1 ** 
ND 
The following phenolic acids were absent in all subjects during all supplements: 2,3-diOH-
benzoic acid; 2,6-diOH-benzoic acid; 2,3,4-triOH-benzoic acid; 2,4,6-triOH-benzoic acid; 2-
OCH3-benzoic acid; 3-OCH3-benzoic acid; 4-OCH3-benzoic acid; 2,3-diOCH3-benzoic acid; 2,4-
diOCH3-benzoic acid; 2,6-diOCH3-benzoic acid; 3,4-diOCH3-benzoic acid; 3,5-diOCH3-benzoic 
acid; 3,4,5-triOCH3-benzoic acid; 2,5-diOH-phenylacetic acid (homogentisic acid); 2-OCH3-
phenylacetic acid; 3-OCH3-phenylacetic acid; 4-OCH3-phenylacetic acid; 3,4,5-triOCH3-
phenylacetic acid; cinnamic acid; 2-OH-cinnamic acid; 2-OCH3-cinnamic acid; 3-OCH3-cinnamic 
acid; 4-OCH3-cinnamic acid; 3-(phenyl)propionic acid; 3-(2-OH-phenyl)propionic acid; 3-(4-OH-
phenyl)propionic acid; 3-(2,4-diOHphenyl)propionic acid; 3-(2-OCH3-phenyl)propionic acid; 3-
(4-OCH3-phenyl)propionic acid; 3-(3,4-diOCH3-phenyl)propionic acid; 3-(3,4,5-triOCH3-
phenyl)propionic acid; phenylaceturic acid 
The following phenolic acids were above the detection limit in less than half of the subjects after 
each supplement period and therefore they are not shown in the table: 2-OH-benzoic acid and 
2,5-OH-benzoic acid. 
ND = non-detectable; peaks had to be above the detection limit in at least half of the subjects, 
otherwise the phenolic acid is not shown in the table. 
t = peaks of 1 - 5 subjects were below detection limit or missing 
# = peaks of 6 -10 subjects were below detection limit or missing 
* = 0.001 < p< 0.01, one-sided, significantly different from placebo 
** = p < 0.001, one-sided, significantly different from placebo 
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Table 4.2 Amount (nmol/24h; mean ± SE) of phenolic acids excreted in urine in subject without a colon. 
Seven subject ingested placebo, 1 g (2.8 mmol) chlorogenic acid, 220 mg (0.3 mmol) quercetin-3-
rutinoside and 500 mg (2.8 mmol) caffeic acid on 1 day each. Supplements were ingested in random 
order. 
Supplements 
Phenolic acids in urine* 
Placebo Chlorogenic acid Quercetin-3- Caffeic acid 
rutinoside 
Total phenolic acids 
Phenyl-^ metabolites 
4-OH-benzoic acid 
3,4-diOH-benzoic acid 
(protocatechuic acid) 
3,5-diOH-benzoic acid 
3-OCH3-4-OH-benzoic acid 
(vanillic acid) 
N-benzoylglycine (hippuric 
acid) 
N(2-OH-benzoyl)glycine 
(salicyluric acid) 
Phenyl-C2 metabolites 
Phenylacetic acid 
2-OH-phenylacetic acid 
3-OH-phenylacetic acid 
4-OH-phenylacetic acid 
3,4-diOH-phenylacetic acid 
3-OCH3-4-OH-phenylacetic 
acid (homovanillic acid) 
Phenylhydroxyacetic acid 
(mandelic acid) 
Phenyl-C3 metabolites 
3,4-diOH-cinnamic acid 
(caffeic acid) 
3-OCH3-4-OH-cinnamic acid 
(ferulic acid) 
3-(3,4-diOH-phenyl)propionic 
acid 
5-caffeoylquinic acid 
(chlorogenic acid) 
1000 
7.5 
7 
9 
33 
510 
40 
18 
6.1 
8.6 
300 
6.0 
32 
8 
±200 
±2.5 
± 1 
± 1 
± 12 
±70 
±30 
± 7 
±0.6 
±0.8 
±200 
±0.8 
± 2 
± 2 
ND 
8 ± 1 
ND 
not 
measured 
± 
± 
t 
t 
t 
t 
t 
t 
1100 ± 200 
6.9 ± 0.7 
9 ± 1 
10 ± 2 
24 ± 5 
490 ± 30 
ND 
ND 
5.8 ± 0.6 
7.5 ± 0.6 
400 ± 200 
7.2 ± 0.8 
33 ± 3 
7 ± 2 
9 ± 2 
21 ± 3 
ND 
9.3 ± 1.4 
± 
± 
± 
t 
t 
t 
1100 
7.9 
9 
10 
46 
460 
30 
32 
5.9 
8.6 
400 
7.3 
33 
10 
± 300 
± 1.6 * 
± 2 
± 2 * 
± 17 
±40 
±30 * 
± 13 * 
± 0.4 
±0.5 
±200 
± 1.1 
± 3 
± 3 * 
ND 
9 ± 1 
ND 
not 
measured 
2100 
6.0 
68 
20 
141 
590 
31 
5.6 
8.4 
400 
7.0 
35 
14 
300 
361 
20 
± 
± 
± 
± 
± 
± 
ND 
± 
+ 
± 
± 
± 
± 
± 
± 
± 
± 
ND 
300 
1.2 
10 
8 
25 
70 
6 
0.3 
0.5 
300 
0.9 
2 
2 
30 
24 
3 
± 
* 
± 
t 
t 
t 
t 
The following phenolic acids were absent in all subjects during all supplements: 2,3-diOH-
benzoic acid; 2,6-diOH-benzoic acid; 2,3,4-triOH-benzoic acid; 2,4,6-triOH-benzoic acid; 2-
OCH3-benzoic acid; 3-OCH3-benzoic acid; 4-OCH3-benzoic acid; 2,3-diOCH3-benzoic acid; 
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2,4-diOCH3-benzoic acid; 2,6-diOCH3-benzoic acid; 3,4-diOCH3-benzoic acid; 3,5-diOCH3-
benzoic acid; 3,4,5-triOCH3-benzoic acid; 2,5-diOH-phenylacetic acid (homogentisic acid); 2-
OCH3-phenylacetic acid; 3-OCH3-phenylacetic acid; 4-OCH3-phenylacetic acid; 3,4,5-triOCH3-
phenylacetic acid; cinnamic acid; 2-OH-cinnamic acid; 2-OCH3-cinnamic acid; 3-OCH3-cinnamic 
acid; 4-OCH3-cinnamic acid; 3-(phenyl)propionic acid; 3-(2-OH-phenyl)propionic acid; 3-(4-OH-
phenyl)propionic acid; 3-(2,4-diOH-phenyl)propionic acid; 3-(2-OCH3-phenyl)propionic acid; 3-
(4-OCH3-phenyl)propionic acid; 3-(3,4-diOCH3-phenyl)propionic acid; 3-(3,4,5-triOCH3-
phenyl)propionic acid; phenylaceturic acid 
The following phenolic acids were above the detection limit in less than half of the subjects after 
each supplement period and therefore they are not shown in the table: benzoic acid; 2-OH-
benzoic acid; 3-OH-benzoic acid; 2,4-diOH-benzoic acid; 2,5-diOH-benzoic acid, 3,4,5-triOH-
benzoic acid; 3,5-diOCH3-4-OH-benzoic acid; 3-OH-cinnamic acid; 4-OH-cinnamic acid; 3,5-
diOCH3-4-OH-cinnamic acid. 
ND = non-detectable; peaks had to be above the detection limit in at least half of the subjects, 
otherwise the phenolic acid is not shown in the table. 
$ = peaks of 1 - 3 subjects were below detection limit or missing 
* = 0.001 < p< 0.01, one-sided, significantly different from placebo 
** = p < 0.001, one-sided, significantly different from placebo 
*** = 0.001< p< 0.01, one-sided, significantly different from caffeic acid 
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Table 4.3 Amounts of metabolites of phenols in urine as percentage (calculated on a molar basis) of the 
amount of the parent compound ingested. 20 healthy volunteers with a colon ingested chlorogenic acid 
(5.5 mmol), quercetin-3-rutinoside (0.7 mmol), black tea solids (~4.3 mmol phenols) and placebo on 7 
days each, in random order. 7 healthy volunteers without a colon ingested chlorogenic acid (2.8 mmol), 
caffeic acid (2.8 mmol) and quercetin-3-rutinoside (0.3 mmol) and placebo on 1 day each, in random 
order. 
Chloroaenic acid supplement 
• 5-caffeoylquinic acid (chlorogenic acid) 
• N-benzoylglycine (hippuric acid) 
• 3(3,4-dihydroxyphenyl)propionic acid 
• 3,4-dihydroxycinnamic acid (caffeic acid) 
• 3-methoxy-4-hydroxycinnamic acid (ferulic acid) 
• 3,4-dihydroxybenzoic acid (protocatechuic acid) 
• 3-hydroxycinnamic acid 
• Benzoic acid 
• 3-hydroxybenzoic acid 
• 3,5-dimethoxy-4-hydroxybenzoic acid (syringic 
acid) 
• 3,4-dihydroxyphenylacetic acid 
• N(2-OH-benzoyl)glycine (salicyluric acid) 
Caffeic acid supplement** 
• 3-methoxy-4-hydroxycinnamic acid (ferulic acid) 
• 3,4-dihydroxycinnamic acid (caffeic acid) 
• 3-methoxy-4-hydroxybenzoic acid (vanillic acid) 
• 3,4-dihydroxybenzoic acid (protocatechuic acid) 
• 3-(3,4-dihydroxyphenyl)propionic acid 
Quercetin-3-rutinoside supplement 
• 3-hydroxyphenylacetic acid 
• 3-methoxy-4-hydroxyphenylacetic acid 
(homovanillic acid) 
• 3,4-dihydroxyphenylacetic acid 
Black tea supplement*** 
• N-benzoylglycine (hippuric acid) 
• 3-hydroxyphenylacetic acid 
• 3,4,5-trihydroxybenzoic acid (gallic acid) 
• 3,4-dihydroxyphenylacetic acid 
• 3-hydroxybenzoic acid 
• N(2-OH-benzoyl)glycine (salicyluric acid) 
• 3-(3,4-dihydroxyphenyl)propionic acid 
Volunteers with colon 
Mean 
1.7 
49.5* 
1.7 
1 
0.8 
0.3 
0.3 
0.1 
0.1 
0.1 
0.1 
0.1 
39.7 
8.5 
5.5 
42.8 
1.1 
0.3 
0.2 
0.1 
0.1 
0.1 
95% CI 
1.0-2.4 
37.1-61.8 
1.1-2.3 
0.6-1.3 
0.6-1.0 
0.2-0.5 
0.2-0.4 
0.1-0.2 
0.1-0.1 
0.0-0.2 
0.0-0.2 
0.0-0.1 
21.9-57.4 
4.0-13.1 
3.4-7.6 
29.6-55.9 
0.8-1.4 
0.3-0.4 
0.1-0.3 
0.1-0.2 
0.1-0.2 
0.0-0.1 
Volunte* 
Mean 
0.2 
0.3 
0.5 
12.7 
10.6 
3.9 
2.2 
0.7 
;rs without colon 
95% CI 
0.1-0.4 
0.1-0.4 
0.2-0.7 
10.7-14.8 
8.0-13.2 
1.9-5.9 
1.3-3.1 
0.4-1.0 
no metabolites were 
found 
Based on the assumption that each molecule of chlorogenic acid yields 2 molecules of hippuric acid. 
For the other phenolic acids we assumed that each molecule of chlorogenic acid yields one 
molecule of the phenolic acid 
this supplement was not ingested by volunteers with a colon 
' this supplement was not ingested by volunteers without a colon 
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Table 4.4 Amount of conjugated phenolic acids as proportion of the total amount of phenolic acids. The 
total amount of phenolic acids includes the unconjugated phenolic acids and the phenolic acids 
conjugated with sulfates and/or glucuronic acid. Twenty volunteers with a colon ingested chlorogenic 
acid, quercetin-3-rutinoside, black tea solids and placebo on 7 days each, in random order. 
Position on the aromatic ring 
-OH -OCH3 
Phenyl-C, Phenyl-C2 Phenyl-C3 
(benzoic acids) (phenylacetic acids) (cinnamic acids) 
% conjugated phenolic acid 
2 
3 
4 
4 3 
4 3,5 
2,4 
3,4 
3,5 
3,4,5 
Phenylhydroxyacetic 
acid (mandelic acid) 
* 
100 
74 
79 
100 
52 
100 
45 
25 
100 
13 
13 
48 
* 
* 
74 
• 
* 
90 
* 
100 
100 
72 
* 
* 
73 
100 
* 
* We did not measure these compounds in this study 
DISCUSSION 
We found that phenols from foods are extensively metabolized in the human body. 
Further, a large part of the ingested phenols will probably never enter the peripheral 
circulation as such, because of prior metabolism. Evidently the dietary phenols that 
reach the colon are degraded there into metabolites. These are then absorbed from 
the colon and after circulation and further metabolism in the liver and kidneys they are 
excreted into urine. It is also possible that part of the ingested phenols is absorbed in 
the jejuno-ileum and returned to the gut with the bile via the enterohepatic circulation. 
Thus the colon plays an important role in the metabolism of phenols that reach the 
colon. In subjects with a colon we recovered in urine about half of ingested 
chlorogenic acid and tea phenols as hippuric acid, and about half of the quercetin-3-
rutinoside as phenylacetic acids. In contrast, in subjects without a colon we recovered 
only minor amounts of metabolites after they had ingested chlorogenic acid or 
quercetin-3-rutinoside. The fraction that we did not recover in urine was probably 
metabolized into compounds that we could not measure, or were excreted with feces. 
The difference between subjects with a colon and subjects without a colon can be 
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explained by the fact that chlorogenic acid as well as quercetin-3-rutinoside are not 
well absorbed in the small intestine and thus will become available for metabolism by 
the colonic microflora, which is absent in subjects without a colon. Indeed we found 
that 67% of the ingested chlorogenic acid was excreted unchanged with the stoma 
effluent and 84% of the ingested quercetin-3-rutinoside was excreted in the form of 
quercetin or its conjugates (Olthof et al. 2001a, Hollman et al. 1995). To our 
knowledge this is the first controlled trial that identified and quantified the main 
metabolites of 3 major dietary phenols in humans. 
Metabolism of chlorogenic acid 
The most pronounced difference in the metabolic profile of chlorogenic acid between 
volunteers with and without a colon was the absence of hippuric acid in volunteers 
without a colon (Table 4.3). After caffeic acid, again no hippuric acid was found in 
volunteers without a colon. Unfortunately we have no data on caffeic acid metabolism 
in volunteers with a colon. 
We previously found in subjects without a colon that almost all caffeic acid and about 
one-third of ingested chlorogenic acid appeared to be absorbed from the small 
intestine (Olthof et al. 2001a). Our results therefore suggest that hippuric acid arises 
from the fraction of chlorogenic acid that reaches the colon. This would mean that the 
colonic microflora is required for the metabolism of chlorogenic acid and caffeic acid 
into hippuric acid. Dehydroxylation is a main metabolic reaction that is carried out by 
the colonic microflora (Scheline 1978b, Dayman & Jepson 1969). Therefore this might 
be a limiting step in the formation of hippuric acid from chlorogenic acid and caffeic 
acid in subjects lacking the colon. 
In volunteers with a colon, two-thirds of the ingested chlorogenic acid reaches the 
colon, where the colonic microflora probably first hydrolyses chlorogenic acid into 
caffeic acid and quinic acid (Olthof et al. 2001a, Scheline 1978a, Plumb et al. 1999). 
Subsequently, the caffeic acid moiety is dehydroxylated by bacteria in the colon, and 
then to a large extent beta-oxidized into benzoic acid after absorption (Figure 4.2). 
The quinic acid moiety is dehydroxylated into cyclohexane carboxylic acid, and then 
aromatized into benzoic acid by the colonic microflora (Adamson et al. 1969 and 1970, 
Cotran et al. 1960, Indahl & Scheline 1973) or, after absorption in body tissues (Beer 
et al. 1951, Svardal & Scheline 1985). The benzoic acid formed is conjugated with 
glycine and excreted in urine as hippuric acid (Figure 4.2, Table 4.3). 
In volunteers without a colon, one-third of the ingested chlorogenic acid and almost all 
caffeic acid is absorbed from the small intestine (Olthof et al. 2001a). After chlorogenic 
acid is hydrolyzed into caffeic acid and quinic acid, the caffeic acid moiety of 
chlorogenic acid is probably beta-oxidized into benzoic acids, without prior 
dehydroxylation (Scheline 1978a, Booth et al. 1957, Azuma et al. 2000). This is 
supported by the presence of small amounts of 3,4-dihydroxybenzoic acid and 3-
methoxy-4-hydroxybenzoic acid as metabolites of caffeic acid in volunteers without a 
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colon (Table 4.3). Part of these benzoic acids might also be conjugated with glycine 
and excreted in urine as hydroxylated hippuric acids. Unfortunately, we could not 
measure the hydroxylated hippuric acid derivatives because we did not have their 
standards, except for 2-hydroxyhippuric acid that was not present (Table 4.2). The 
quinic acid moiety of chlorogenic acid is probably not aromatized into benzoic acid 
without prior dehydroxylation (Beeretal. 1951, Scheline 1978a). 
Another explanation for the fact that we did not find hippuric acid as a metabolite of 
chlorogenic acid and caffeic acid in subjects without a colon might be that subjects 
without a colon received a single dose of the phenols while subjects with a colon 
received the phenols for 7 days. It is possible that a single dose was not enough to 
produce hippuric acid. However, others (Jacobson et al. 1983, Booth et al. 1957) did 
find metabolites of a single dose of chlorogenic acid and caffeic acid which makes this 
explanation less likely. 
Dietary chlorogenic acid 
Figure 4.2 Proposed metabolic pathway of chlorogenic acid in humans (based on the results in this 
paper and (Hollman & Katan 1998)) 
Metabolism of tea phenols 
The phenols in black tea were mainly metabolized into hippuric acid (Tables 4.1 and 
4.3) which agrees with results of Clifford et al. (2000). Hippuric acid probably 
originates from catechins in tea, which are the major phenols in tea (Balentine et al. 
1997). Part of the catechins are absorbed and excreted in urine as catechin 
conjugates and as 3'-methoxycatechin (Hollman et al. 1997b, Hackett et al. 1983 and 
1985, Yang et al. 1998). Catechins that reach the colon will undergo cleavage of the 
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catechin ring into valerolactones by microorganisms in the colon (Figure 4.3). 
Valerolactones are then metabolized into phenylpropionic acids in the colon, which are 
further metabolized into benzoic acids and excreted in urine as hippuric acid (Das 
1969a, 1969b and 1971, Groenewoud & Hundt 1986, Scheline 1970). We did not 
measure the valerolactones in urine but others did find them in urine (Hollman et al. 
1997b, Li etal. 2000). 
Gallic acid (3,4,5-trihydroxybenzoic acid) was present in urine only in the tea period. It 
probably originates from gallic acid present in tea, or from its esters with catechins 
(epigallocatechin gallate, epicatechin gallate) (Aucamp et al. 2000, Hodgson et al. 
2000). We also found a small amount of 3-hydroxyphenylacetic acid as a metabolite in 
urine after intake of tea. This could be a metabolite of quercetin-3-rutinoside, a 
flavonoid which is present in small amounts in tea (Table 4.3) (Hertog et al. 1993c). 
colon 
OH OH 
• catechin • aJ^-c-^-m — • a = Q - c - @ 
3,4-dihydroxyphenyl 
valerdactone 
3-hydroxyphenyl 
valerdactooe 
phenylpropionic add 
Intestinal cell wall 
liver/kidney 3,4-dihydroxyphenyl 3-hydroxyphenyl 
valerdactone valerdactone 
OCH, 
3-methoxy-4-hydroxyphenyl 
valerdactone 
benzoic add 
I 
phenylpropionic 
' add 
Nppuricadd 
+ 
excretion in urine 
Figure 4.3 Proposed metabolic pathway of catechin in humans (based on the results in this paper 
and (Hollman & Katan 1998)) 
Metabolism of quercetin-3-rutinoside 
Quercetin-3-rutinoside is not well absorbed in the small intestine of humans and about 
83% will be transported into the colon and metabolized there (Hollman et al. 1995, 
Olthof et al. 2001a). Therefore it was not surprising that we did not find metabolites of 
quercetin-3-rutinoside in humans without a colon. In volunteers with a colon we 
recovered more than half of the ingested quercetin-3-rutinoside in humans as 
phenylacetic acids (phenyK^ acids), which agrees with results of other studies (Baba 
et al. 1981 and 1983, Sawai et al. 1987, Booth et al. 1956). Our results indicate that 
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the quercetin-3-rutinoside is probably first deglycosylated to quercetin aglycone 
(Bokkenheuser et al. 1987) and then ring cleavage of the quercetin moiety into 
phenolic acids occurs by the colonic microflora (Figure 4.4). In contrast to humans, in 
rats the metabolites of quercetin-3-rutinoside also include phenylpropionic acid 
(phenyl-C3 acids) in addition to phenylacetic acids (Baba et al. 1983, Nakagawa et al. 
1965). This might be explained by differences in the colonic microflora of rats versus 
that of humans and thereby in the sites of ring cleavage. A microorganism which is 
present in human feces that produces phenylacetic acid from quercetin is Eubacterium 
Ramulus (Schneider & Blaut 2000, Schneider et al. 1999). Our data suggest that 
phenylacetic acids are subsequently absorbed from the colon and further metabolized 
in the liver and kidneys. The main metabolic reactions that occur after absorption is 
methylation in the liver, as indicated by the presence of 3-methoxy-4-
hydroxyphenylacetic acid in urine (Tables 4.1 and 4.3) (Baba et al. 1983, Booth et al. 
1956). 
Dietary quercetin-3-rutinoside 
I 
mouth 
small intestine colon 
- ^ quercebn-3-. 
rutinoside 
quercetirv3-njtinoside 
3,4-dihydroxyphenyl-
aceticacid 
HO 
3-hydroxypnenyl-
aceticadd 
I Intestinal cell wall 
quercetin 
liver/kidney H,CO 
~s» 
3,4-dihydroxy " " 
phenylacetic add 
' 3-methoxy44iydroxy 3-hydroxyphenyl-
phenylaceticadd acetic add 
excretion in urine 
Figure 4.4 Proposed metabolic pathway of quercetin in humans (based on the results in this paper 
and (Hollman & Katan 1998)) 
Because the colonic microflora plays an important role in the metabolism of quercetin 
the metabolites of quercetin could differ between quercetin forms that are well 
absorbed in the small intestine and those that are less well absorbed. However, 50% 
of the well-absorbed quercetin forms will still reach the colon and is thus available for 
metabolism there (Hollman et al. 1995). Therefore, we expect that the amount of each 
metabolite excreted in urine might differ between various quercetin forms, but not the 
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type of metabolites. Further, more of the original quercetin reaches the circulation after 
ingestion of well-absorbed quercetin forms than after less-absorbed quercetin forms 
(Hollman et al. 1999b). However, data on the metabolites of well-absorbed quercetin 
forms, such as quercetin glucosides are as yet incomplete. 
Antioxidant activity 
Dietary phenols are strong antioxidants in vitro (Rice-Evans et al. 1996), but our data 
show that their antioxidant action in vivo is uncertain because they are extensively 
metabolized. In general, the metabolites of dietary phenols that we found have much 
lower antioxidant activity than their parent compounds, or have no antioxidant activity 
at all. Hippuric acid, the most important metabolite of chlorogenic acid and of tea 
phenols has no antioxidant activity, because it has lost its hydroxyl groups. 
Phenylacetic acids, the major metabolites of quercetin-3-rutinoside, have antioxidant 
activity in vitro that is similar to that of vitamin E, but lower than that of the parent 
compound quercetin (Rice-Evans et al. 1996, Pietta et al. 2000). 
However, because we measured the metabolites of dietary phenols in urine it is 
possible that intact phenols or intermediary metabolites actually circulate in blood and 
that these might act as antioxidants in vivo. Unfortunately we did not measure 
metabolites in blood, because we did not have an analysis method available. 
However, we hypothesize that the metabolic reactions that lower antioxidant activity of 
the parent compound occur mainly before they can reach the circulation (Figures 4.2 -
4.4). The breakdown of flavonoids and phenolic acids into smaller molecules through 
ring cleavage and beta-oxidation in the colon and the liver drastically lowers their 
antioxidant activity (Rice-Evans et al. 1996, Natella et al. 1999). Subsequently, 
phenols and their metabolites are conjugated with glucuronic acid, sulphates or 
glycine, which also lowers their antioxidant activity (Table 4.4) (Morand et al. 1998, 
Manach et al. 1998). 
Conclusion 
Dietary phenols are extensively metabolized in humans into compounds with lower 
antioxidant activity, mainly before they enter the circulation. The antioxidant activity of 
dietary phenols in vivo might thus be lower than is expected based on their in vitro 
antioxidant activity. 
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Consumption of high doses of chlorogenic acid, present in 
coffee, or of black tea increases plasma total homocysteine 
concentrations in humans 
Margreet R. Olthof, Peter C Hollman, Peter L. Zock, Martijn B. Katan 
Background: In population studies, high intakes of coffee are associated with raised concentrations of 
plasma homocysteine, a predictor of risk of cardiovascular disease. Chlorogenic acid is a major 
polyphenol in coffee; coffee drinkers consume up to 1 g chlorogenic acid/d. 
Objective: We studied whether chlorogenic acid affects plasma total homocysteine concentrations in 
humans. For comparison we also studied the effects of black tea rich in polyphenols and of quercetin-3-
rutinoside, a major flavonol in tea and apples. 
Design: In this crossover study, 20 healthy men and women ingested daily 2 g (5.5 mmol) chlorogenic 
acid, 4 g black tea solids containing ~4.3 mmol polyphenols and comparable to ~2 L strong black tea, 
440 mg (0.7 mmol) quercetin-3-rutinoside, or a placebo daily. Each subject received each of the 4 
treatments for 7 d, in random order. 
Results: Total homocysteine in plasma collected 4-5 h after supplement intake was 12% (1.2 nmol/L; 
95% CI: 0.6,1.7) higher after chlorogenic acid and 11% (1.1 (imol/L ;95% CI: 0.6, 1.5) higher after black 
tea than after placebo. Total homocysteine in fasting plasma collected 20 h after supplement intake was 
4% (0.4 nmol/L; 95% CI: 0.0, 0.8) higher after chlorogenic acid and 5% (0.5 nmol/L; 95% CI: 0.0, 0.9) 
higher after black tea than after placebo. Quercetin-3-rutinoside did not significantly affect homocysteine 
concentrations. 
Conclusions: Chlorogenic acid, a compound in coffee, and black tea raise total homocysteine 
concentrations in plasma. Chlorogenic acid could be partly responsible for the higher homocysteine 
concentrations observed in coffee drinkers. Whether these effects on homocysteine influence 
cardiovascular disease risk remains to be established. 
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INTRODUCTION 
A high homocysteine concentration in blood is a risk factor for cardiovascular disease 
(Nygard et al. 1995, Refsum et al. 1998). Epidemiologic studies suggest that coffee 
consumption might be one of the determinants of plasma homocysteine 
concentrations; plasma homocysteine concentrations in coffee drinkers are up to 
2 fxmol/L higher than those in coffee abstainers (Nygard et al. 1997, Oshaug et al. 
1998, Stolzenberg-Solomon et al. 1999). The results of both an intervention study with 
unfiltered coffee (Grubben et al. 2000) and an intervention study with filtered coffee 
(Urgert et al. 2000) support the homocysteine-raising effects of coffee. 
The compounds in coffee responsible for this effect are not known. The kahweol and 
cafestol present in only unfiltered coffee (Urgert et al. 1995) are not responsible 
because both filtered coffee and unfiltered coffee raise plasma homocysteine 
concentrations (Grubben et al. 2000, Urgert et al. 2000). One candidate compound is 
chlorogenic acid, a polyphenol that occurs in large amounts in coffee but in only small 
amounts in other foods and beverages. Another candidate is caffeine. The amounts of 
chlorogenic acid and caffeine in coffee are comparable (Clifford 1999, Viani 1988). 
No studies have been done to investigate the effect of chlorogenic acid or caffeine on 
plasma homocysteine. 
We thus studied the effect of chlorogenic acid on plasma homocysteine 
concentrations in healthy volunteers. An effect of chlorogenic acid on homocysteine 
might be mediated by metabolites of chlorogenic acid in the human body. Because 
metabolism of chlorogenic acid and other polyphenols is likely to occur via the same 
pathways, we also determined the effect on plasma homocysteine concentrations of 
polyphenols from black tea and of quercetin-3-rutinoside. Black tea is the tea most 
commonly consumed worldwide (Balentine et al. 1997) and quercetin-3-rutinoside is a 
major flavonol in tea and apples (Engelhardt et al. 1992, Herrmann 1976). 
SUBJECTS AND METHODS 
Subjects 
Ten men and 10 women with a mean (±SD) age of 24 ± 8 y and body mass index (in 
kg/m2) of 22.2 ± 2.5 participated. The subjects were healthy as judged by a medical 
questionnaire; normal blood values for hemoglobin, hematocrit and white blood cell 
counts; and absence of protein and glucose in urine. All subjects were nonsmokers. 
They were not allowed to take any drugs or other supplements during the study 
except for acetaminophen (paracetamol) and oral contraceptives. The study protocol 
was fully explained to the subjects and they gave their written, informed consent. The 
protocol was approved by the Medical Ethical Committee of the Division of Human 
Nutrition and Epidemiology. 
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Methods 
Throughout the 4-weeks study, subjects consumed a controlled diet low in 
polyphenols. To achieve this, we supplied the subjects daily with foods low in 
polyphenols that provided 90% of the energy required to maintain body weight. The 
remaining 10% of energy was chosen by the subjects from a list of food items low in 
polyphenols. Foods were considered low in polyphenols if they contained <15 mg 
quercetin or chlorogenic acid/kg; beverages were considered low in polyphenols if 
they contained <4 mg quercetin or chlorogenic acid/L (Clifford 1999, Hertog et al. 
1992 and 1993a). Because consumption of coffee and tea was not allowed, we 
provided the volunteers with the following substitutes: for coffee, an extract made of 
chicory, rye and barley (Swiss coffee-like; Tayala AG, Birsfelden, Switzerland), and for 
tea, tea bags containing a mix of herbs (droommix; Piramide, Veenendaal, 
Netherlands) or tea bags containing stinging nettle (Jacob Hooy, Limmen, 
Netherlands). Chemical analyses indicated that these substitutes contained only 
minor amounts of catechins, flavonols or chlorogenic acid. In addition to the controlled 
diet subjects ingested one of the following supplements each day: 1) 2 g (5.5 mmol) 
chlorogenic acid (Fluka Chemie AG, Buchs, Switzerland), 2) 4 g black tea solids 
(LN0173-02; kindly provided by Unilever Research Vlaardingen, Vlaardingen, 
Netherlands) with 30-40% polyphenols by weight (4 g black tea solids contains ~4.3 
mmol polyphenols, mainly catechins) (Balentine et al. 1997), 3) 440 mg (0.7 mmol) 
quercetin-3-rutinoside (Rutosidum DAB, BUFA BV, Uitgeest, Netherlands), or 4) 0.5 g 
citric acid as a placebo (AC Citricum; Fagron, Nieuwerkerk a/d Ussel, Netherlands) 
(Table 5.1). The 2 g chlorogenic acid is comparable with the amount of chlorogenic 
acid in ~1.5 L strong coffee, the 4 g black tea solids is comparable with ~2 L strong 
black tea, and the amount of quercetin in 440 mg quercetin-3-rutinoside is 
comparable with the amount in -13 L black tea (Hertog et al. 1993a) and is 13 times 
higher than the average daily intake of quercetin (Hertog et al. 1993b). Subjects 
ingested each of these 4 supplements for 1 week in random order. Before ingestion, 
the chlorogenic acid, quercetin-3-rutinoside, citric acid and one-half of the black tea 
solids (2 g) were dissolved in hot water. Subjects consumed the supplements under 
our supervision just before the hot meal at noon. The other one-half of the black tea 
solids was used for tea preparation and consumption at home: 1 g between 0800 and 
1000 (on Saturdays and Sundays, between 0800 and 1100) and 1 g between 1800 
and 2000. The volunteers were urged to maintain their usual pattern of physical 
activity during the study. 
On day 7 of each supplement period we collected 2 blood samples: 1 sample in the 
morning after subjects had fasted overnight, collected ~20 h after the last supplement 
intake, and 1 postprandial sample, collected 4-5 h after the last supplement intake. 
We chose to take a fasting blood sample to exclude interference from food 
consumption shortly before blood sampling. We chose to collect the postprandial 
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blood sample 4-5 h after supplement intake because the peak concentration of 
homocysteine after methionine loading, a precursor of homocysteine, occurs at this 
time point (Andersson et al. 1990, Ueland et al. 1993a). Because the black tea 
supplement was ingested 3 times daily, the blood sampling times after intake of the 
black tea supplement were as follows: the fasting sample in the morning was collected 
~12 h after the intake of the 1-g dose of black tea solids and ~20 h after the intake of 
the 2-g dose on the previous day and the postprandial blood sample was collected 4-
5 h after intake of 2-g dose of black tea solids at 1200. Blood was collected into 
vacuum tubes (Venoject II; Terumo Europe NV, Leuven, Belgium) containing EDTA. 
Blood samples were immediately placed on ice and within 1 h were centrifuged at 
2500 x g for 10 min at 4°C to obtain plasma. Plasma was separated and stored at 
-80°C. We also collected urine for the measurement of polyphenol^ metabolites; 
these results will be published elsewhere. 
Total homocysteine concentrations were measured by HPLC with fluorometric 
detection (Ubbink et al. 1991, Ueland et al. 1993b). The interassay CV of the 
homocysteine assay was <8%. Folate and vitamin B-12 concentrations were 
measured with ion-capture IMx (Abbott Laboratories, Abort Park, IL) (Wilson et al. 
1995, Kuemmerle et al. 1992). The interassay CV of the folate assay was <12% and 
that of the vitamin B-12 assay was <7%. For the measurement of vitamin B-6 in the 
chlorogenic acid and the placebo periods, we also collected fasting blood samples 
into vacuum tubes containing lithium-heparin and immediately stored the tubes at 
-80°C until analysis. The vitamin B-6 concentration was measured as pyridoxal-5'-
phosphate (PLP) in EDTA-treated whole blood by HPLC (Schrijver et al. 1981) after 
precolumn derivatization with semicarbazide to obtain PLP-semicarbazone (Ubbink et 
al. 1985). The interassay CV of the vitamin B-6 assay was <7%. 
We measured all postprandial blood samples in the same series of analyses. The 
fasting plasma samples for measurement of total homocysteine, vitamin B-12, and 
folate concentrations were analyzed in 2 separate series of analyses on separate 
occasions: in the first series we measured the fasting plasma samples obtained after 
placebo and chlorogenic acid periods and in the second series we measured the 
fasting plasma samples obtained after the placebo, black tea, and quercetin-3-
rutinoside periods. Thus, a subject's plasma or blood samples obtained after 
treatment with chlorogenic acid, black tea, or quercetin-3-rutinoside were always 
analyzed together with the plasma or blood sample of that same volunteer obtained 
after the placebo period. Therefore, differences between each supplement and the 
placebo were not affected by analytic variation between series. 
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Statistical analyses 
For each subject, we calculated the differences between values for each of the 3 
supplement periods and values for the placebo period. Statistical significance and 
95% CIs of the mean differences were calculated by using Student's f test. Results 
were analyzed with use of SAS (version 6.12; SAS Institute, Inc, Cary, NC). 
RESULTS 
Ingestion of chlorogenic acid raised total homocysteine concentrations by 12% (1.2 
nmol/L) in postprandial plasma and by 4% (0.4 nmol/L) in fasting plasma relative to 
placebo (Table 5.1, Figure 5.1). The rise of total homocysteine in postprandial plasma 
was 0.8 |amol/L (95% CI: 0.4, 1.2) higher than the rise in fasting plasma. Chlorogenic 
acid lowered the concentration of folate in fasting plasma by 8% (1.3 nmol/L; 95% CI: 
0.6, 2.1) relative to placebo (Table 5.2). Concentrations of vitamins B-6 and B-12 
were not significantly affected by chlorogenic acid. 
Ingestion of black tea raised total homocysteine concentrations by 11% (1.1 nmol/L) 
in postprandial plasma and by 5% (0.5 nmol/L) in fasting plasma relative to placebo 
(Table 5.1, Figure 5.2). The rise in postprandial plasma was 0.6 nmol/L (95% CI: -0.0, 
1.2) higher than the rise in fasting plasma. Concentrations of B vitamins were not 
significantly affected by black tea (Table 5.2). 
Ingestion of quercetin-3-rutinoside did not significantly affect total homocysteine 
concentrations in postprandial and fasting plasma (Table 5.1, Figure 5.3), but lowered 
the concentration of folate by 11% (2.5 nmol/L, 95% CI: 0.1, 5.0) in fasting plasma 
(Table 5.2). Concentrations of vitamins B-6 and B-12 were not significantly affected by 
quercetin-3-rutinoside. It is possible that we did not find an effect of quercetin-3-
rutinoside on plasma homocysteine because the dose of quercetin-3-rutinoside used 
in this study was only 12-16% of the dose of chlorogenic acid and of black tea 
polyphenols. However, this dose of quercetin-3-rutinoside is -13 times higher than the 
average intake of quercetin in the population (Hertog et al. 1993b). 
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Table 5.1 Change in plasma total homocysteine concentrations compared with placebo in postprandial 
and fasting plasma samples collected from 20 healthy volunteers after ingestion of chlorogenic acid, 
black tea, or quercetin-3-rutinoside for 7 d each1. 
Supplement 
Chlorogenic acid 
Black tea 
Quercetin-3-rutinoside 
Intake of 
polyphenols 
mmol/d 
5.5 
4.3 
0.7 
Change in total homocysteine concentration 
compared with placebo2 
Postprandial plasma Fasting plasma 
nmol/L 
1.2(0.6,1.7) 
1.1 (0.6, 1.5) 
0.3 (-0.2, 0.7) 
0.4 (0.0, 0.8) 
0.5 (0.0, 0.9) 
-0.0 (-0.4, 0.3) 
Mean (±SD) homocysteine concentrations after each supplement are shown in Figures 5.1-5.3. 
Postprandial blood samples were collected 4-5 h after the last supplement intake and fasting blood 
samples were collected ~20 h after the last supplement intake. 
Mean (95% CI). 
Table 5.2 Concentrations of folate and vitamin B-12 in postprandial and fasting plasma and 
concentrations of vitamin B-6 in fasting whole blood collected from 20 healthy volunteers after ingestion 
of placebo, chlorogenic acid, black tea, or quercetin-3-rutinoside for 7 d each1 
Supplement 
Placebo 
Chlorogenic acid 
Black tea 
Quercetin-3-
rutinoside 
Folate 
Fasting 
plasma 
Postprandial 
plasma 
nmol/L 
22.6 ± 8.8 
15.3 ±4.82'3 
21.4 ±6.9 
20.0 ± 5.63 
19.2 ±5.0 
19.6 ±5.8 
19.5 ±5.3 
19.3 ±5.8 
Vitamin B-12 
Fasting 
plasma 
Postprandial 
plasma 
pmol/L 
235 ± 65 
247 ± 672 
238 ± 65 
245 ± 82 
229 ± 66 
224 ± 57 
239 ± 69 
233 ± 61 
Vitamin B-6: 
Fasting whole 
blood 
nmol/L 
81 ±17 
81 ±14 
4 
4 
Mean ± SD. Postprandial blood samples were collected 4-5 h after the last supplement intake and 
fasting blood samples were collected ~20 h after the last supplement intake. 
2
 Folate and vitamin B-12 after chlorogenic acid were measured in another series of analyses. The 
concentration of folate in plasma after placebo in this series of analyses was 16.7 ± 5.1 nmol/L and 
that of vitamin B-12 was 242 ± 67 pmol/L 
'Significantly different from placebo, P<0.05. 
' Not measured. 
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Figure 5.1 Plasma total homocysteine in 20 healthy volunteers after they had consumed 2 g (5.5 
mmol) chlorogenic acid or a placebo daily, for 7 d each, in random order. Postprandial blood 
samples were collected 4-5 h after the last supplement intake and fasting samples were collected 
-20 h after the last supplement intake. Shown are the individual (o) and mean ± SD (•) changes. 
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Figure 5.2 Plasma total homocysteine in 20 healthy volunteers after they had consumed 4 g black 
tea solids (containing ~4.3 mmol polyphenols) or a placebo daily, for 7 d each, in random order. 
Postprandial blood samples were collected 4-5 h after the last supplement intake and fasting 
samples were collected -20 h after the last supplement intake. Shown are the individual (o) and 
mean ± SD (•) changes. 
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Figure 5.3 Plasma total homocysteine in 20 healthy volunteers after they had consumed 440 mg (0.7 
mmol) quercetin-3-rutinoside or a placebo daily, for 7 d each, in random order. Postprandial blood 
samples were collected 4-5 h after the last supplement intake and fasting samples were collected ~20 
h after the last supplement intake. Shown are the individual (o) and mean ± SD (•) changes. 
DISCUSSION 
We found that consumption of 2 g chlorogenic acid/d by healthy humans raises 
homocysteine concentrations in postprandial plasma by 12% and in fasting plasma by 
4%. Furthermore, we found that consumption of 4 g black tea solids/d also raises 
homocysteine concentrations in postprandial plasma by 11% and in fasting plasma by 
5%. The dose of 2 g chlorogenic acid used in this study is comparable with ~1.5 L 
strong coffee; the dose of 4 g black tea solids is comparable with 2 L strong black tea. 
This implies that both black tea and coffee increase plasma homocysteine to the 
same extent. Thus chlorogenic acid in coffee is at least partly responsible for the 
higher plasma homocysteine concentrations observed in coffee drinkers (Nygard et al. 
1997, Oshaug et al. 1998, Stolzenberg-Solomon et al. 1999, Grubben et al. 2000, 
Urgert et al. 2000). 
Chlorogenic acid and plasma total homocysteine 
The rise in homocysteine in postprandial plasma of 12% after daily consumption of 2 
g chlorogenic acid in this study was lower than the rise of 10-20% in 2 intervention 
studies after daily consumption of 1 L coffee, which contains ~1 g chlorogenic acid 
(Grubben et al. 2000, Urgert et al. 2000). The rise in plasma homocysteine 
concentrations in the present study was also lower than that found in epidemiological 
studies (Nygard et al. 1997, Oshaug et al. 1998, Stolzenberg-Solomon et al. 1999). 
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The fact that the rise in plasma homocysteine was lower in our study than in the 
studies with coffee might indicate that chlorogenic acid is not the only homocysteine-
raising factor in coffee. 
Beforehand, we did not know how long we had to give the supplements to induce an 
effect on plasma homocysteine. We expected that a supplementation period of 7 d 
would be long enough to stabilize plasma homocysteine because the half-life of 
elimination of plasma homocysteine after a methionine load is ~12 h (Guttormsen et 
al. 1993). In the present study we indeed showed that a supplementation period of 7 d 
is long enough to induce an effect on plasma homocysteine. However, we do not 
know the magnitude of the effect of chlorogenic acid on plasma homocysteine when 
chlorogenic acid is supplied for >7 d. Furthermore, we found that the effect of 
chlorogenic acid on homocysteine seems to subside within hours because the rise in 
homocysteine concentration in postprandial plasma samples, collected ~5 h after 
ingestion of chlorogenic acid, was significantly higher than that in fasting plasma 
samples, collected ~20 h after ingestion. We do not know whether the rise in 
homocysteine might have been even higher at other time points after intake because 
we collected blood only twice after ingestion of each supplement. We also saw a 
larger rise of homocysteine in postprandial plasma than in fasting plasma after the 
intake of black tea, although the fasting blood sample was collected ~12 h after the 
intake of the last dose (1 g) of the black tea solids. It is possible that the rise in 
homocysteine was higher in the postprandial blood samples than in the fasting blood 
samples because the effect of chlorogenic acid and black tea on homocysteine 
metabolism is fast and short term, like the effect of methionine on plasma 
homocysteine (Andersson et al. 1990). Other studies are necessary to establish the 
kinetics of the effect of chlorogenic acid and black tea on plasma homocysteine. We 
conclude that changes in homocysteine induced by chlorogenic acid or black tea 
apparently occur within hours rather than days and that the supplementation period of 
7 d was adequate. 
Black tea and plasma total homocysteine 
We found that intake of 4 g black tea solids/d, containing 4.3 mmol polyphenols, 
raises homocysteine in postprandial plasma by 11% and in fasting plasma by 5%. The 
magnitude of these rises is similar to that observed after intake of 5.5 mmol 
chlorogenic acid. However, the dose of black tea used is higher than the mean daily 
consumption of black tea in the general population (Hulshof et al. 1998) and we do 
not know the effects of lower doses on plasma homocysteine. 
We studied black tea because it is the tea most commonly consumed worldwide and 
because the only epidemiological study that investigated the association between 
black tea consumption and homocysteine concentration indicated that black tea might 
affect plasma homocysteine (Nygard et al. 1997). 
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In future studies of the effect of tea polyphenols on plasma homocysteine, it might be 
interesting to study the effect of green tea. Whereas black tea contains mainly 
polymerized catechins, the major polyphenols in green tea are monomeric catechins 
(Balentine et al. 1997). 
Quercetin-3-rutinoside and plasma total homocysteine 
In contrast with chlorogenic acid and black tea, quercetin-3-rutinoside did not 
significantly affect plasma homocysteine concentrations. This difference might be 
explained by the relatively low dose of quercetin-3-rutinoside used, which was only 
12-16% of the dose of chlorogenic acid and of polyphenols from black tea. 
Nevertheless, the dose of 0.7 mmol quercetin-3-rutinoside is ~13 times higher than 
the average quercetin intake in the general population, which is ~0.05 mmol (Hertog 
et al. 1993b). Therefore, we believe that quercetin intake in the general population 
does not have a substantial effect on homocysteine concentrations, although we can 
not exclude the possibility that doses of quercetin higher than used in our study might 
raise homocysteine. Quercetin-3-rutinoside lowered plasma folate concentrations by 
11%. We do not have an explanation for this finding. 
Mechanism of the effect of polyphenols on plasma total homocysteine 
The mechanisms by which chlorogenic acid and black tea raise plasma homocysteine 
are not clear. First, changes in plasma homocysteine might be mediated by vitamin B-
6, vitamin B-12, and folate, which are involved in the homocysteine pathway. We 
found that of these vitamins only folate was affected by the supplements. A decrease 
in plasma folate can lead to an increase in plasma homocysteine as a result of a 
decrease in remethylation of homocysteine into methionine (Figure 5.4) (Selhub et al. 
1993). A decrease in plasma folate, which could explain an increase in plasma 
homocysteine, was found in fasting plasma only after supplementation with 
chlorogenic acid and not black tea. In contrast, plasma folate also decreased in 
fasting plasma after quercetin-3-rutinoside, without a concomitant rise in plasma 
homocysteine. Furthermore, plasma folate concentrations in the postprandial blood 
samples were also not significantly affected by the supplements, whereas the largest 
increase in plasma homocysteine was found in postprandial plasma. Thus, a direct 
role for folate in the homocysteine-raising effect of chlorogenic acid and black tea 
polyphenols is unlikely. 
We speculate that O-methylation reactions that occur in the metabolism of 
polyphenols are involved in the homocysteine-raising effect of polyphenols. Such 
methylation reactions transfer a methyl group from S-adenosylmethionine to 
polyphenols and thereby produce homocysteine (Figure 5.4) (Finkelstein 1990). Thus, 
consumption of a high dose of polyphenols might increase homocysteine production 
through increased methylation reactions (Zhu et al. 1994). This notion is supported by 
data from studies on L-dopa (L-3,4-dihydroxyphenylalanine). Like polyphenols, L-dopa 
84 
PHENOLS INCREASE HOMOCYSTEINE 
is O-methylated. Indeed, both rats fed L-dopa and Parkinson disease patients treated 
with L-dopa have higher homocysteine concentrations than do control subjects (Daly 
et al. 1997, Allain et al. 1995, Kuhn et al. 1998a and 1998b, Muller et al. 1999). Thus, 
an increase in the O-methylation reactions in the body could result in higher plasma 
homocysteine concentrations, which might explain why high intakes of polyphenols 
raise plasma homocysteine. 
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Figure 5.4 Proposed interaction between the hepatic metabolism of homocysteine (A) and the O-
methylation of polyphenols (B). 
Conclusion 
High intakes of chlorogenic acid, which is present in coffee, and of black tea raise 
plasma homocysteine concentrations. Thus, chlorogenic acid in coffee might be at 
least partly responsible for the higher plasma homocysteine concentrations of coffee 
drinkers. A high plasma homocysteine concentration is a predictor of risk of 
cardiovascular disease (Nygard et al. 1995, Refsum et al. 1998, Ueland et al. 1993a). 
However, it is still unclear whether a high homocysteine concentration is causally 
related to cardiovascular disease or is merely an indicator of another process that 
causes cardiovascular disease. 
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Effect of chlorogenic acid and its metabolites on plasma total 
homocysteine concentrations in healthy volunteers 
Margreet R. OKhof, Peter C.H. Hollman, Martijn B. Katan 
Chlorogenic acid (5-caffeoylquinic acid) is partly responsible for the homocysteine-raising effect of 
coffee. However the mechanism underlying this effect is unknown. The major metabolite of chlorogenic 
acid in urine is hippuric acid (N-benzoylglycine). We tested whether exhaustion of endogenous glycine 
through conversion of chlorogenic acid into hippuric acid increased plasma homocysteine. To that end 
we fed 11 volunteers chlorogenic acid and benzoic acid, which use glycine for formation of hippuric acid, 
hippuric acid itself and a placebo. We followed plasma homocysteine concentrations, and excretion of 
hippuric acid and the supplements in urine. We found a slight increase of 6% in plasma homocysteine in 
the first 4 hours after ingestion of chlorogenic acid relative to placebo. Benzoic acid and hippuric acid 
had no effect. After ingestion of chlorogenic acid, benzoic acid and hippuric acid we recovered 72-76 
mol% of the dose as hippuric acid in urine. Most of the hippuric acid was rapidly excreted after ingestion 
of benzoic acid and of hippuric acid, whereas it was excreted between 10-24h after ingestion of 
chlorogenic acid. Thus glycination of metabolites of phenols does not explain the homocysteine-raising 
effect of chlorogenic acid, and hippuric acid itself does not either. The mechanism behind the 
homocysteine-raising effects of chlorogenic acid remains unknown. 
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INTRODUCTION 
A high homocysteine concentration in blood is a risk factor for cardiovascular disease 
(Nygard et al. 1995, Refsum et al. 1998). Coffee consumption is one of the 
determinants of plasma homocysteine concentration; coffee drinkers have up to 20% 
(2 (imol/L) higher plasma homocysteine concentration than coffee abstainers (Nygard 
et al. 1997, Oshaug et al. 1998, Stolzenberg-Solomon et al. 1999, Grubben et al. 
2000, Urgert et al. 2000). 
Chlorogenic acid (5-caffeoylquinic acid) is a major phenol in coffee (Clifford 1999) and 
we found in a previous study that 2 g chlorogenic acid (present in ~1.5 L of coffee) 
raises plasma homocysteine concentrations up to 12%. Black tea solids, which largely 
consists of phenols, had a similar effect (Olthof et al. 2001b). 
The mechanism by which chlorogenic acid and tea solids raise homocysteine 
concentrations is unknown. B-vitamins probably do not play a role (Olthof et al. 
2001b). We speculate that use of glycine for the formation of hippuric acid (N-
benzoylglycine) is involved because chlorogenic acid as well as phenols from black 
tea are metabolized mainly into hippuric acid (Olthof et al. 2001c, Booth et al. 1957, 
Clifford et al. 2000). This speculation is supported by our finding that quercetin-3-
rutinoside was not metabolized into hippuric acid and did not affect plasma 
homocysteine either. Glycine is involved in several pathways in homocysteine 
metabolism (Figure 6.1). Glycine is a precursor for serine and both compounds are 
needed for catabolism of homocysteine into glutathione. Serine is a methyl donor in 
the folate metabolism. Further, glycine accepts methyl groups from S-
adenosylmethionine (SAM) in case an excess of SAM occurs (Finkelstein 1990, 
Selhub 1999, Wagner 1995). However, we do not know what the effect is on plasma 
homocysteine of a shortage of endogenous glycine. 
We hypothesized that conversion of chlorogenic acid into hippuric acid limits the 
availability of endogenous glycine which results in an increase in plasma 
homocysteine. The availability of glycine is indeed a limiting factor in the conjugation 
of benzoic acid with glycine into hippuric acid (Kubota & Ishizaki 1991, Jackson et al. 
1987, Amsel & Levy 1969, Gregus et al. 1992 and 1993, Beliveau & Brusilow 1987). 
To test our hypothesis we compared the plasma homocysteine concentrations after 
ingestion of chlorogenic acid and benzoic acid with that after ingestion of hippuric acid 
and a placebo in healthy volunteers. Chlorogenic acid and benzoic acid will both use 
glycine for metabolism into hippuric acid, while hippuric acid will not use glycine 
(Booth et al. 1957, Quick 1931). This enables us to study the effect of the use of 
glycine for formation of hippuric acid on plasma homocysteine concentrations. We 
also studied the kinetics of excretion of several phenolic acid metabolites in urine after 
intake of the supplements. This provides further insight into the sites where 
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metabolism takes place. In addition it might give clues to the mechanism behind the 
homocysteine-raising effect of chlorogenic acid. 
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Figure 6.1 Homocysteine metabolism (Finkelstein 1990, Selhub 1999, Wagner 1995) 
SUBJECTS AND METHODS 
Subjects 
Five men and six women with a mean (±SD) age of 29 ± 14 y and a mean body mass 
index of 22 ± 2 kg/m2 participated. They were healthy as judged by a medical 
questionnaire; normal blood values for plasma homocysteine concentrations, liver 
enzymes, hemoglobin, hematocrit and white blood cell counts; and absence of protein 
and glucose in urine. All subjects were nonsmokers. They were not allowed to take 
any drugs or other supplements during the study except for acetaminophen 
(paracetamol) that was provided by us, and oral contraceptives. The study protocol 
was fully explained to the subjects and they gave their written informed consent. 
Methods 
The protocol was approved by the Medical Ethical Committee (Wageningen 
University). Throughout the 4-weeks randomized cross-over study subjects consumed 
a controlled diet low in phenols on 2 d per week. To achieve this, we supplied the 
subjects on these 2 d with foods low in phenols, which provided 100% of the energy 
required to maintain body weight and subjects were not allowed to eat foods which 
were not provided by us. Foods were considered low in phenols if they contained <15 
mg quercetin or chlorogenic acid/kg, and beverages if they contained <4 mg quercetin 
or chlorogenic acid/L (Clifford 1999, Hertog et al. 1992 and 1993). Because coffee 
and tea consumption were not allowed we provided the volunteers with the following 
substitutes: for coffee, an extract made of chicory, rye and barley (Swiss coffee-like; 
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Tayala AG, Birsfelden, Switzerland) and for tea, tea bags containing a mix of herbs 
(droommix; Piramide, Veenendaal, Netherlands) or tea bags containing stinging nettle 
(Jacob Hooy, Limmen, Netherlands). Chemical analyses indicated that these 
substitutes contained only minor amounts of catechins, flavonols or chlorogenic acid. 
In addition to the controlled diet subjects daily ingested one of 4 supplements on the 2 
days per week on which the diet was provided by us. The following supplements were 
provided by us in random order: either 2.0 g (5.5 mmol) chlorogenic acid (Fluka 
Chemie AG, Buchs, Switzerland), 1.4 g (8.0 mmol) hippuric acid (Fluka Chemie AG) 
and 1.2 g (8.0 mmol) sodium benzoate (kindly provided by Flevochemie, Harderwijk, 
Netherlands) or 0.1 g citric acid as a placebo (AC Citricum; Fagron, Nieuwerkerk a/d 
Ussel, Netherlands). The 2 g chlorogenic acid is comparable to the amount of 
chlorogenic acid in ~1.5 L of strong coffee. Before ingestion the supplements were 
dissolved in hot water. Subjects took the supplements under our supervision, just 
before breakfast in the morning. The volunteers were urged to maintain their usual 
pattern of physical activity during the study. 
On the second day of each supplement period we collected 8 blood samples: one 
fasting sample in the morning, and at 1, 2, 4, 6, 8, 10, 24 h after ingestion of the 
supplement. Just after the blood sample at 4 h, the hot meal was served. 
Blood was collected into vacuum tubes (Venoject II; Terumo Europe NV, Leuven, 
Belgium) containing EDTA. Blood samples were immediately placed on ice, and within 
1 hour centrifuged at 2500 x g for 10 minutes at 4°C to obtain plasma. Plasma was 
separated and stored at -80°C. Total homocysteine concentrations were measured by 
HPLC and fluorometric detection (Ubbink et al. 1991, Ueland et al. 1993). The 
interassay CV of the homocysteine assay was <8%. Plasma or blood samples a 
volunteer after ingestion of chlorogenic acid, benzoic acid, hippuric acid and placebo 
were always analyzed at the same time. Thus differences between each supplement 
and placebo were not affected by interassay variation. 
Urine 
On the second day of each supplement period subjects collected urine for 24 h. They 
started collection just before supplement intake and subsequently collected urine 
every 2 h after supplement intake, until 10 h after supplement intake. From 10-24 h 
after intake they collected urine only when needed. Subjects collected urine in 0.5 L 
plastic bottles with 0.13 g thymol (# 8167; Merck, Amsterdam, Netherlands) as a 
preservative and stored the bottles with urine on dry ice immediately after voiding. We 
checked the completeness of urine collection by assessment of recovery of 238 nmol 
lithium in urine. Lithium was measured in undiluted, acidified urine by atomic 
absorption spectrophotometry (Anonymous 1976). Subjects ingested lithium chloride, 
dissolved in 10 ml of tap water, daily during the study from 7 days before the first 
urine collection. Lithium chloride is completely absorbed and 95% is excreted in urine 
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(Sanchez-Castillo et al. 1987a and 1987b). Urinary recovery of lithium was 111 ± 14% 
(mean ± SD), which indicated good compliance in collecting urine. 
Analyses of hippuric acid, chlorogenic acid and benzoic acid in urine 
We measured hippuric acid, chlorogenic acid and benzoic acid in each urine sample 
collected every 2 h after ingestion of the supplement of each volunteer, and in a urine 
sample collected between 10-24 h after ingestion (Figures 6.3-6.5). We measured 
hippuric acid and benzoic acid in urine after deconjugation with p-
glucuronidase/arylsulfatase. Chlorogenic acid was measured in urine without prior 
deconjungation with p-glucuronidase/arylsulfatase. We measured chlorogenic acid 
only in urine samples collected after ingestion of the chlorogenic acid supplement and 
after placebo supplement. Urine was acidified and brought onto an Solid Phase 
Extraction (SPE) column. The column was eluted with ethyl acetate. Ethyl acetate was 
evaporated and acids were derivatized with bis(trimethylsilyl)trifluoroacetamide 
(BSTFA). Derivates were injected onto a capillary column CP-SH-5B (Chrompack, the 
Netherlands) and separated using a temperature gradient. On-line MS was used to 
quantify and identify phenolic acids (Hollman in preparation). The detection limit in 
urine was 5 mg/L for hippuric acid, 0.8 mg/L for chlorogenic acid, and 0.4 mg/L for 
benzoic acid. Due to technical problems we could not measure benzoic acid in 4 
volunteers and we could not measure chlorogenic acid in 2 volunteers. Furthermore, 
in 1 volunteer we found unexplained high excretion values for hippuric acid in urine 
after placebo that were 10-20 times higher than in other volunteers. We calculated the 
mean excretion of hippuric acid, benzoic acid and chlorogenic acid in urine with and 
without including this volunteers and reported the results in the results section. For 
homocysteine measurements we did not exclude the results of this volunteers 
because they did not differ from that of the other volunteers. 
Statistical analyses 
For the homocysteine concentrations and for excretion of phenolic acids in urine we 
calculated at each time point for each subject the differences relative to placebo. The 
total excretion of a phenolic acid was calculated for each person by summarizing the 
excretion values at each time point. We reported a missing value in case excretion 
value at one time point was missing. 
Statistical significance and 95% confidence intervals of the mean differences were 
calculated using Student's f test (SAS Institute, Cary, USA). 
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RESULTS 
Four hours after ingestion of chlorogenic acid total homocysteine concentrations were 
6 % (0.5 urnol/L; 95%CI: -0.3, 1.3) higher than after placebo (Figure 6.2). Ingestion of 
benzoic acid and hippuric acid did not affect plasma homocysteine concentrations 
relative to placebo. 
Plasma homocysteine concentrations increased after the hot meal, irrespective of the 
supplement the subjects ingested at breakfast. At 5-6 h after the hot meal (t=10 h 
after supplement intake) the plasma homocysteine concentration was 0.5-0.7 |amol/L 
higher than 1-2 hours after the hot meal (t=6 h) (Figure 6.2). The rise in plasma 
homocysteine concentrations might have been even higher at later time points, but we 
do not know this because we did not take blood samples between 10 and 24 h after 
ingestion of the supplements. 
placebo supplement 
chlorogenic acid supplement 
hippuric acid supplement 
benzoic acid supplement 
10 12 14 
Time (h) 
Figure 6.2 Plasma total homocysteine concentrations (mean) after ingestion of 1.2 g (8 mmol) of 
benzoic acid, 1.4 g (8 mmol) of hippuric acid, 2 g (5.5 mmol) of chlorogenic acid and placebo. Eleven 
healthy volunteers ingested the supplements, for 2 d each, in random order 
Excretion of hippuric acid, chlorogenic acid and benzoic acid in urine 
About 72-76 mol% of the ingested chlorogenic acid, benzoic acid and hippuric acid 
was recovered in urine in the form of hippuric acid (Table 6.1). For chlorogenic acid 
we calculated the recovery under the assumption that 1 molecule of chlorogenic acid 
provides 2 molecules of hippuric acid: the caffeic acid moiety as well as the quinic 
acid moiety of chlorogenic acid can be metabolized into hippuric acid (Adamson et al. 
1970, Quick 1931, Scheline 1978). 
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Hippuric acid was mainly excreted between 10 and 24h after ingestion of chlorogenic 
acid, whereas it was excreted within the first 4 hours after ingestion of benzoic acid 
and hippuric acid supplement (Figure 6.3). 
Chlorogenic acid and benzoic acid were mainly excreted in urine in the first 4 hours 
after ingestion of the supplement, but only small amounts were recovered (Figures 6.4 
and 6.5). 
We excluded one volunteer from the phenolic acid results because of extremely high 
excretion of hippuric acid after the placebo supplement. When we included the results 
of this volunteer the recoveries of hippuric acid, chlorogenic acid and benzoic acid in 
urine were as follows. The mean (95% CI) recoveries of hippuric acid in urine were 74 
mol% (44, 104) after chlorogenic acid supplement, 36 mol% (-46, 119) after benzoic 
acid supplement, and 48 mol% (-15, 112) after hippuric acid supplement. The 
recovery of chlorogenic acid in urine was 0.4 mol% (0.3, 0.5) after chlorogenic acid 
supplement. The recoveries of benzoic acid in urine were 0.1 mol% (-0.0, 0.3) after 
chlorogenic acid supplement, 1.1 mol% (0.6, 1.5) after benzoic acid supplement and 
0.3 mol% (0.1, 0.4) after hippuric acid supplement. 
Table 6.1 Recovery of hippuric acid, benzoic acid and chlorogenic acid relative to placebo in 24 h urine. 
Eleven healthy volunteers ingested 1.2 g (8 mmol) of benzoic acid, 1.4 g (8 mmol) of hippuric acid, and 
2 g (5.5 mmol) of chlorogenic acid for 2 d each, in random order1. 
Supplement 
Chlorogenic acid 
Benzoic acid 
Hippuric acid 
Chlorogenic acid 
0.4 (0.2, 0.5) 
(n=7) 
Not measured 
Not measured 
Recovery 
mol per 
n urine relative to placebo 
Benzoic acid 
100 mol of supplement 
0.2 (-0.1, 0.4) 
(n=5) 
1.2(0.9,1.5) 
(n=6) 
0.2 (0.0, 0.4) 
(n=6) 
Hippuric acid 
76(42,110) 
(n=8) 
72 (46, 98) 
(n=10) 
75 (52, 99) 
(n=10) 
Mean (95%CI). We excluded one volunteer because of unexplained, extremely high excretion values 
of hippuric acid after ingestion of the placebo. The results when we included this volunteer are 
presented in the results section. Data of other volunteers might have been excluded because we had no 
data on the amount excreted during 24 h. Therefore we indicated in the table on how many volunteers 
the results were based. 
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• chlorogenic acid supplement 
a benzoic acid supplement 
8 hippuric acid supplement 
Time after ingestion of the supplements (h) 
Figure 6.3 Recovery of hippuric acid in urine (mean ±SE) relative to placebo after ingestion of 1.2 
g (8 mmol) of benzoic acid, 1.4 g (8 mmol) of hippuric acid and 2 g (5.5 mmol) of chlorogenic 
acid. Eleven healthy volunteers ingested the supplements for 2 d each, in random order. One 
volunteer with unexplained high excretion of hippuric acid in the placebo period was excluded in 
this figure. 
6-8h 8-10h 10-24h 
Time after ingestion of chlorogenic acid supplement (h) 
Figure 6.4 Recovery of chlorogenic acid in urine (mean ±SE) relative to placebo after ingestion of 2 g 
(5.5 mmol) chlorogenic acid. Eleven healthy volunteers ingested the supplements for 2 d each, in 
random order. One volunteer with unexplained high excretion of hippuric acid in the placebo period 
was excluded in this figure. 
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• chlorogenic acid supplement 
a benzoic acid supplement 
S hippuric acid supplement 
8-10h 10-24h 
Time after ingestion of the supplements (h) 
Figure 6.5 Recovery of benzoic acid in urine (mean ±SE) relative to placebo after ingestion of 1.2 (8 
mmol) of benzoic acid, 1.4 g (8 mmol) of hippuric acid and 2 g (5.5 mmol) of chlorogenic acid. 
Eleven healthy volunteers ingested the supplements for 2 d each, in random order. One volunteer 
with unexplained high excretion of hippuric acid in the placebo period was excluded in this figure. 
DISCUSSION 
We found in a previous study that the homocysteine-raising effect of coffee might be 
partly due to chlorogenic acid, a major component in coffee (Olthof et al. 2001b). 
In this study we also found that chlorogenic acid raised plasma homocysteine at 4 
hours after ingestion although the effect was smaller than in the previous study. The 
rise in this study was 6% whereas the rise in the previous study was 12% (Olthof et al. 
2001b). This difference between the two studies could be due to chance because the 
95% confidence interval of the difference between the homocysteine rise in this study 
and in the previous study included zero. However, other factors could have played a 
role. 
First, in this study subjects ingested the chlorogenic acid before breakfast while in the 
previous study it was ingested before a hot meal. We saw in this study that the hot 
meal at noon increased plasma homocysteine, while a breakfast did not. This might 
be caused by methionine present in a hot meal, because this amino acid is the 
precursor for homocysteine (Guttormsen et al. 1994, Chambers et al. 1999). We 
speculate that chlorogenic acid might affect plasma homocysteine more when 
ingested just before a hot meal, which 'triggers' the homocysteine metabolism, than 
when ingested before a breakfast. 
Second, the length of the supplement periods differed between the two studies: in this 
study subjects ingested chlorogenic acid for 2 consecutive days while in our previous 
study it was 7 days. However, we do not think that the length of the supplement period 
plays an important role because we found in our previous study that the effect of 
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chlorogenic acid on plasma homocysteine concentration was fast, and almost gone at 
20 hours after ingestion of chlorogenic acid (Olthof et al. 2001b). 
We conclude that the difference between this study and the previous study is probably 
due to chance. More studies are needed to determine the effects of chlorogenic acid 
on plasma homocysteine under various circumstances, such as after ingestion of 
chlorogenic acid throughout the day, or after ingestion together with various types of 
foods. 
Mechanism behind the homocysteine-raising effect of chlorogenic acid 
We speculated that the effect of chlorogenic acid on homocysteine might be due to 
exhaustion of endogenous glycine which is used for the metabolism of chlorogenic 
acid into hippuric acid. Therefore we gave volunteers benzoic acid which requires 
glycine for its conversion into hippuric acid, and hippuric acid itself which does not 
require glycine. We found that benzoic acid did not affect plasma homocysteine and 
neither did hippuric acid. One reason for this might be that the dose of benzoic acid in 
this study was too low to exhaust the glycine pool (Amsel & Levy 1969, Quick 1931). 
On the other hand, the amount of hippuric acid produced after benzoic acid was 
comparable to that after chlorogenic acid, and chlorogenic acid did affect plasma 
homocysteine. Therefore it seems unlikely that the use of glycine in the metabolism of 
dietary phenols causes their homocysteine-raising effect. Another observation in this 
study supports this conclusion. We found that hippuric acid is excreted in urine 
between 10 and 24 h after intake of chlorogenic acid, while plasma homocysteine 
increased during the first 4 h after intake (Figures 6.2 and 6.3) (Olthof et al. 2001b). 
Thus the timing of formation of hippuric acid did not seem to coincide with the timing 
of the rise in homocysteine. 
Hippuric acid itself is also not responsible for the homocysteine raising effect of 
chlorogenic acid, because hippuric acid did not raise plasma homocysteine. 
Another mechanism the homocysteine-raising effects of phenols might be that 
homocysteine is formed through methylation of phenols in the liver. The methyl 
groups that are needed for methylation of phenols are donated by S-
Adenosylmethionine (SAM) which then yields homocysteine. Therefore ingestion of 
phenols might increase the methylation process which results in an increase in 
plasma homocysteine concentration. We found only minor amounts of methylated 
metabolites in urine after chlorogenic acid in the previous study (Olthof et al. 2001c) 
However, measurements in urine might not represent the situation in the body and 
therefore this methylation hypothesis should be investigated. 
Metabolism of chlorogenic acid and benzoic acid into hippuric acid 
Small amounts of chlorogenic acid were recovered in urine, mainly in the first 4 h after 
ingestion (Figure 6.4). This chlorogenic acid in urine probably originates from the 
fraction that is absorbed in the small intestine. In contrast, hippuric acid mainly 
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appeared in urine between 10 and 24 h after ingestion of chlorogenic acid (Figure 
6.3). This indicates that the colonic microflora is involved in the formation of hippuric 
acid from chlorogenic acid (Booth et al. 1957), because transit time through the small 
intestine is about 10 h (Fallingborg et al. 1989 and 1990). Degradation of chlorogenic 
acid in the colon rather than endogenously is also supported by our previous findings 
that two-third of ingested chlorogenic acid is not absorbed in the small intestine but 
goes to the colon (Olthof et al. 2001a). In addition we found that subjects without a 
colon did not produce hippuric acid from chlorogenic acid (Olthof et al. 2001c). We 
recovered 76 mol% of the chlorogenic acid supplement as hippuric acid in urine, this 
indicates that most of the chlorogenic acid that reaches the colon is metabolized into 
hippuric acid. In addition, some chlorogenic acid which is absorbed in the small 
intestine might also reach the colon via the enterohepatic cycle and be metabolized by 
the colonic microflora. A major part of the degradation products is absorbed from the 
colon, further metabolized and excreted in urine. 
The rapid appearance of hippuric acid in urine within 4 h after ingestion of benzoic 
acid indicates that benzoic acid is first absorbed and then metabolized into hippuric 
acid probably in the liver. The recovery of 72% of the ingested benzoic acid dose as 
hippuric acid as well as the rapid excretion of hippuric acid in urine correlated well with 
the results of Kubota et al. (1991). 
One volunteer had unexplained high excretion of hippuric acid in the placebo period. 
Although volunteers were instructed to adhere to the controlled diet this volunteer 
might have eaten something in addition to the controlled diet that lead to the high 
excretion of hippuric acid in urine. However we have no proof for this. The recoveries 
of hippuric acid in urine after ingestion of benzoic acid and hippuric acid were 
drastically affected by the results of this one volunteer. Therefore we showed the 
results with and without including the results of this volunteer. The kinetics of 
excretion of hippuric acid after ingestion of the supplements were not affected by the 
results of this volunteer. We did include the results of this volunteer in our 
homocysteine analyses because these results were not different from those of the 
other 10 volunteers. Therefore, we do not believe that the results of this one volunteer 
affected the conclusions of this study. 
Conclusion 
Chlorogenic acid in coffee remains a candidate for part of the homocysteine-raising 
effect of coffee. Exhaustion of endogenous glycine due to the formation of hippuric 
acid from chlorogenic acid is not involved. Further research is necessary to elucidate 
the mechanism underlying the homocysteine-raising effects of coffee and of 
chlorogenic acid. 
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CHAPTER 7 
GENERAL DISCUSSION 
The objective of this thesis was to investigate whether bioavailability data on 
flavonoids and cinnamic acids support the hypothesis that they can affect health in 
humans. 
We found that the flavonol quercetin, black tea phenols, and cinnamic acids are 
bioavailable and thus might affect health. However, they are extensively metabolized, 
mainly before they reach the circulation. Because the metabolites of phenols that we 
found have lower antioxidant activity in vitro than their parent phenols, the role of 
dietary phenols as antioxidants in vivo might be less than expected. Therefore, studies 
on health effects of dietary phenols should include the effects of their metabolites. 
Furthermore, we found that chlorogenic acid from coffee, and black tea solids might 
be harmful because they raised concentrations of plasma homocysteine, a potential 
risk factor for cardiovascular disease. In contrast, the flavonol quercetin did not affect 
plasma homocysteine. 
This chapter discusses the implications of these findings and suggestions for further 
research. 
BIOAVAILABILITY 
Why are bioavailability studies important? 
Research on bioavailability of dietary phenols is scarce. Nevertheless, it is important 
for many purposes. Examples of the importance of bioavailability research are: 
• Knowledge of the bioavailability of nutrients can clarify discrepancies in 
epidemiological research. For example, the association between the intake of 
flavonols, such as quercetin, and health in epidemiological studies is inconclusive 
(see introduction Table 1.2). This can partly be explained by the fact that these 
studies did not account for the variation in bioavailability of various quercetin 
glycosides in foods. Differences in bioavailability of quercetin glycosides might 
result in different effects in vivo. 
• Bioavailability studies will give insight into the concentrations of phenols and their 
metabolites presented to target tissues, which will help to evaluate their potential 
biological effects. 
• Bioavailability data can be used to improve the design of in vitro studies. For 
example, the in vitro antioxidant activity of the ingested phenols is often used as an 
indicator of their activity in vivo. However, we showed that dietary phenols are 
rapidly and extensively metabolized in humans (chapters 4 and 6). Thus, in vitro 
antioxidant activity of the metabolites of phenols would be more representative for 
the antioxidant activity of dietary phenols in vivo than that of the ingested phenols. 
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• Knowledge of the bioavailability of food compounds opens ways for targeted 
modifications of food compounds according to the desired bioavailability 
characteristics. For example, modification of the conjugated moieties of quercetin 
or caffeic acid will change the bioavailability (chapters 2 and 3). Compounds that 
are well absorbed will be directed toward the blood circulation. Compounds that are 
less well absorbed will be directed toward the colon. Therefore the question: 
"where does this compound go?" might in the future change to "where do we want 
this compound to go, and where do we want it to stay away?" 
Implications of the bioavailability of quercetin, chlorogenic acid and tea 
phenols 
The bioavailability of quercetin and chlorogenic acid depends upon their conjugated 
moieties. The bioavailability of quercetin-3-rutinoside is much lower than that of 
quercetin glucosides (chapter 2) (Hollman et al. 1999a). The absorption of caffeic acid 
esterified with quinic acid, yielding chlorogenic acid, is only 30% of that of free caffeic 
acid (chapter 3) (Azuma et al. 2000). Thus differences in the conjugated moieties 
result in differences in bioavailability of dietary phenols, and in the target tissues that 
they can reach. 
information regarding bioavailability of phenols will provide insight into which forms are 
present at which target tissues, and thus into their potential health effects. For 
example, we found that a large part of chlorogenic acid, present in coffee, will reach 
the colon after ingestion. This implies that chlorogenic acid, or metabolites formed in 
the colon might play a role in the potential protective effect of coffee against colon 
cancer (Tavani & La Vecchia 2000, Giovannucci 1998, Baron et al. 1994, Favero et al. 
1998, La Vecchia et al. 1989, Tavani et al. 1997). Furthermore, we found that 
quercetin-3-rutinoside, chlorogenic acid and tea phenols are extensively metabolized 
into phenolic acids (chapter 4). These phenolic acids, rather than the parent phenols 
will reach target tissues, and thus might exert biological effects. Therefore, in vitro 
studies with regard to health effects of phenols should also include the metabolites 
that reach target tissues. 
Insight into the bioavailability of phenols opens up ways for modification of phenols in 
foods. Increasing the amount of phenols in foods is already possible: the amounts of 
the flavonols quercetin and kaempferol in tomatoes have each been increased 70-fold 
by means of genetic modification approaches (personal communication with A. Bovy, 
Plant Research International, Wageningen, the Netherlands). In addition, our results 
indicate that it might also be interesting to modify the type of the conjugated moieties 
of phenols. For example, the poor-bioavailable quercetin-3-rutinoside present in tea 
can be transformed into the well-bioavailable quercetin-3-glucoside (Bokkenheuser et 
al. 1987, Gunata et al. 1988, Kurosawa et al. 1973) (Figure 7.1). 
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glucose 
rhamnose 
Quercetin-3-rutinoside Quercetin-3-glucoside 
Figure 7.1 Transformation of quercetin-3-rutinoside into quercetin-3-glucoside 
The bioavailability of quercetin from tea would then drastically improve, because the 
bioavailability of quercetin rutinoside is only 20% of that of the quercetin glucosides 
(chapter 2) (Hollman et al. 1999a). The opposite is also possible: if quercetin 
glucosides would be transformed into rutinosides, less of the quercetin would be 
absorbed from the small intestine and more would be directed toward the colon. 
Similarly, the bioavailability of caffeic acid can also be changed: the absorption of 
caffeic acid esterified with quinic acid (chlorogenic acid) is only 30% of that of free 
caffeic acid (chapter 3). Because caffeic acid in foods is mainly present as chlorogenic 
acid, it will for the most part be directed toward the colon. Hydrolysis of chlorogenic 
acid into caffeic acid and quinic acid before ingestion will improve the absorption of 
caffeic acid. 
Consequently, in the future we might modify the conjugated moieties of phenols so as 
to target to which tissues the phenols should go or stay away. However, information 
on bioavailability and health effects of phenols is as yet too limited to justify such 
modification. 
Phenolic acid metabolites as biomarkers for intake of dietary phenols. 
Phenolic acid metabolites in urine can be potential markers for intake of total dietary 
phenols. Markers of intake that objectively measure intake in individual persons are 
important tools for epidemiological studies on phenols and health. Currently, intake of 
individual phenols, such as flavonols and gallic acid, can be estimated by means of 
measurements of these compounds in blood or urine after ingestion (de Vries 1998, 
Hodgson et al. 2000). However, no markers are available for the intake of the total 
group of dietary phenols. 
We found approximately half of the ingested chlorogenic acid, black tea phenols, and 
quercetin-3-rutinoside as phenolic acids in urine, which indicates that these acids 
could be used as markers of total phenol intake. In addition, the metabolic profile of 
metabolites in urine might indicate the types of phenols that were ingested. For 
example, we found that chlorogenic acid and tea phenols are mainly metabolized via 
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the phenylpropionic acid pathway into hippuric acid (phenyl-C-i). Flavonols, such as 
quercetin-3-rutinoside, are metabolized via the phenylacetic acid pathway into 
phenylacetic acids (phenyl-C2) (chapter 4) (Hollman & Katan 1998). One potential 
problem in using phenolic acids in urine as markers of phenol intake is that not only 
dietary phenols, but also amino acids such as tyrosine and phenylalanine can be 
metabolized to phenolic acids and end up in urine (Booth et al. 1960, Teuchy & Van 
Sumere 1971). This should be taken into consideration when phenolic acids would be 
used as markers for intake of dietary phenols. 
HEALTH 
Phenols as antioxidants: important to health? 
Phenols are strong antioxidants in vitro, even stronger than antioxidant vitamins such 
as vitamin E (Rice-Evans et al. 1996). However, antioxidant effects of phenols in the in 
vivo situation are uncertain. 
We found that the dietary phenols, chlorogenic acid, black tea solids and quercetin-3-
rutinoside are extensively metabolized into metabolites with no or less in vitro 
antioxidant activity than their parent phenols (chapter 4). This raises doubts as to 
whether dietary phenols may be important as antioxidants in vivo. Nevertheless, we 
measured the metabolites of phenols in urine and not in the blood circulation or in 
specific target tissues. Thus it is possible that other metabolites are present in the 
blood circulation and are available for antioxidant effects. In intervention studies, the 
effects of phenols and phenol-rich foods on several markers of antioxidant status are 
inconsistent. Some studies find that phenols affect antioxidant markers (Wang et al. 
2000, Rein et al. 2000, Leenen et al. 2000, Boyle et al. 2000b) but others do not 
(Boyle et al. 2000a, O'Reilly et al. 2000, Caccetta et al. 2000, Princen et al. 1998). 
The uncertainty about efficacy of antioxidants in vivo is also illustrated by the 
inconsistent results from large intervention trials on antioxidant vitamins and cancer or 
cardiovascular disease (Marchioli 1999, Buring & Hennekens 1997, McDermott 2000). 
The effect of vitamin E on cardiovascular disease is not conclusive (Hooper et al. 
1999, Yusuf et al. 2000, Collaborative Group of the Primary Prevention Project 2001). 
Another example is that supplementation of beta-carotene to smokers increased 
rather than decreased the risk of lung cancer (Anonymous 1994, Omenn et al. 1996). 
The lack of reliable markers of in vivo oxidative processes is a major problem in the 
field of antioxidants, which hinders a proper evaluation of the effects of antioxidants on 
health (Zock & Katan 1998, Witztum 1998). Isoprostanes as markers for lipid 
peroxidation in vivo and autoantibodies against oxidized LDL cholesterol might be 
promising (Roberts & Morrow 2000, Holvoet et al. 1998). More research is necessary 
before any dietary recommendations can be made with regard to antioxidants. 
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Coffee and tea: good or bad for health? 
Coffee and tea are major sources of dietary phenols. Phenols are believed to be 
beneficial to health through their antioxidant activity. On the other hand, we found that 
phenols from coffee and tea might be harmful because they increased homocysteine 
concentrations in plasma (chapter 5), which is a potential risk factor for cardiovascular 
disease. This apparent inconsistency raises the question whether coffee and tea are 
good or bad for health. 
Unfiltered, boiled coffee increases serum cholesterol concentrations and thereby 
increases risk of cardiovascular disease (Aro et al. 1987, Urgert & Katan 1997). 
Although filtered coffee does not raise cholesterol, the data on coffee and 
cardiovascular disease are inconsistent; case-control studies indicate that coffee is 
associated with an increased risk, while most prospective studies find no association, 
or a decreased risk of cardiovascular disease among coffee drinkers (Greenland 
1993, Kawachi et al. 1994). Furthermore, coffee might protect against colon cancer, 
but data are not consistent; case-control studies indicate the coffee protects against 
colon cancer, whereas the association in prospective studies is less clear 
(Giovannucci 1998, Tavani & La Vecchia 2000). Nevertheless, chlorogenic acid in 
coffee could be involved in the potential protective effect of coffee against colon 
cancer, because two-thirds of the ingested chlorogenic acid are transported into the 
colon where it might exert biological effects (chapter 3). 
Tea is a major source of catechins, a subgroup of flavonoids, which are believed to be 
involved in potential beneficial health effects of tea. However, there is no clear 
association between intake of tea catechins and risk of cardiovascular disease and 
cancer in epidemiological studies (Arts 2001). Furthermore, like for coffee, the relation 
between tea consumption and disease is inconsistent (Tijburg et al. 1997, Hollman et 
al. 1999b). Epidemiological studies show no clear association between tea 
consumption and cancer risk (Blot et al. 1996 and 1997, Hollman et al. 1999b, 
Goldbohm et al. 1996). Epidemiological studies on tea and cardiovascular disease are 
also inconsistent. Some studies suggest a protective effect of tea (Hertog et al. 1993, 
Keli et al. 1996, Geleijnse et al. 1999), but others find no association (Stensvold et al. 
1992, Klatsky et al. 1990 and 1993). In Wales and Scotland tea drinking is associated 
with an increased risk of cardiovascular disease (Woodward & Tunstall-Pedoe 1999, 
Hertog etal. 1997). 
Thus, the association between consumption of coffee or tea and disease is not clear. 
Differences between populations in tea or coffee drinking habits might explain part of 
the inconsistency, but the most likely explanation is confounding of the associations by 
other risk factors, or the absence of a true underlying effect. Epidemiological studies 
cannot completely control for confounding by accompanying lifestyle factors. For 
example, in most countries tea drinking is associated with a healthy lifestyle, while 
coffee drinking is associated with a less healthy lifestyle (Schwarz et al. 1994). The 
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opposite applies to Wales and Scotland: tea drinking is associated with a less healthy 
lifestyle than coffee drinking (Woodward & Tunstall-Pedoe 1999). This might explain 
the discrepant finding for tea and cardiovascular disease in these studies. However, 
the data from all epidemiological studies together are also compatible with no effect of 
tea and coffee on health. 
Thus, it is not yet clear whether tea and coffee are either good or bad for health. Long 
term intervention trials with tea and coffee can provide definite answers on this issues, 
but these trials are hardly feasible. However, coffee and tea are common parts of the 
human diet all over the world. Therefore, it is important to further investigate health 
effects of these beverages. 
Plasma homocysteine 
Is homocysteine a causal risk factor for cardiovascular disease? 
A high homocysteine concentration is proposed as a biomarker for cardiovascular 
disease risk. However, the causality of homocysteine in the development of 
cardiovascular disease is still unclear (Brattstrom & Wilcken 2000, Ueland et ai. 2000). 
The homocysteine-raising effects of coffee, black tea solids and chlorogenic acid raise 
additional questions about the causal role of plasma homocysteine in cardiovascular 
disease. If homocysteine is a causal factor we would expect that coffee and tea 
consumption is related to an increased risk of cardiovascular disease. However, this is 
not clear from observational studies. 
A high coffee consumption is associated with 10-20% rise in plasma homocysteine 
concentrations in most observational studies (Nygard et al. 1997, Oshaug et al. 1998, 
Stolzenberg-Solomon et al. 1999), although not in all (Nieto et al. 1997). This 
homocysteine-raising effect of coffee is confirmed in two intervention studies (Urgert et 
al. 2000, Grubben et al. 2000). A 10-20% rise in plasma homocysteine would coincide 
with ~5-10% increased risk of cardiovascular disease in coffee consumers (Ueland et 
al. 2000). This small increase in risk is probably hard to detect in observational studies 
which might explain the inconsistent results on the association between coffee 
consumption and cardiovascular disease (Greenland 1993, Kawachi et al. 1994). 
Furthermore, we found that strong black tea raised plasma homocysteine by 11% 
(chapter 5). Only one observational study reported a weak positive association 
between tea consumption and plasma homocysteine in tea drinkers (Nygard et al. 
1997). Other studies do not report on this association. If homocysteine is causal, a 
homocysteine-raising effect of strong tea might partly explain the positive association 
between tea and cardiovascular disease risk in the studies in Wales and Scotland, 
where tea habits differ from those in other populations (Hertog et al. 1997, Woodward 
& Tunstall-Pedoe 1999). Therefore it would be worthwhile to measure the effects of 
tea on concentrations of plasma homocysteine in the UK. 
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Long term, placebo-controlled, homocysteine-lowering intervention trials are 
necessary to investigate the causality of homocysteine in the development of 
cardiovascular disease. Only when the results of these intervention studies are known, 
potential harmful effects of coffee and tea can be discussed. 
Possible mechanisms causing the homocysteine-raising effect of dietary phenols. 
We found that chlorogenic acid and black tea solids raised plasma homocysteine, 
while quercetin did not (chapter 5). Knowledge of the mechanism causing this 
homocysteine-raising effect of phenols will give further insight into the effects of 
dietary compounds on homocysteine metabolism. Furthermore, it helps to predict the 
effects of other food compounds on plasma homocysteine. 
Our study (chapter 5) and two intervention studies with coffee (Urgert et al. 2000, 
Grubben et al. 2000) did not indicate that coffee, black tea solids and chlorogenic acid 
affect homocysteine metabolism through changes in B-vitamins. Three other possible 
mechanism that might be involved in the homocysteine-raising effect of phenols are 
discussed. 
• In chapter 6 we tested whether the use of glycine for the metabolism of chlorogenic 
acid and tea phenols into hippuric acid might be involved in the homocysteine-raising 
effect (Figure 7.2). Our finding that quercetin was not metabolized into hippuric acid 
(chapter 4), and neither affected plasma homocysteine (chapter 5) supports this 
hypothesis. Glycine is involved in several pathways in the homocysteine metabolism 
and therefore we hypothesized that possible exhaustion of glycine through the 
formation of hippuric acid might affect homocysteine metabolism. However, we could 
not confirm that glycination of metabolites of phenols is involved in the homocysteine-
raising effect of phenols. 
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•The^ hydroxyl groups of phenols are O-methylated in the liver. The necessary methyl 
group is derived from S-adenosylmethionine which results in production of 
homocysteine (Figure 7.3) (Finkelstein 1990). Thus consumption of a high dose of 
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phenols might increase homocysteine production through increased methylation of 
phenols (Zhu et al. 1994, Miller et al. 1997). The fact that we did not find many O-
methylated metabolites of phenols in urine does not support this hypothesis {chapter 
4). However, measurements in urine might not reflect the situation in the body. 
Therefore we should test this hypothesis in humans, using substances that are 
known to undergo O-methylation such as L-dopa (L-3,4-dihydroxyphenylalanine). 
Rats fed L-dopa, and Parkinson disease patients treated with L-dopa have higher 
homocysteine concentrations than do controls (Daly et al. 1997, Allain et al. 1995, 
Kuhn et al. 1998a and 1998b, Muller et al. 1999). If this methylation hypothesis is 
true, then other food compounds or drugs that are O-methylated in the liver, might 
also affect plasma homocysteine. 
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Figure 7.3 Possible relation between methylation of phenols and the homocysteine metabolism 
•Another possibility might be that the rise in homocysteine is explained through 
diuretic effects of coffee, chlorogenic acid and black tea solids: loss of body fluids 
might increase homocysteine concentrations. However, our results do not support 
this. Chlorogenic acid and black tea solids increased plasma homocysteine relative to 
placebo and quercetin-3-rutinoside, but not the amount of urine excreted during 24 
hours after intake (chapter 5). 
FUTURE STUDIES 
Metabolites of phenols in blood 
We measured metabolites of phenols in urine (chapter 4). Measurements of 
metabolites in blood would have been preferable, but were not possible in the present 
studies. Future studies should aim at measuring phenols and their metabolites in the 
blood circulation and target tissues. This will provide ideas about mechanisms behind 
potential health effects of phenols and it can improve the design of in vitro studies so 
that they better represent the in vivo situation. Furthermore, this information can be 
useful in the development of markers for intake of phenols from foods. 
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Bioavailability of other phenols 
Numerous phenols are present in foods, but information with regard to their 
bioavailability is scarce or lacking. In addition to the current knowledge regarding 
bioavailability, more research on the bioavailability of other dietary phenols and on 
factors that influence their bioavailability is necessary. 
Role of antioxidants in disease 
Currently available biomarkers for measurement of antioxidant activity in vivo are 
mainly based on in vitro or ex vivo methods that do not necessarily represent the 
situation in vivo. To assess the importance to health of antioxidants such as phenols, 
in vivo markers of oxidative damage are needed that both respond to dietary changes 
and at the same time predict changes in disease risk. 
Mechanism underlying the homocysteine-raising effect of phenols 
Knowledge about the mechanism underlying the homocysteine-raising effect of dietary 
phenols will add to the current knowledge about effects of food compounds on the 
homocysteine metabolism. In addition, it will enable to predict the effects of other food 
components or drugs on the homocysteine metabolism. This will provide ideas about 
potential homocysteine-lowering substances. 
Causality of plasma homocysteine in cardiovascular disease 
Placebo-controlled homocysteine-lowering interventions trials are needed to prove 
that a decrease in plasma homocysteine lowers the risk of disease. This information is 
crucial in risk-assessment of food components that increase homocysteine, such as 
certain phenols. 
CONCLUSION 
Our studies indicate that dietary phenols could play a role in human health because 
they are available in the body. We found that the absorption of phenols is dependent 
upon their conjugated moiety: quercetin glucosides are better absorbed than 
quercetin-rutinoside; and free caffeic acid is better absorbed than its conjugated 
derivative chlorogenic acid. This suggests that bioavailability can be modulated by 
modification of dietary phenols. We also found that phenols are extensively 
metabolized into phenolic acids, mainly before they reach the circulation. Thus the 
metabolites of phenols probably circulate in the body and reach target tissues, rather 
than the ingested phenols. The phenolic acid metabolites have no, or less, antioxidant 
activity in vitro than their parent phenols. Therefore, the role of dietary phenols as 
antioxidants in vivo might be less important than suggested by the in vitro antioxidant 
activity of the parent compounds. We also showed that phenols might have adverse 
effects on health because some phenols raise plasma homocysteine, a potential risk 
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factor for cardiovascular disease. Whether beneficial effects of phenols outweigh the 
adverse effects is as yet unclear. 
Our results justify further research with regard to bioavailability and health effects of 
dietary phenols. 
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SUMMARY 
Dietary phenols are strong antioxidants in vitro and they are therefore thought to 
protect against cardiovascular disease and cancer. However, formal proof that 
phenols can affect health is still lacking. For a proper evaluation of potential health 
effects of phenols, information on their bioavailability in humans is crucial. The 
recognition of the need for information on bioavailability of phenols is increasing, but 
data on bioavailability are still scarce. The aim of this thesis was to investigate 
whether bioavailability data on flavonoids and cinnamic acids support the hypothesis 
that they can affect health in humans. We studied quantitatively important flavonoids 
and cinnamic acids from foods: the flavonol quercetin, black tea phenols and 
chlorogenic acid (5-caffeoylquinic acid). 
Impact of conjugated moieties of quercetin and chlorogenic acid on their bioavailability 
In chapter 2 we investigated whether the position of glucose plays a role in the 
bioavailability of quercetin glucosides. Quercetin is a major representative of the 
flavonols, a subgroup of flavonoids. In foods, quercetin occurs mainly as quercetin 
glycosides. Previous studies of Hollman et al. showed that the sugar moiety 
determines the bioavailability: the bioavailability of quercetin-3-rutinoside (quercetin 
attached to a rutinose) is only 20% of that of quercetin-4'-glucoside (quercetin 
attached to a glucose). Tea is the major source of quercetin, but it is present in the 
poor bioavailable form quercetin-3-rutinoside. Quercetin-3-rutinoside can be 
transformed into quercetin-3-glucoside by splitting off a rhamnose molecule and it 
would be interesting to see if this will improve its bioavailability. Therefore, we 
investigated whether quercetin-3-glucoside had the same high bioavailabilty as the 4'-
glucoside. Nine healthy volunteers ingested a single dose of pure quercetin-3-
glucoside (325 (imol) and a single dose of pure quercetin-4'-glucoside (331 urnol). 
Indeed, we found that the quercetin-3-glucoside had the same high bioavailability as 
the quercetin-4'-glucoside. Thus the position of the glucose moiety did not affect 
bioavailability of quercetin glucosides. This implies that the bioavailability of quercetin-
3-rutinoside will increase considerably when it would be transformed into quercetin-3-
glucoside. In general, conversion of quercetin glycosides into glucosides is a 
promising approach to improve bioavailability of quercetin from foods. 
Caffeic acid is a major dietary cinnamic acid, but in foods it is mainly conjugated with 
quinic acid, called chlorogenic acid. Coffee is its major source. Very little is known 
about the bioavailability of caffeic acid and chlorogenic acid in humans. In chapter 3 
we investigated the absorption of chlorogenic acid and of caffeic acid in the small 
intestine of humans. For this purpose we performed our study in ileostomy volunteers. 
Ileostomy volunteers lack their colon, which provides the opportunity to study the 
absorption in the small intestine without degradation of the phenols by the colonic 
microflora. After 7 ileostomy volunteers ingested a single dose of 1 g of chlorogenic 
acid and a single dose of 0.5 g of caffeic acid we recovered 67% of the ingested 
chlorogenic acid and 5% of the ingested caffeic acid in ileostomy fluid. This implies 
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that 33% of the ingested chlorogenic acid and 95% of the caffeic acid is absorbed in 
the small intestine. Thus, chlorogenic acid from foods can be absorbed but the 
conjugation of caffeic acid with quinic acid hinders absorption. 
Metabolism of phenols in humans 
Phenols are extensively metabolized in the human body. Therefore it is important to 
identify the metabolites of phenols that are actually circulating in the body and may 
have biological effects. Information on the metabolites of phenols and on the site of 
metabolism of phenols in humans is scarce. In chapter 4 we identified and quantified 
metabolites of chlorogenic acid, quercetin-3-rutinoside and black tea phenols in 
humans. Twenty healthy volunteers with a colon ingested daily 2 g chlorogenic acid, 4 
g black tea solids, 440 mg quercetin-3-rutinoside and a placebo for 7 days each, in 
random order. We measured 59 phenolic acids in 24-h urine as potential metabolites. 
Further, we investigated the role of the colonic microflora in the metabolism of dietary 
phenols by comparing the metabolites formed in volunteers with an intact colon with 
those formed in 7 volunteers who lack a colon (ileostomy subjects). We found in 
volunteers with a colon that half of the ingested chlorogenic acid and 43% of the tea 
phenols was metabolized into hippuric acid (A/-benzoylglycine). Quercetin-3-rutinoside 
was mainly metabolized into phenylacetic acids: 3-hydroxyphenylacetic acid (40% of 
the amount of ingested quercetin-3-rutinoside), 3-methoxy-4-hydroxyphenylacetic acid 
(9%) and 3,4-dihydroxyphenylacetic acid (6%). In contrast, in volunteers without a 
colon we found only traces of phenolic acid metabolites after they had ingested 
chlorogenic acid and quercetin-3-rutinoside. This implies that the colonic microflora 
converts most of these dietary phenols into metabolites which then reach the 
circulation. Thus the metabolites of phenols will mainly reach target tissues, rather 
than the ingested phenols. These metabolites have lower antioxidant activity in vitro 
than their parent phenols. Therefore the antioxidant activity of dietary phenols in vivo 
might be lower than suggested by their in vitro antioxidant activity. Furthermore, in 
vitro studies should include potential health effects of metabolites of phenols and not 
only those of the phenols ingested. 
Effect of phenols on plasma homocysteine 
In chapter 5 we studied the effects of phenols on plasma homocysteine, a potential 
risk factor for cardiovascular disease. Previous studies showed that coffee 
consumption increases plasma homocysteine concentrations. Because chlorogenic 
acid is a major phenol in coffee, we investigated in 20 healthy volunteers whether 
chlorogenic acid might be responsible for the homocysteine-raising effect of coffee. 
Homocysteine concentrations in plasma collected 4-5 h after ingestion of 2 g 
chlorogenic acid (~1.5 L strong coffee) was 12% higher relative to placebo. In plasma 
collected 20 h after ingestion it was 4% higher. Thus chlorogenic acid is indeed partly 
responsible for the homocysteine-raising effect of coffee. The homocysteine-raising 
effect of black tea solids (~2 L strong tea) was similar to that after chlorogenic acid. 
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Quercetin-3-rutinoside did not affect plasma homocysteine. If homocysteine is proven 
to be a causal risk factor for cardiovascular disease then consumption of large 
amounts of coffee or black tea might be a risk for health. 
In chapter 6 we tried to find the mechanism underlying the homocysteine-raising 
effects of chlorogenic acid and black tea solids. We investigated whether the 
metabolism of chlorogenic acid and black tea solids into hippuric acid (chapter 4) 
might be related to their homocysteine-raising effect (chapter 5). This was supported 
by the fact that quercetin-3-rutinoside was not metabolized into hippuric acid and did 
not raise plasma homocysteine either. Hippuric acid is formed through esterification of 
benzoic acid with glycine. Because glycine is also involved in the homocysteine 
metabolism, we hypothesized that exhaustion of glycine through formation of hippuric 
acid might affect homocysteine metabolism. A second objective of this study was to 
study the kinetics of excretion of several phenolic acid metabolites in urine after intake 
of the supplements. Eleven healthy volunteers ingested daily 2 g chlorogenic acid and 
1.2 g sodium benzoate, which both use glycine for formation of hippuric acid, and 1.4 
g hippuric acid and a placebo for 2 days each, in random order. Our results did not 
indicate that the formation of hippuric acid was involved in the homocysteine-raising 
effect of phenols. Furthermore, hippuric acid appeared in urine between 10 and 24 h 
after ingestion of chlorogenic acid. This indicates that the colonic microflora is involved 
in the formation of hippuric acid from chlorogenic acid, because transit time through 
the small intestine is about 10 h. This agrees with our findings in chapter 3 and 
chapter 4 that chlorogenic acid is mainly metabolized in the colon. 
Conclusion 
Consumption of phenols from foods will lead to increased concentrations of phenols 
and their metabolites in the human body. Whether or not this is favorable for health is 
not yet known. The bioavailability of quercetin and chlorogenic acid depends on their 
conjugated moieties. Quercetin, chlorogenic acid and black tea phenols are 
extensively metabolized into phenolic acid metabolites. These metabolites might 
contribute to the antioxidant activity in vivo, but their antioxidant activity in vitro is less 
than that of the parent phenols. Therefore, the contribution of dietary phenols to the 
antioxidant activity in vivo is uncertain. Furthermore, some phenols might also have 
adverse effects on health. Chlorogenic acid and black tea solids raised plasma 
homocysteine, a potential risk factor for cardiovascular disease. 
In this thesis we studied only a small number of dietary phenols, while the variety in 
foods is huge. The results of our studies warrant further research on the bioavailability, 
and on beneficial as well as adverse effects of dietary phenols in humans. Only when 
we have the complete picture we can decide on the relevance of dietary phenols to 
human health. 
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SAMENVATTING 
Bij gezond leven hoort een gezonde voeding. De consumptie van groente en fruit is 
een onderdeel van een gezonde voeding omdat het de kans op hart- en vaatzieken en 
kanker mogelijk verkleind. Voedingsstoffen zoals vitamines in groente en fruit zijn 
hiervoor deels verantwoordelijk. Maar ook andere voedingsstoffen in groenten en fruit, 
zoals 'fenolen', spelen mogelijk een rol (Figuur 1). Fenolen komen veel voor in groente 
en fruit en daarnaast in dranken zoals koffie, thee en rode wijn. In dit proefschrift 
hebben we onderzoek gedaan naar deze fenolen. 
De chemische basisstructuur van fenolen bestaat uit een ringstructuur waaraan een 
hydroxylgroep (OH-groep) gebonden is: ^ J / - 0 " . In de voeding bestaan er veel 
variaties op deze basisstructuur wat tot gevolg heeft dat er veel verschillende fenolen 
in de voeding voorkomen. 
Groente & Fruit 
i 
Fenolen 
Basisstructuur 
-OH 
/"A 
Flavono'i'den Kaneelzuren 
Basisstructuur Basisstructuur 
^ > - c = c - c 
/ \ 
Koffiezuur Chlorogeenzuur 
/ \ 
Quercetine Flavono'i'den 
in zwarte thee 
Figuur 1 Schematisch overzicht van fenolen in de voeding 
Op welke manier fenolen de gezondheid zouden kunnen beinvloeden is niet duidelijk. 
Mogelijk spelen fenolen een belangrijke rol als 'antioxidanten' en beschermen ze op 
die manier tegen ziekten zoals hart- en vaatziekten en kanker. Antioxidanten kunnen 
de vorming van schadelijke vrije radicalen in het lichaam voorkomen of beperken. 
Vrije radicalen kunnen weefsels beschadigen en daardoor leiden tot ziekte. 
Voorbeelden van andere antioxidanten in de voeding zijn de vitamines C en E en de 
voorloper van vitamine A: beta-caroteen. 
Echter, er zijn ook aanwijzingen dat fenolen de gezondheid negatief kunnen 
beinvloeden. Wij hebben in ons onderzoek onderzocht of fenolen het 
homocystelnegehalte in het bloed kunnen verhogen. Een hoog homocystei'negehalte 
is een risicofactor voor het ontstaan van hart- en vaatziekten. 
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In dit proefschrift hebben we onderzocht hoe fenolen zich gedragen in het menselijk 
lichaam en welk effect fenolen hebben op het homocysteTnegehalte bij mensen. 
Omdat in de voeding veel soorten fenolen voorkomen hebben we ons beperkt tot 2 
groepen fenolen: de flavonoTden en de kaneelzuren (Figuur 1). Binnen deze 2 
groepen hebben we weer 4 individuele fenolen gekozen: uit de groep van de 
flavonoTden hebben we het quercetine en de flavonoTden uit zwarte thee onderzocht; 
uit de groep van de kaneelzuren hebben we koffiezuur en chlorogeenzuur onderzocht. 
In de voeding is koffiezuur gebonden met kinazuur en dan heet het chlorogeenzuur. 
In het onderzoek in dit proefschrift stonden 3 vragen centraal: 
Onderzoeksvraag 1) Worden fenolen opgenomen vanuit de darmen in het bloed en 
wat is de invloed van de koppeling van fenolen met andere 
stoffen op de opname? 
Onderzoeksvraag 2) Wat gebeurt er met de fenolen in het lichaam? Hiervoor 
hebben we onderzocht in welke stoffen de fenolen worden 
omgezet in het lichaam. De stoffen die ontstaan uit fenolen 
noemen we metabolieten van fenolen. 
Onderzoeksvraag 3) Wat is het effect van fenolen op het homocysteTnegehalte? 
Een hoog homocysteTnegehalte zou kunnen leiden tot hart- en 
vaatziekten. 
De onderzoeksvragen 1) en 2) van dit proefschrift kunnen we onderbrengen onder het 
begrip 'biobeschikbaarheid' van fenolen uit de voeding. Maar wat is biobeschikbaar-
heid en waarom willen we daar iets over weten? Een belangrijke voorwaarde voor een 
gezonde werking van voedingsstoffen is dat ze in voldoende mate op de juiste plek in 
het lichaam terecht moeten komen waar ze nun werking kunnen verrichten. Dit heet 
'biobeschikbaarheid'. Biobeschikbaarheid omvat meerdere processen in het lichaam 
(Figuur 2): 
a) Het eerste proces is opname van de stof vanuit de darmen in het bloed. Nadat we 
een voedingsmiddel of een pil doorslikken komt het via de maag in de dunne damn. 
In de dunne darm kunnen voedingsstoffen worden opgenomen in het bloed. 
b) Het tweede proces is verdeling van de voedingsstof over het lichaam. Via o.a. het 
bloedvatenstelsel worden de voedingsstoffen verdeeld over het lichaam. Op deze 
manier kunnen voedingsstoffen verschillende plaatsen in het lichaam bereiken. 
c) Een derde proces is metabolisme. Metabolisme in het lichaam houdt in dat stoffen 
uit de voeding in het lichaam worden afgebroken of worden omgezet in andere 
stoffen. De stoffen waarin de fenolen worden omgezet noemen we metabolieten 
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van fenolen. De belangrijkste organen waar metabolisme plaatsvindt zijn de dikke 
darm, de lever en de nieren. 
d) Het vierde proces is de uitscheiding van de voedingsstoffen en/of hun 
metabolieten in de urine of in de ontlasting. Dit is dus een manier van het lichaam 
om schadelijke, onbruikbare of overtollige stoffen kwijt te raken. 
voedingsstof 
maag I 
dunne darm 
hier kunnen voedingsstoffen _ 
worden opgenomenin het bloed 
k 
ever 
Opname in het bloed NEE 
dikke damn 
hier worden voedingsstoffen 
gemetaboliseerden 
kunnen dan alsnog worden 
opgenomenin het bloed' 
Opname in het bloed JA 
Stof wordt verdeeldover 
het lichaamen kan 
worden gemetaboliseerd 
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i 
Uitscheidingvia urine 
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Figuur 2 Schematisch overzicht van biobeschikbaarheid van voedingsstoffen in het lichaam 
Onderzoeksvraag 1) Worden fenolen opgenomen vanuit de darmen in het bloed en 
wat is de invloed van de koppeling van fenolen met andere 
stoffen op de opname? 
Fenolen zoals quercetine en koffiezuur komen in de voeding vaak voor gekoppeld met 
andere stoffen. Omdat deze koppeling invloed kan hebben op de opname van fenolen 
in het bloed hebben we dit voor quercetine en koffiezuur onderzocht. 
Quercetine 
Quercetine is in de voeding gekoppeld aan suikers. We weten uit eerder onderzoek 
dat quercetine wordt opgenomen in het bloed, maar dat het type suiker waaraan 
quercetine gekoppeld is invloed heeft op de opname. Quercetine waaraan op de 4'-
plaats het suiker glucose is gekoppeld (quercetine-4'-glucoside) komt vooral voor in 
uien en het wordt voor 50% opgenomen in het bloed. Quercetine waaraan op de 3-
plaats het suiker rutinose is gekoppeld (quercetine-3-rutinoside) komt vooral voor in 
thee en wordt maar voor 20% worden opgenomen in het bloed (Figuur 3). Nu is het 
mogelijk om quercetine-3-rutinoside om te zetten in quercetine-3-glucoside, maar de 
124 
SAMENVATTING 
vraag was of dit quercetine-3-glucoside net zo goed opgenomen kon worden als het 
quercetine-4'-glucoside? 
Dit hebben we onderzocht in 9 vrijwilligers. De vrijwilligers namen quercetine-4'-
glucoside in op een dag en quercetine-3-glucoside op een andere dag. Na inname 
hebben we de concentratie quercetine in het bloed en de urine gedurende 24 uur 
gevolgd. Uit dit onderzoek bleek dat het quercetine-3-glucoside net zo goed 
opgenomen wordt als het quercetine-4'-glucoside (Figuur 3, hoofdstuk 2). Dit betekent 
dat de beschikbaarheid van quercetine uit thee (quercetine-3-rutinoside) verbeterd 
wordt als de rutinose wordt omgezet in een glucose. Mocht in de toekomst blijken dat 
quercetine goed is voor de gezondheid, dan zou het quercetine in onze voeding zo 
kunnen worden aangepast dat er zoveel mogelijk quercetine vanuit de voeding 
beschikbaar komt in het lichaam. 
darm 
.glucose 
Quercetine-4'-glucosid< 
I A Quercetine-3-rutinoside 
glucose—rhamnose 
Quercetine-3-glucosidj 
glucose 
bloed 
Figuur 3 Opname van verschillende vormen van quercetine vanuit de darmen in het bloed: quercetine 
gebonden aan een glucose wordt beter opgenomen dan quercetine gebonden aan rutinose 
Koffiezuur 
Koffiezuur is een belangrijke vertegenwoordiger van de kaneelzuren in de voeding. 
Koffiezuur komt veel voor in koffie, maar in koffie is koffiezuur gebonden aan kinazuur 
en dan heet het 'chlorogeenzuur'. Wij hebben onderzocht of de koppeling van 
koffiezuur met kinazuur invloed heeft op de opname vanuit de dunne darm in het 
bloed in mensen. Dit hebben we onderzocht bij 7 vrijwilligers met een dunne 
darmstoma. Een stoma is een kunstmatige uitgang voor de ontlasting aan het eind 
van de dunne darm. Een stoma is nodig als de dikke darm moet worden verwijderd 
om medische redenen. We hebben voor deze groep vrijwilligers gekozen omdat we 
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aan het eind van de dunne darm willen meten hoeveel er nog over is van de stoffen 
die we hebben gegeven. De hoeveelheid stof die is opgenomen vanuit de dunne darm 
in het bloed kunnen we berekenen uit het verschil tussen de hoeveelheid van de stof 
die mensen hebben ingenomen en de hoeveelheid stof die we aan het eind van de 
dunne darm terugvinden. 
We vonden dat de opname van chlorogeenzuur (koffiezuur gekoppeld aan kinazuur) 3 
keer lager was dan dat van 'vrij' koffiezuur (Figuur 4, hoofdstuk 3). Dit betekent dat het 
kinazuur de opname van koffiezuur remt en dat de opname van chlorogeenzuur uit de 
voeding zou kunnen worden verbeterd door het kinazuur eraf te halen. Als in de 
toekomst blijkt dat koffiezuur een gezonde werking heeft, dan zouden 
voedingsmiddelen zo kunnen worden aangepast dat het koffiezuur wordt 
losgekoppeld van het kinazuur. Hierdoor wordt het koffiezuur beter beschikbaar. 
LoJfVc-
darm 
Chlorogeenzuu 
-C—kinazuur 
bloed 
HO 
Figuur 4 Opname van chlorogeenzuur en koffiezuur vanuit de darmen in het bloed: koffiezuur wordt 
beter opgenomen dan chlorogeenzuur. 
Onderzoeksvraag 2) Wat gebeurt er met de fenolen in het lichaam? Hiervoor 
hebben we onderzocht in welke stoffen fenolen worden 
omgezet in het lichaam. De stoffen die ontstaan uit fenolen 
noemen we metabolieten van fenolen. 
Naast opname van fenolen uit de darmen in het bloed kan het lichaam ook sleutelen 
aan de fenolen waardoor er andere stoffen ontstaan of waardoor ze worden 
afgebroken (Figuur 5). De stoffen die ontstaan uit fenolen noemen we metabolieten. 
De metabolieten van fenolen kunnen ook een fenol-structuur hebben of het zijn stoffen 
die niet meer op fenolen lijken. Omdat deze metabolieten van fenolen ook in het 
lichaam circuleren kunnen ze een effect hebben op de gezondheid. Daarom is het 
belangrijk te weten welke metabolieten er ontstaan uit fenolen. Uit eerder onderzoek is 
bekend dat fenolen intensief worden omgezet in het lichaam, maar niemand weet 
precies welke metabolieten er uiteindelijk ontstaan. 
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In ons onderzoek hebben we onderzocht in welke metabolieten quercetine, 
chlorogeenzuur en fenolen uit zwarte thee worden omgezet. In ons onderzoek hebben 
20 vrijwilligers quercetine, chlorogeenzuur en zwarte thee fenolen ingenomen en 
daarna hebben wij in de urine van deze vrijwilligers metabolieten van de fenolen 
gemeten. We vonden dat ongeveer de helft van het chlorogeenzuur en de thee 
fenolen in het lichaam wordt omgezet in hippuurzuur. Het quercetine werd voor 
ongeveer de helft omgezet in fenylazijnzuren (hoofdstuk 4). 
F P -
Fenolen v**^ 
in de voeding 
Metabolieten 
in de urine 
Figuur 5 Fenolen uit voeding worden in het lichaam omgezet in metabolieten 
Tja, en dan....wat zegt dit nu? Om deze vraag te beantwoorden moeten we even 
terug naar de mogelijke gezondheidseffecten van fenolen. Er wordt gedacht dat 
fenolen uit voeding gezond zouden kunnen zijn omdat ze sterke antioxidanten zijn. 
Echter, wij vonden in onze studie dat fenolen die we met de voeding binnenkrijgen 
door het lichaam worden omgezet in metabolieten die minder goede antioxidanten zijn 
dan de fenolen uit voeding. Daarom zou de antioxidantwerking van fenolen in het 
lichaam minder kunnen zijn dan tot nu toe werd gedacht. Helaas kunnen we de 
antioxidantwerking van voedingsstoffen niet meten in het lichaam, maar in de 
toekomst wordt dit misschien wel mogelijk. 
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Onderzoeksvraag 3) Wat is het effect van fenolen op het homocyste'i'negehalte? 
Een hoog homocyste'i'negehalte zou kunnen leiden tot hart- en 
vaatziekten. 
Het effect van fenolen op de gezondheid van mensen is nog onbekend. De ideale 
manier om dit te onderzoeken is om te kijken of in een grote groep mensen die veel 
fenolen eet minder mensen ziek worden dan in een groep mensen die weinig fenolen 
eet. Helaas is dit soort onderzoek in de praktijk moeilijk uit te voeren. 
Een oplossing hiervoor is het meten van de effecten van fenolen op markers in het 
lichaam die het risico op ziekte kunnen voorspellen. Een marker is bijvoorbeeld een 
stof die we kunnen meten in het lichaam en waarvan de concentratie in het lichaam 
iets zegt over het risico op ziekte. Een voorbeeld van zo'n marker is het 
homocyste'i'negehalte. Homocysteine is een eiwitdeeltje dat bij iedereen in het bloed 
aanwezig is. Mensen met hart- en vaatziekten hebben vaker een verhoogd 
homocyste'i'negehalte dan gezonde mensen en daarom wordt gedacht dat een 
verhoogd homocyste'i'negehalte kan leiden tot hart- en vaatziekten. Het 
homocyste'i'negehalte als marker voor hart- en vaatziekten is dus te vergelijken met 
het cholesterolgehalte, omdat een verhoogd cholesterolgehalte ook kan leiden tot 
hart- en vaatziekten. 
Ons vermoeden dat fenolen een effect hebben op het homocyste'i'negehalte, is 
ontstaan omdat in eerder onderzoek is gevonden dat koffieconsumptie het 
homocyste'i'negehalte verhoogd. Chlorogeenzuur (koffiezuur gekoppeld aan kinazuur) 
is een belangrijk fenol in koffie en zou daarom dus de oorzaak kunnen zijn van het 
homocyste'fne-verhogende effect van koffie. Wij hebben het effect van chlorogeenzuur 
op het homocyste'i'negehalte gemeten bij 20 gezonde vrijwilligers. Na inname van 
chlorogeenzuur werd in het bloed van de vrijwilligers het homocyste'i'negehalte 
gemeten. Daarnaast hebben we ook het effect van quercetine en van fenolen uit 
zwarte thee op het homocyste'i'negehalte gemeten bij deze vrijwilligers. We vonden 
dat chlorogeenzuur en fenolen uit zwarte thee het homocyste'i'negehalte verhogen, 
maar quercetine niet (hoofdstuk 5). Dit betekent dat het chlorogeenzuur in koffie dus 
deels verantwoordelijk is voor het homocyste'i'ne-verhogende effect van koffie. Naast 
chlorogeenzuur kunnen nog andere stoffen in koffie aanwezig zijn die het 
homocyste'i'negehalte kunnen verhogen. 
Naar aanleiding van het homocyste'i'ne-verhogende effect van chlorogeenzuur en thee 
fenolen hebben we onderzocht of de omzetting van chlorogeenzuur en thee fenolen in 
hippuurzuur (hoofdstuk 4), misschien kon verklaren op welke manier fenolen het 
homocyste'i'negehalte kunnen be'i'nvloeden. Namelijk, als blijkt dat de omzetting van 
chlorogeenzuur en thee fenolen in hippuurzuur de stijging van het 
homocyste'i'negehalte veroorzaakt, dan zouden we dit ook kunnen verwachten van 
andere fenolen in de voeding die worden omgezet in hippuurzuur. Echter, in ons 
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onderzoek hebben we gevonden dat de omzetting van fenolen in hippuurzuur 
waarschijnlijk niets te maken heeft met de stijging in homocysteine (hoofdstuk 6). Op 
welke manier fenolen het homocysteTnegehalte wel kunnen be'i'nvloeden blijft 
vooralsnog onbekend. 
Uit ons onderzoek blijkt dat chlorogeenzuur uit koffie en fenolen uit zwarte thee het 
homocysteTnegehalte kunnen verhogen. Wat dit betekent voor de gezondheid is nog 
onduidelijk. Als een verhoogd homocysteTnegehalte leidt tot hart- en vaatziekten, dan 
zou dit kunnen betekenen dat koffie en thee dus ongezond zijn. Echter, uit grote 
studies die het verband tussen koffie en thee consumptie en hart- en vaatziekten 
hebben onderzocht komt niet naar voren dat koffie en thee ongezond zijn. Daamaast 
is het ook nog niet zeker of mensen met een verhoogd homocysteTnegehalte 
inderdaad meer risico hebben op hart- en vaatziekten dan mensen met een normaal 
gehalte. Een verhoogd homocysteTnegehalte zou ook nog een gevolg kunnen zijn van 
de ziekte. Momenteel wordt veel onderzoek gedaan naar de vraag of een verhoogd 
homocysteTnegehalte een risico is voor de gezondheid en over een paar jaar zullen 
we hierover meer weten. Dus voor nu geldt: geniet van een heerlijk kopje koffie of 
thee! 
Conclusie 
In ons onderzoek hebben we gevonden dat fenolen uit de voeding wel worden 
opgenomen in het bloed, maar dat de hoeveelheid die wordt opgenomen afhankelijk is 
van de koppeling van de fenolen met andere stoffen. 
In het lichaam worden fenolen omgezet in metabolieten en deze metabolieten zijn 
minder goede antioxidanten dan de fenolen uit voeding zelf. Daarom is de werking 
van fenolen als antioxidanten in het lichaam waarschijnlijk minder belangrijk dan tot nu 
toe werd gedacht. 
Tenslotte hebben we gevonden dat chlorogeenzuur uit koffie en fenolen uit zwarte 
thee het homocysteTnegehalte kunnen verhogen. Wat dit betekent voor de gezondheid 
is nog niet duidelijk. 
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Vele handen hebben het werk wat in dit proefschrift beschreven staat licht(er) en 
plezierig gemaakt! 
Ten eerste, dank aan alle proefpersonen die hebben deelgenomen aan de koffie- en 
theeloze proeven. Door de geweldige inzet en een dosis humor hebben jullie mijn 
werk een stuk gemakkelijker en vooral leuker gemaakt. Al die liters bloed, urine en 
stomavloeistof die jullie hebben gedoneerd zijn echt niet voor niets geweest! 
Martijn Katan, nadat ik 1 jaar als 'pre-aio' had gewerkt gaf je me de kans om door te 
stromen in een aio-project. Jouw enthousiasme bij de eerste resultaten van proeven 
werkte aanstekelijk en van jouw kritische noten tijdens alle fases van het onderzoek 
heb ik heel veel geleerd (en ik zal het 'idnr.' nooit meer vergeten te vermelden). 
Onmisbaar was voor mij de wetenschap dat ik altijd op je kon rekenen als dat nodig 
was en dat heb ik zeer gewaardeerd. Ik heb in de afgelopen jaren met heel veel 
plezier met je samengewerkt en ik ben blij dat dit nog een paar jaar zal worden 
voortgezet. 
Peter Hollman, je hebt me met (chemische) raad en daad bijgestaan in dit 
fenolenproject. Ik kon altijd bij je terecht met vragen over proefopzetten en de 
interpretatie van de gegevens. Op het moment dat het project even op een kritiek punt 
belandde, kwam jij met een geweldig idee dat vele kansen bood voor het project. 
Bedankt voor de onmisbare steun die jij en je lab aan dit project hebben gegeven! 
Hans van Amelsvoort en Peter Zock. Bedankt voor jullie input bij onze halfjaarlijkse 
fenolenvergaderingen. Jullie stonden iets verder van het onderzoek af en juist 
daardoor kwamen soms verrassend nieuwe inzichten naar boven. Lilian Tijburg en 
Jeanne de Vries, vooral bij de start van het aio-project hebben jullie me tijdens de 
fenolenvergaderingen met raad terzijde gestaan, hartelijk dank! 
Frans Russel, Pieter van 't Veer, Fons Voragen en Jan Weststrate hebben vanaf de 
zijlijn met mijn onderzoek meegedacht in de begeleidingscommissie. Jullie originele 
ideeen en inzichten hebben me geholpen om het onderzoek in een breder perspectief 
te zien; ik had dat niet graag willen missen. 
Karin, jij hebt me indertijd wegwijs gemaakt op de afdeling, zodat ik het wiel niet 
steeds zelf uit hoefde te vinden. Dank daarvoor! 
Michel en Gerrit van het Rikilt: wat een klus hebben jullie geklaard! Het viel niet mee 
om een analysemethode op te zetten voor zo'n 60 (!) fenolische zuren in de urine, 
maar het is jullie wel gelukt! Bedankt voor het vele werk wat jullie verzet hebben. 
Michel, ook nadat de methode was opgezet heb jij nog vele uren in het lab gestaan 
om al die liters urine te analyseren. De hele Rikilt-clan Dini, Michel, Gerrit, John en 
Betty: elke keer weer was het gezellig als ik op het Rikilt kwam binnenvallen. Bedankt 
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voor jullie bijdragen aan het welslagen van dit fenolenproject en hulp als ik jullie lastig 
kwam vallen met lab-vragen. 
Geen voedingsproef zonder dietisten! Els, Saskia, Marieke, Dieneke hartelijk dank 
voor jullie meedenkwerk over een fenol-arme voeding en voor de perfecte uitvoer van 
de voedingsproeven. 
Margje, Ingrid, Carla, Sandra, Marjan en Mieneke: jullie hebben veel werk verzet in 
het kader van jullie afstudeerprojecten en dat heeft een belangrijke bijdrage geleverd 
aan het onderzoek in dit proefschrift. Ik vond het erg prettig om met jullie samen te 
werken. 
Monique Maas en Marina Grubben van het St. Radboud ziekenhuis Nijmegen, jullie 
hulp bij de uitvoering van de eerste proef binnen mijn aio-project was onmisbaar. 
Monique, ook al had je het druk met je eigen promotiewerk, je hebt je belangeloos 
ingezet om mijn proef gladjes te laten verlopen, bedankt. 
Joke en Anita, hartelijk dank voor jullie flexibele inzet bij de vele bloedafnames in de 
laatste proef: 's avonds laat en 's ochtends vroeg! 
Petra, jij bedankt voor je support in het afgelopen jaar om mijn aio-baan te combineren 
met het postdoc-schap. We werken nog maar kort samen, maar ik zie er naar uit om 
dit de komende jaren voort te zetten. 
Alle medewerkers van de vakgroep Humane Voeding & Epidemiologie wil ik graag 
heel hartelijk bedanken voor de behulpzaamheid en steun in welke vorm dan ook 
gedurende de afgelopen jaren! 
De werksfeer bepaalt een zeer groot deel van het plezier in het werk. Maud, Nicole, 
Ingeborg, Edine, Liesbeth, Machteld, Saskia, Els, Baukje, Annelies, Nynke, Dorien, 
Martine, Rianne, Alida, Anouk, Floor, Mariska, Jane, Tiny en alle andere collega's: 
bedankt voor al jullie hulp, maar vooral voor de kletspraat tijdens pauzes en in de 
kroeg, squash-activiteit, schaatsgezelligheid, en vakantie-uitjes naar Zuid-Afrika en 
Portugal. Door deze 'afleidingen' van het aio-werk fietste ik elke dag weer met plezier 
die berg op. 
Wat hebben we een geweldige aio-reis naar Zuid-Afrika gemaakt! Alida, Machteld, 
Maud, Andre, Edine en Martijn, het was fantastisch om met jullie als team deze grote 
ondememing te organiseren en daarna het avontuurte beleven. Martijn van der Gaag, 
altijd de vrolijke (mannelijke) noot in ons team, we hebben veel lol gehad met z'n 
alien. Ik kan nog steeds niet geloven dat je er niet meer bent. 
Cecile, Sonja, Femmie, Marleen, Renate en Linda. Bedankt voor jullie vriendschap, 
interesse en gezelligheid van tijd tot tijd. 
En dan de engelen van de engelenbak H'93: Rolf, Judith, Thijs, Noeky, Joost, Ludo, 
Hauke, Koen en Helena. Heerlijk eten, gezellig met een wijntje op de bank, uitjes naar 
Belgie, Italie en Frankrijk, op het dakterras bakken in de zon en op de barbecue. Wie 
wil er nu niet in zo'n huis wonen ? Bedankt! 
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Maud en Miranda, ik ben blij dat jullie straks als paranimfen naast me staan op het 
podium. Maud, lieve kamergenoot, zonder jou was het de afgelopen aio-jaren lang 
niet zo leuk geweest. We hebben heel wat afgelachen en afgekletst (V2 wat moeten 
we ermee?), maar ook wel eens een traantje weggepinkt: het kon allemaal op 218. 
Onze projecten leken zo op elkaar dat we soms het gevoel hadden dat we een soort 
duobaan hadden. Vrienden zullen we altijd blijven en wie weet belanden we ooit nog 
eens weer op een kamer! Miranda, al vanaf de lagere school kennen we elkaar en ook 
al zien we elkaar niet zo vaak, dat maakt niets uit voor de gespreksstof die we elke 
keer weer opnieuw hebben. Ik hoop dat onze vriendschap nog heel lang blijft. 
Gerben, Frederike, Klaas, Aly, Rutger, Saskia, Mini en Freek. Bedankt voor jullie 
interesse. En die gezellige familie sinterklaasfeesten en barbecues moeten we er 
zeker in houden! Aly, jij bedankt voor die prachtige tekening die de voorkant van dit 
boekje siert! 
Pap & mam, vanaf het prille begin hebben jullie me altijd gestimuleerd om door te 
zetten. Dit boekwerk is aan jullie opgedragen omdat het er niet geweest was zonder 
jullie voortdurende steun. Pa, bedankt voor je interesse en de telefoontjes om te 
informeren naar je dochter. Mam, ik vind het echt geweldig dat je na 2 jaar hard 
studeren nu zelf carriere aan het maken bent! Ik ben erg trots op jullie. 
Y Y W Q ' ^ 3' 
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